SCHEDULE 14A INFORMATION
Proxy Statement
Pursuant to section 14(a) of the Securities and Exchange Act of 1934 (Amendment No. )
Filed by the
Registrant [X]
Filed by a Party
other than the Registrant [ ]
Check the appropriate
box:
[ ] Preliminary
Proxy Statement
[ ] Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
[X] Definitive
Proxy Statement
[ ] Definitive
Additional Materials
[ ] Soliciting
Material Pursuant to §240.14a-12
Fonar Corporation
………………………………………………………………………………………………
(Name of Registrant
as Specified In Its Charter)
………………………………………………………………………………………………
(Name of Person(s)
Filing Proxy Statement if other than the Registrant)
Payment of Filing
Fee (Check the appropriate box):
[X] No fee required
[ ] Fee computed
on table below per Exchange Act Rules 14-6(i) (1) and 0-11.
1)
Title of each class of securities to which transaction applies:
N/A
………………………………………………………………….
2)
Aggregate number of securities to which transaction applies:
N/A
………………………………………………………………….
3)
Per unite price or other underlying value of transaction computed pursuant to
Exchange
Act Rule 0-11 (Set forth the amount of which the filing fee is
calculated
and state how it was determined:
N/A
…………………………………………………………………..
4)
Proposed maximum aggregate value of transaction:
N/A
………………………………………………………………………
5)
Total fee paid:
N/A
……………………………………………………………………….
[ ] Fee paid
previously with preliminary materials.
[ ] Check box
if any part of the fee is offset as provided by Exchange Act Rule 240.0-11 (a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration number, or the Form or Schedule and the date of its filing.
1)
Amount Previously Paid:
………………………………………
2)
Form, Schedule or Registration Statement No.:
……………………………………….
3)
Filing Party:
………………………………………..
4)
Date Filed:
FONAR CORPORATION
110 Marcus Drive
Melville, New York 11747
(631) 694-2929
NOTICE OF ANNUAL MEETING
OF STOCKHOLDERS
June 24, 2013
To The Stockholders:
The Annual Meeting of the stockholders of Fonar
Corporation will be held at the Double Tree Hotel, Wilmington Downtown, 700 King Street, Wilmington, Delaware 19801 (302-655-0400),
on June 24, 2013, at 10:00 a.m. local time for the following purposes:
1. To elect five Directors to the
Board of Directors.
2. To approve, on an advisory basis,
the compensation of the Company’s named executive officers.
3. To recommend,
in an advisory vote, whether the advisory stockholder vote to approve the compensation of the Company’s named executive officers
be taken every year, every two years, or every three years.
4. To ratify
the selection of Marcum LLP as the Company’s auditors for the fiscal year ending June 30, 2013.
5. To transact such other business
as may properly come before the meeting.
Only stockholders of record at the close of
business on April 26, 2013 are entitled to notice of, and to vote at, this meeting. A list of such stockholders will be available
for examination by any stockholder for any purpose germane to the meeting, during normal business hours, at the principal office
of the Company, 110 Marcus Drive, Melville, New York, for a period of ten days prior to the meeting.
Whether or not you expect to attend in person,
we urge you to vote your shares at your earliest convenience. You may vote by internet, by phone or by signing, dating, and returning
your proxy at your earliest convenience. Voting by internet, telephone or mail will not prevent you from voting your stock at the
meeting if you desire to do so, as your proxy is revocable at your option.
BY ORDER OF THE BOARD OF DIRECTORS
/s/ Claudette J.V. Chan
Claudette J.V. Chan, Secretary
PROXY STATEMENT
FOR ANNUAL MEETING OF
STOCKHOLDERS TO BE HELD JUNE 24, 2013
This proxy statement, which is first being
made available to shareholders on or about May 15, 2013 on the internet, is furnished in connection with the solicitation of proxies
by the Board of Directors of Fonar Corporation (the "Company"), to be voted at the annual meeting of the stockholders
of the Company to be held at 10:00 a.m. on June 24, 2013 and any adjournment(s) thereof for the purposes set forth in the accompanying
Notice of Annual Meeting of Stockholders. At the same time a paper notice regarding the availability of proxy materials will be
mailed to stockholders. Stockholders who execute proxies retain the right to revoke them at any time prior to the exercise of the
powers conferred thereby. The cost of solicitation of proxies will be borne by the Company.
The stockholders will have several options as to how to view the
materials and vote their shares.
The Company is posting the Notice of Annual Meeting and Proxy
Statement, together with the Annual Report on the internet. You may read the materials online or print out a copy. You will also
have the ability to vote online.
In the alternative, you may elect to receive an e-mail or the
traditional paper copies of the Notice of Annual Meeting and Proxy Statement, and the Annual Report. There is no charge for receiving
e-mail or paper copies, BUT you must request them if you want them. To facilitate timely delivery please make the request as instructed
on or before June 5, 2012.
To view the materials and vote on the internet,
have the 12 Digit Control Number(s) located on the Notice Regarding the Availability of Proxy Materials available and visit:
www.proxyvote.com
.
Stockholders may request a copy of the Proxy Materials:
1. By internet – visit
www.proxy.com
2. By telephone – 1-800-579-1639
3. By e-mail –
sendmaterial@proxyvote.com
Only stockholders of record at the close of
business on April 26, 2013 will be entitled to vote at the meeting. Shares of Common Stock are entitled to one vote per share,
shares of Class B Common Stock are entitled to ten votes per share and shares of Class C Common Stock are entitled to twenty-five
votes per share. At the close of business on April 26, 2013, there were issued and outstanding 5,969,132 shares of Common Stock
held of record by approximately 2,059 stockholders, 146 shares of Class B Common Stock held of record by 11 stockholders and 382,513
shares of Class C Common Stock held of record by 3 stockholders. The shares of Class A Nonvoting Preferred Stock, 313,438 shares
held of record by approximately 1,975 stockholders at the close of business on April 26, 2013, are not entitled to vote. Except
for the shares of Class A Nonvoting Preferred Stock, there are no shares of Preferred Stock issued and outstanding.
Any proxy may be revoked at any time before
it is exercised by delivery of a written instrument of revocation or a later dated proxy to the Secretary of the Company at the
principal executive office of the Company or, while the meeting is in session, to the Secretary of the meeting, without, however,
affecting any vote previously taken. The presence of a stockholder at the meeting will not operate to revoke his proxy. The casting
of a ballot by a stockholder who is present at the meeting, however, will revoke his proxy, but only as to the matters on which
the ballot is cast and not as to any matters on which he does not cast a ballot or as to matters previously voted upon.
Proxies received by management will be voted
at the meeting or any adjournment thereof. EACH PROXY WILL BE VOTED IN ACCORDANCE WITH THE SPECIFICATIONS MADE THEREIN BY THE PERSON
GIVING THE PROXY. TO THE EXTENT NO CHOICE IS SPECIFIED, HOWEVER, THE PROXY WILL BE VOTED FOR MANAGEMENT’S PROPOSALS. All
of management’s proposals have been unanimously approved by the Board of Directors.
1. ELECTION OF DIRECTORS AND MANAGEMENT INFORMATION
Five directors are to be elected at the annual
meeting, to hold office until the next annual meeting of stockholders and until their successors are elected and qualified. It
is intended that the accompanying proxy will be voted in favor of the following nominees to serve as directors unless the stockholder
indicates to the contrary on the proxy. All of the nominees are currently directors. Management expects that each of the nominees
will be available for election.
NOMINEES FOR DIRECTORS AND OFFICERS
Raymond V. Damadian, M.D. (age 77), a nominee
for Director, has been the Chairman of the Board and President of FONAR since its inception and Treasurer since February, 2001.
Dr. Damadian received an M.D. degree in 1960 from Albert Einstein College of Medicine, New York, and a B.S. degree in mathematics
from the University of Wisconsin in 1956. In addition, Dr. Damadian conducted post-graduate work at Harvard University, where he
studied extensively in the fields of physics, mathematics and electronics. Dr. Damadian is a 1988 recipient of the National Medal
of Technology and in 1989 was inducted into the National Inventors Hall of Fame, for his contributions in conceiving and developing
the application of magnetic resonance technology to medical applications including whole body scanning and diagnostic imaging.
Dr. Damadian is also the director and sole officer of the Company’s wholly-owned subsidiary, Health Management Corporation
of America (“HMCA”).
Claudette J.V. Chan (age 75), a nominee for
Director, has been a Director of FONAR since October 1987. She also has been the Secretary of FONAR since January, 2008. Mrs. Chan
has been employed since 1992 by HMCA and its predecessor, Raymond V. Damadian, M.D. MR Scanning Centers Management Company, as
"site inspector," in which capacity she is responsible for supervising and implementing standard procedures and policies
for MRI scanning centers. From 1989 to 1994 Mrs. Chan was employed by St. Matthew's and St. Timothy's Neighborhood Center, Inc.,
as the director of volunteers in the "Meals on Wheels" program, a program which cares for the elderly. She received a
bachelor of science degree in nursing from Cornell University in 1960. Mrs. Chan is the sister of Raymond V. Damadian.
Robert J. Janoff (age 85), a nominee for Director,
has been a Director of FONAR since February, 1989. Mr. Janoff has been a self-employed New York State licensed private investigator
for more than thirty-five years and was a Senior Adjustor in Empire Insurance Group for more than 15 years until retiring from
that position on July 1, 1997. Mr. Janoff also served, from June 1985 to June 1991, as President of Action Data Management Strategies,
Ltd., a supplier of computer programs for use by insurance companies. Mr. Janoff is a Director Emeritus of Harmony Heights of Oyster
Bay, New York, which is a nonprofit residential school for girls with learning disabilities.
Charles N. O'Data (age 77), a nominee for Director,
has been a Director of FONAR since February, 1998. From 1968 to 1997, Mr. O'Data was the Vice President for Development for Geneva
College, a liberal arts college located in western Pennsylvania. In that capacity, he acted as the College's chief investment officer.
His responsibilities included management of the College's endowment fund and fund raising. In July 1997, Mr. O'Data retired from
Geneva College after 36 years of service to assume the position of National Sales Executive for SC Johnson Company's Professional
Markets Group (a unit of SC Johnson Wax), and specialized in healthcare and education sales, a position he held until the spring
of 1999. He founded The Beaver County Foundation, a Community Foundation, in 1992, and serves as its President. Mr. O’Data
served as a director of Heritage Valley Health System, The Medical Center, Beaver for 25 years, three years as Chairman. Mr. O'Data
is a graduate of Geneva College, where he received a B.S. degree in Economics in 1958.
Ronald G. Lehman (age 36), a nominee for Director,
has been a Director of Fonar since April, 2012, when he was unanimously appointed by the remaining four Directors to fill the vacancy
resulting from the death of former Director Robert Djerejian. From October, 2009 to the present, Mr. Lehman has served as Managing
Director of Investment Banking with Bruderman Brothers, Inc., a private New York-based broker-dealer registered with the Securities
and Exchange Commission and which is a member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor
Protection Corporation (SIPC). Mr. Lehman directly manages all facets of the firm’s transaction processes, from deal origination,
to sourcing capital, to negotiating deal structures, through documentation and closing. The firm provides buy and sell-side advisory,
capital raising, and consulting services to lower middle-market companies. Mr. Lehman specializes in advising healthcare services
companies and has recently completed several recapitalizations in the industry. He also participates in the firm’s merchant
banking investments and oversees many of these assignments. From May, 2008 to October, 2009, Mr. Lehman served as Senior Vice President
of Acquisitions at Health Diagnostics, LLC, where he managed the company’s acquisition and corporate finance activities.
From March, 2000 to May, 2008, Mr. Lehman worked for various Bruderman entities as a buy and sell-side advisor and as a principal
in several private equity transactions. From September, 1998 to March, 2000, Mr. Lehman worked at Deutsche Bank Securities, Inc.
and last held the position of Associate in their Global Custody Group. Mr. Lehman graduated from Columbia University with a B.A.
in 1998.
CORPORATE GOVERNANCE, THE BOARD AND ITS COMMITTEES
All of the nominees are presently directors
of the Company. The five nominees will be elected to hold office for the ensuing year or until their respective successors are
elected and qualified. Of the five nominees, Messrs. Charles N. O’Data, Robert J. Janoff and Ronald G. Lehman are independent,
as defined in the Securities and Exchange Commission Regulations and Nasdaq Market Place Rules. In making such determinations,
there were no transactions, relationships or arrangements not disclosed in our SEC filings to be considered by the Board of Directors,
in determining whether the director was independent.
BOARD MEETINGS
During the year ended June 30, 2012, the Board
of Directors unanimously consented to take action in lieu of a meeting on two occasions, and the audit committee met four times.
The attendance of the Board of Directors at
annual meetings is not required. The Chairman of the Board and Chief Executive Officer, however, attends the annual meeting of
stockholders where he acts as Chairman of the Meeting.
Dr. Damadian receives no compensation for serving
on the Board. The other directors are each paid $20,000 per year in their capacities as directors. This is the sole compensation
payable to the directors.
Board Leadership Structure.
The current
Board Chairman, Dr. Raymond V. Damadian, is also the current President and Chief Executive Officer of the Company. In addition,
although the Company has not selected a lead independent director, Charles N. O’Data, in his capacity as Chairman of the
Audit Committee, effectively functions as such. The Company believes that the Company’s current model of the combined Chairman/Chief
Executive Officer role is the appropriate leadership structure for the Company at this time. The Company believes that each of
the possible leadership structures for a board has its particular pros and cons, which must be considered in the context of the
specific circumstances, culture and challenges facing a company, and that such consideration fall squarely on the shoulders of
a company’s board and necessitates a diversity of views and experiences. The combined Chairman/Chief Executive Officer model
is a leadership model that has served our shareholders well since the inception of the Company.
The lead independent director, Charles N. O’Data,
is the Chairman of the Audit Committee. As such he plays a leading role in the engagement of auditors and the review of the Company’s
financial statements. Under certain circumstances, he also serves as a contact point for employees.
The Company believes the combined Chairman/Chief
Executive Officer position has certain advantages over other board leadership structures that continue to best meet the Company’s
current needs, including:
|
·
|
Efficient communication between management and the Board;
|
|
·
|
Clarity for the Company’s stockholders on corporate leadership
and accountability;
|
|
·
|
The Chairman of the Board possessing the best knowledge of the Company’s
strategy, operations and financial conditions; and
|
|
§
|
Continuity in the Company’s leadership, as Dr. Damadian founded
the Company in 1978.
|
The Company's Board of Directors has an audit
committee. There is no standing compensation committee, nominating committee or other committee of the Board.
In accordance with the Nasdaq Marketplace Rules,
the Board of Directors adopted a written charter for the audit committee which took effect in June, 2001 and was revised on November
17, 2004. All of the directors on the audit committee are independent.
Stockholders may communicate with directors
by writing to them at the Company in accordance with the Company’s corporate governance policies and code of conduct, or
in any other manner the particular director may provide. Depending on the sensitivity and timing of a matter raised by a stockholder
and the need for disclosure of matters to be made not to just one stockholder, but to the stockholders as a whole, it may not be
possible for the director to reply to the stockholder.
Due to the shareholdings of the Company’s
Chairman of the Board and Chief Executive Officer, Dr. Raymond V. Damadian, which total more than 50% of the voting power of the
Company, the Company is a controlled company for purposes of NASDAQ Marketplace Rule 4350(c).
AUDIT COMMITTEE
The Audit Committee, which is comprised solely
of independent directors, is governed by a Board approved charter that contains, among other things, the Committee’s membership
requirements and responsibilities. The audit committee oversees the Company’s accounting, financial reporting process, internal
controls and audits, and consults with management and the independent public accountants on, among other items, matters related
to the annual audit, the published financial statements and the accounting principles applied. As part of its duties, the audit
committee appoints, evaluates and retains the Company’s independent public accountants. It also maintains direct responsibility
for the compensation, termination and oversight of the Company’s independent public accountants and evaluates the independent
public accountants’ qualifications, performance and independence.
Financial Expert on Audit Committee: The Board
has determined that Mr. Charles N. O’Data, who currently is a financial consultant to various entities and previously was
the Vice President for Development for Geneva College, is the audit committee financial expert. The Board made a qualitative assessment
of Mr. O’Data’s level of knowledge and experience based on a number of factors, including his formal education and
experience.
Board Oversight of Risk Management.
The Company faces risk in many different areas, including business strategy; government regulation; financial condition; health
care compliance; product research and development; competition for talent; business vitality; operational efficiency; quality assurance;
reputation; intellectual property; and trade secrets, among others. The oversight function is carried out in the quarterly and
annual Audit Committee meetings and by communication and meetings with the Company’s Chief Executive Officer, who also serves
as Chairman of the Board and exercises the principal responsibility for oversight of risk management.
AUDIT COMMITTEE REPORT
The audit committee has (a) reviewed and discussed
the audited financial statements with management, (b) discussed with the independent auditors the matters required to be discussed
by SAS 61 (Statement on Auditing Standards No. 61) and (c) has received the written disclosures and the letter from the independent
accountants required by Independence Standards Board, Standard No. 1 and has discussed with the independent accountants the independent
accountant’s independence.
Based on the foregoing review and discussions,
the audit committee recommended to the Board of Directors that the audited financial statements be included in the Company’s
Annual Report on Form 10-K for the fiscal year ended June 30, 2012.
The members of the audit committee are Messrs.
Charles N. O’Data, Robert J. Janoff and Ronald G. Lehman. Messrs. O’Data, Janoff and Lehman are independent directors,
as defined in the Securities and Exchange Commission Regulations and Nasdaq Market Place Rules.
NOMINATING COMMITTEE
The Board of Directors does not believe it
requires a separate standing nominating committee because the Board of Directors is relatively small and can make the nominations
acting as a whole. The Board does not have a policy with regard to director candidates recommended by stockholders because the
absence of such recommendations makes a formal policy unnecessary. Historically, there usually has not been a need to identify
new nominees in the absence of the resignation or death of an existing director. The remaining directors evaluate a new nominee
based on his integrity, loyalty, competence and experience, and how his background complements that of the remaining directors.
Promoting diversity in the selection of nominees
has not yet been considered. Traditionally, the Board has followed a policy of nondiscrimination and equal opportunity.
COMPENSATION COMMITTEE
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
The Board of Directors does not believe it
requires a separate standing compensation committee because the management, under the authority of the Chairman of the Board and
Chief Executive Officer, is best equipped to make compensation decisions. The Board reserves the right to change this policy at
any time.
Dr. Raymond V. Damadian, who serves as Chairman
of the Board, Chief Executive Officer and President of the Company, participates in deliberation and the determination of executive
officer and director compensation.
VOTE REQUIRED AND BOARD RECOMMENDATION
The directors will be elected by the vote of
a plurality of the votes represented at the meeting. THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR ALL OF THE NOMINEES FOR THE DIRECTORS
OF THE COMPANY.
INFORMATION REGARDING BENEFICIAL OWNERSHIP
OF PRINCIPAL STOCKHOLDERS, DIRECTORS, AND MANAGEMENT
The following table sets forth information
regarding the beneficial ownership of the Company's common shares by the nominees for directors, the Company's Chief Executive
Officer, and the directors and executive officers as a group as of April 26, 2013.
Name and Address of Beneficial Owner (1)
|
|
Shares Beneficially Owned
|
|
Percent of Class
|
Raymond V. Damadian, M.D.
c/o FONAR Corporation Melville, New York Nominee for Director, Director, President, PEO, PFO 5% Stockholder
|
|
|
|
|
|
|
|
|
Common Stock
|
|
|
120,302
|
|
|
|
2.02
|
%
|
Class C Stock
|
|
|
382,447
|
|
|
|
99.98
|
%
|
Class A Preferred
|
|
|
19,093
|
|
|
|
6.09
|
%
|
|
|
|
|
|
|
|
|
|
Claudette Chan
Nominee for Director, Director and Secretary
|
|
|
|
|
|
|
|
|
Common Stock
|
|
|
106
|
*
|
|
|
|
|
Class A Preferred
|
|
|
32
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Robert J. Janoff
Nominee for Director and Director
|
|
|
|
|
|
|
|
|
Common Stock
|
|
|
3,000
|
*
|
|
|
|
|
Class A Preferred
|
|
|
79
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Charles N. O'Data
Nominee for Director and Director
|
|
|
|
|
|
|
|
|
Common Stock
|
|
|
528
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ronald G. Lehman,
Nominee for Director and Director
|
|
|
|
|
|
|
|
|
Common Stock
|
|
|
0
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All Officers, Directors and Nominees as a Group (6 persons)
|
|
|
|
|
|
|
|
|
Common Stock
|
|
|
123,936
|
|
|
|
2.08
|
%
|
Class C Stock
|
|
|
382,447
|
|
|
|
99.98
|
%
|
Class A Preferred
|
|
|
19,204
|
|
|
|
6.13
|
%
|
* Less than one percent
|
|
|
|
|
|
|
|
|
1. Address provided for each beneficial owner
owning more than five percent of the voting securities of the Company.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
See Item 13, “Certain Relationships and
Related Transactions” of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2012 which is
specifically incorporated by reference herein. A copy of the Form 10-K is included in the Annual Report to Stockholders which is
being sent to the Company’s stockholders with this Proxy Statement.)
The Company believes that each of the related
transactions described therein were on terms at least as favorable to the Company as were available from non-affiliated parties.
COMPENSATION DISCUSSION AND ANALYSIS OF DIRECTORS AND EXECUTIVE
OFFICERS
With the exception of the Principal Executive
Officer and Principal Financial Officer, Dr. Raymond V. Damadian, the compensation of the Company’s executive officers is
based on a combination of salary and bonuses based on performance. Decisions concerning compensation are made on a case by case
basis and not pursuant to standardized formulas, programs, policies or criteria. Dr. Damadian, who serves as both the Principal
Executive Officer and Principal Financial Officer, receives compensation which consists only of a salary, which has remained at
modest levels to conserve funds. The Board of Directors does not have a compensation committee and does not believe such a committee
is required, in view of the manner in which compensation matters are handled. Dr. Raymond V. Damadian and Claudette J.V. Chan are
executive officers as well as members of the Board of Directors. Dr. Damadian, who also has voting control of the Company and serves
as Chairman of the Board and President, participates in the determination of executive compensation for the Company’s officers.
As noted above, the Company's compensation
policy is primarily based upon the practice of pay-for-performance. Section 162(m) of the Internal Revenue Code imposes a limitation
on the deductibility of nonperformance-based compensation in excess of $1 million paid to the Principal Executive Officer. No officer
of the Company received compensation in excess of $1 million in fiscal 2012 or in any previous fiscal year. The Board currently
believes that the Company should be able to continue to manage its executive compensation program for others so as to preserve
the related federal income tax deductions.
The Company does not believe that there are
any risks arising from its compensation policies and practices for its employees that are likely to have a material adverse effect
on the Company.
The Company maintains no pension or deferred
compensation plans except for a noncontributory 401(k) plan.
SUMMARY COMPENSATION TABLE
The following table discloses compensation
received for the three years ended June 30, 2012 by the Company’s Principal Executive Officer and Principal Financial Officer.
Name and Principal Position Position
|
|
|
Year
|
|
|
|
Salary
|
|
|
|
Bonus
|
|
|
|
Stock and Option Awards
|
|
|
|
Plans, Pension, Deferred Compensation
|
|
|
|
All Other Compensation
|
|
|
|
Total
|
|
Raymond V. Damadian
|
|
|
2012
|
|
|
$
|
36,111.42
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
$
|
3,6111.42
|
|
Chairman of the Board; President;
|
|
|
2011
|
|
|
|
35,934.29
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
$
|
35,934.29
|
|
Acting Principal Executive Officer; Acting Principal
|
|
|
2010
|
|
|
$
|
57,358.12
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
$
|
57,358.12
|
|
No executive officer has a written or unwritten
employment agreement with the Company. Salaries, bonuses
No executive officer has a written or unwritten
employment agreement with the Company. Salaries, bonuses and discretionary stock and stock option awards comprise the full amount
of total compensation. The only exceptions are commissions, based on a percentage of the sales prices, payable to salesmen.
Compensation Pursuant to Stock Options and SAR Grants
No stock options or stock appreciation rights
were granted to the Company’s Principal Executive Officer and Principal Financial Officer during fiscal 2012.
Option/SAR Exercises and Year End Values
No options or stock appreciation rights were
exercised by the Company’s Chief Executive Officer during fiscal 2012. The Company’s Chief Executive Officer did not
hold any unexercised stock options or stock appreciation rights at the end of fiscal 2012.
DIRECTOR COMPENSATION
The following
table shows the compensation paid to the Directors for fiscal 2012:
Name
|
|
|
Fees earned or paid in cash ($)
|
|
|
|
Stock awards ($)
|
|
|
|
Option awards ($)
|
|
|
|
Non-equity incentive plan compensation ($)
|
|
|
|
Nonqualifed deferred compensation earnings ($)
|
|
|
|
All other compensation ($)
|
|
|
|
Total($)
|
|
(a)
|
|
|
(b)
|
|
|
|
(c)
|
|
|
|
(d)
|
|
|
|
(e)
|
|
|
|
(f)
|
|
|
|
(g)
|
|
|
|
(h)
|
|
A. Claudette J.V. Chan
|
|
$
|
20,000.24
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
$
|
20,000.24
|
|
B. Charles N. O’Data
|
|
$
|
20,000.24
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
$
|
20,000.24
|
|
C. Robert Janoff
|
|
$
|
20,000.24
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
$
|
20,000.24
|
|
D. Ronald G. Lehman
|
|
$
|
20,000.24
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
|
0
|
|
|
$
|
20,000.24
|
|
With the exception of Dr. Damadian who receives
no compensation for serving as a director, each director is entitled to receive $20,000 per annum for his or her services as a
director of the Company, including service on any committee of the Board of Directors. No other fees are paid to the directors
for their services as directors of the Company.
2. ADVISORY VOTE ON COMPENSATION OF THE
COMPANY’S NAMED EXECUTIVE OFFICERS
The following proposal provides the Company’s
stockholders with an opportunity to vote to approve, on an advisory basis, the compensation of the Company’s named executive
officers, as disclosed in this proxy statement. In considering your vote, you may wish to review with care the “Compensation
Discussion and Analysis” section beginning on page 9, which provides details as to the Company’s compensation policies,
procedures and decisions, as well as the Summary Compensation Table and other related compensation tables, notes and narrative
disclosures under the executive compensation section of this proxy statement. This vote is not intended to address any specific
element of the Company’s executive compensation program, but rather the overall compensation program for the Company’s
named executive officers.
In accordance with Section 14A of the Securities
Exchange Act of 1934, we are asking stockholders to approve the following advisory resolution at the Annual Meeting of Stockholders:
RESOLVED, that the stockholders of Fonar Corporation
(the “Corporation”) approve, on an advisory basis, the overall compensation of the Corporation’s named executive
officers disclosed in the Compensation Discussion and Analysis, Summary Compensation Table and related compensation tables, notes
and narrative discussion in this Proxy Statement for the Annual Meeting of Stockholders.
The Board of Directors recommends a vote FOR
this resolution because it believes that the policies and practices described in the Compensation Discussion and Analysis are effective
in achieving the Company’s goals of rewarding sustained financial and operating performance and leadership excellence and
aligning the executives’ long-term interests with those of the stockholders, as well as motivating the executives to remain
with the Company for long and productive careers.
This advisory resolution, commonly referred
to as a “say-on-pay” resolution, is non-binding on the Board of Directors. Although non-binding, the Board will review
and consider the voting results when evaluating our executive compensation program.
3. ADVISORY VOTE ON FREQUENCY OF AN ADVISORY
VOTE ON COMPENSATION OF THE COMPANY’S NAMED EXECUTIVE OFFICERS
The following proposal provides the Company’s
stockholders with an opportunity to vote, on an advisory basis, on the frequency of the stockholders’ advisory vote on the
compensation of the Company’s named executive officers. On the proxy card, stockholders will be able to select one of four
options for this proposal: one year; two years; three years; or abstain. Section 14A of the Securities Exchange Act requires the
Company to hold at least once every six years this advisory stockholder vote on the frequency of the stockholders’ advisory
vote on executive compensation.
After careful consideration of this proposal,
the Company’s Board of Directors recommends at this time that an advisory vote on executive compensation occur each year.
The Board believes that holding the advisory vote annually will provide Management and the Board with more frequent stockholder
feedback on compensation disclosures. You are not voting to approve or disapprove the Board of Directors’ recommendation
for an annual vote. Rather, you are being asked to select the frequency of advisory stockholder votes on executive compensation
that is preferable to you.
The Board of Directors will review and take
the voting results of this proposal into account in making a determination concerning the frequency of future advisory votes on
executive compensation. However, this advisory vote is not binding upon the Board of the Company and the Board may decide in the
future to conduct the advisory vote on executive compensation on a less frequent basis.
Recommendation of the Board
The Board of Directors recommends at this time
that stockholders vote to conduct future advisory votes on the compensation of the Company’s named executive officers EVERY
YEAR.
4. RATIFICATION OF SELECTION OF AUDITORS
The Board of Directors selected Marcum LLP,
as the Company's independent auditors for the fiscal year ending June 30, 2013. The stockholders will be asked to ratify this action
by the Board. Marcum LLP were the Company’s auditors for the fiscal years ended June 30, 2010, June 30, 2011 and June 30,
2012.
One or more representatives of Marcum LLP,
are expected to be present at the Meeting with the opportunity to make a statement if they desire to do so, and to be available
to respond to appropriate questions.
The affirmative vote of shares holding a majority
of the votes represented at the meeting is required to ratify the selection of auditors by the Board of Directors. THE BOARD OF
DIRECTORS RECOMMENDS A VOTE FOR THE PROPOSAL.
AUDIT FEES
The aggregate fees billed by Marcum LLP for
the audit of the Company’s annual financial statements for the fiscal year ended June 30, 2012 and the reviews of the financial
statements included in the Company’s Forms 10-Q for the fiscal year ended June 30, 2012 were $446,417.
The aggregate fees billed by Marcum LLP for
the audit of the Company’s annual financial statements for the fiscal year ended June 30, 2011, and the reviews of the financial
statements included in the Company’s Forms 10-Q for the fiscal year ended June 30, 2011 were $448,482.
All work on the audits in each of the last
two fiscal years was performed by full-time permanent employees of Marcum LLP.
AUDIT-RELATED FEES
No audit-related fees were billed by Marcum
LLP for the fiscal years ended June 30, 2012 and June 30, 2011 for services related to the audit or review of our financial statements
that are not included under the caption “AUDIT FEES”.
TAX FEES
The aggregate
fees billed by Marcum LLP for tax compliance, tax advice and tax planning in the fiscal years ended June 30, 2012 and June 30,
2011 were $93,017 and $106,107, respectively.
ALL OTHER FEES
The aggregate fees billed by Marcum LLP for
all other services rendered by them during the fiscal years ended June 30, 2012 and June 30, 2011 were $7,597 and $63,138, respectively,
which included services in connection with the registration of securities, employee benefit plans and reviews and procedures that
we requested Marcum LLP to undertake to provide assurances on matters not required by laws or regulations.
No fees were billed by Marcum LLP for the fiscal
years ended June 30, 2012 or June 30, 2011 for designing, operating, supervising or implementing any of our financial information
systems or any hardware or software systems for our financial information.
Since January 1, 2003, the audit committee
has adopted policies and procedures for pre-approving all non-audit work performed by its auditors. Specifically, the committee
must pre-approve the use of the auditors for all such services. The audit committee has pre-approved all non-audit work since that
time and in making its determination has considered whether the provision of such services was compatible with the independence
of the auditors.
The Company’s audit committee believes
that the provision by Marcum LLP of services in addition to audit services in fiscal 2012 and 2011 were compatible with maintaining
their independence. The services to be performed are presented by Marcum LLP to the committee or its chairman. The matter is then
evaluated and a decision made.
PROPOSALS OF STOCKHOLDERS
Proposals of stockholders intended to be presented
at next year’s annual meeting of stockholders must be received by the Company no later than January 15, 2014 to be included
in the Company's proxy statement and form of proxy related to that meeting.
SOLICITATION OF PROXIES
The proxy accompanying this proxy statement
is solicited by the Board of Directors of the Company. Proxies may be solicited by officers, directors, and regular supervisory
and executive employees of the Company, none of whom will receive any additional compensation for their services. Such solicitations
may be made personally, or by mail, e-mail, facsimile, telephone, telegraph, or messenger. The Company will pay persons holding
shares of stock in their names or in the names of nominees, but not owning such shares beneficially, such as brokerage houses,
banks, and other fiduciaries, for the expense of forwarding solicitation materials to their principals. All of the costs of solicitation
of proxies will be paid by the Company.
VOTING TABULATION
The election of the Company's directors requires
a plurality of the votes represented in person or by proxy at the meeting. The ratification of proposals and the selection of auditors
requires the affirmative vote of a majority of the votes represented in person or by proxy at the meeting. Votes cast by proxy
or in person at the meeting will be tabulated by the Company.
A stockholder who abstains from voting on any
or all proposals will be included in the number of shareholders present at the meeting for the purpose of determining the presence
of a quorum. Abstentions will not be counted either in favor of or against the election of the nominees or other proposals. Under
the rules of the National Association of Securities Dealers, brokers holding stock for the accounts of their clients who have not
been given specific voting instructions as to a matter by their clients in certain cases may vote their clients' proxies in their
own discretion. Where a proposal requires a majority of the votes present for its passage, an abstention or broker non-vote will
have the same effect as a negative vote.
OTHER MATTERS
The Board of Directors does not intend to bring
any other business before the meeting, and so far as is known to the Board, no matters are to be brought before the meeting except
as specified in the notice of the meeting. However, as to any other business which may properly come before the meeting, it is
intended that proxies, in the form enclosed, will be voted in respect thereof in accordance with the judgment of the persons voting
such proxies, where the authorization to do so has been granted.
DATED: Melville, New York, May 15, 2013
A COPY OF THE COMPANY'S FORM 10-K REPORT
FOR FISCAL YEAR 2012, CONTAINING INFORMATION ON OPERATIONS, FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, IS AVAILABLE UPON
REQUEST. PLEASE WRITE TO:
INVESTOR RELATIONS DEPARTMENT
FONAR CORPORATION
110 MARCUS DRIVE
MELVILLE, NEW YORK 11747
*** Exercise Your
Right
to Vote ***
Important Notice Regarding the
Availability of Proxy Materials for the
Shareholder Meeting to Be Held
on (date).
FONAR CORPORATION
|
Meeting Information
Meeting Type:
Annual Meeting
For holders as of:
April 26, 2013
Date:
June 24, 2013
Time: 10:00 AM EDT
Location:
Double Tree Hotel
Wilmington Downtown
700 King Street
Wilmington Delaware 19801
|
FONAR CORPORATION
110 MARCUS DRIVE
MELVILLE, NY 11747
|
You are receiving this communication because
you hold shares in the above named company.
This is not a ballot. You cannot use this
notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are
available to you on the Internet. You may view the proxy materials online at ww.proxyvote.com or easily request a paper
copy (see reverse side).
We encourage you to access and review all
of the important information contained in the proxy materials before voting.
|
|
See the reverse side of this notice to obtain proxy materials and voting instructions.
|
--- Before You Vote ---
How to Access the Proxy Materials
Proxy Materials Available to VIEW or RECEIVE:
1. Annual Report 2. Notice & Proxy Statement
How to View Online:
Have the information that is printed in the box marked
by the arrow
¢
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
(located on the following page) and visit: www.proxyvote.com.
How to Request and Receive a PAPER or E-MAIL Copy:
If you want to receive a paper or e-mail copy of
these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to
make your request:
1) BY INTERNET: www.proxyvote.com
2) BY TELEPHONE: 1-800-579-1639
3) BY E-MAIL*: sendmaterial@proxyvote.com
* If requesting materials by e-mail, please send
a blank e-mail with the information that is printed in the box marked by the arrow
¢
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
(located on the following page) in the
subject line.
|
--How to
Vote –
Please Choose One of the Following Voting Methods
|
Vote In Person:
Many shareholder meetings
have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity
holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting,
you will need to request a ballot to vote these shares.
Vote By Internet:
To vote now by Internet,
go to www.proxyvote.com. Have the information that is printed in the box marked by the arrow
¢
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
available and follow the instructions.
Vote By Mail:
You can vote by mail by requesting
a paper copy of the materials, which will include a proxy card.
|
Voting Items
The Board of Directors recommends you vote FOR the
following:
1. Election of Directors
Nominees
01 Raymond V. Damadian
|
02 Claudette J. V. Chan
|
03 Robert J. Janoff
|
04 Charles N. O'Data
|
05 Ronald G. Lehman
|
The Board of Directors recommends you vote FOR proposal
2.
2. To approve, by non-binding vote, executive compensation.
The Board of Directors recommends you vote FOR 1 YEAR
on the following proposal:
3. To recommend, by non-binding vote, the frequency of
executive compensation votes.
The Board of Directors recommends you vote FOR proposals
4 and 5.
4. To ratify the selection of Marcum LLP as the Company's
independent auditors for the fiscal year ended June 30, 2013.
5. In their discretion, the Proxies are authorized to
vote upon such other business as may properly come before the meeting.
FORM
OF PROXY
FONAR CORPORATION
119 MARCUS DRIVE
MELVILLE, NY 11747
Investor Address Line 1
Investor Address Line 2
Investor Address Line 3
Investor Address Line 4
Investor Address Line 5
John Sample
1234 ANYWHERE STREET
ANY CITY, ON A1A 1A1
|
VOTE BY INTERNET – WWW.PROXYVOTE.COM
Use the Internet to transmit your
voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time the day before the cut-off date
or meeting date. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and
to create an electronic voting instruction form.
ELECTRONIC DELIVERY OF FUTURE PROXY
MATERIALS
If you would like to reduce the costs
incurred by our company in mailing proxy materials, you can consent to receiving all future proxy statements, proxy cards and annual
reports electronically via e-mail or the Internet. To sign up for electronic delivery, please follow the instructions above to
vote using the Internet and, when prompted, indicate that you agree to receive or access proxy materials electronically in future
years.
VOTE BY PHONE - 1-800-690-6903
Use any touch-tone telephone to transmit
your voting instructions up until 11:59 P.M. Eastern Time the day before the cut-off date or meeting date. Have your proxy card
in hand when you call and then follow the instructions.
VOTE BY MAIL
Mark, sign and date your proxy card
and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood,
NY 11717.
|
TO VOTE, MARK BLOCKS IN BLUE OR BLACK INK AS FOLLOWS
|
KEEPTHIS PORTION FOR YOUR RECORDS
|
|
DETACH AND RETURN THIS PORTION ONLY
|
THIS PROXY CARD IS VALID ONLY
WHEN SIGNED AND DATED
The Board of Directors recommends you vote
The Board of Directors recommends you vote FOR the following:
|
|
For All
|
Withhold All
|
For All Except
|
To
withhold authority to vote for any individual nominee(s), mark “For All Except” and write the number(s) of the
nominee(s) on the line below.
|
|
|
1. Election of Directors
Nominees
01 Raymond V. Damadian
|
02 Claudette J. V. Chan
|
03 Robert J. Janoff
|
04 Charles N. O'Data
|
05 Ronald G. Lehman
|
The Board of Directors recommends you vote FOR proposal
2.
|
|
|
|
|
2 To approve, by non-binding vote, executive compensation.
|
|
For
|
Against
|
Abstain
|
The Board of Directors recommends you vote FOR 1 YEAR on
the following proposal:
|
|
|
|
|
3 To recommend, by non-binding vote, the frequency
of executive compensation votes
.
|
1
year
|
2
years
|
3
years
|
Abstain
|
The Board of Directors recommends you vote FOR proposals
4 and 5.
|
|
|
|
|
4 To ratify the selection of Marcum LLP as the Company's independent
auditors for the fiscal year ended June 30, 2013.
|
|
For
|
Against
|
Abstain
|
5 In their discretion, the Proxies are authorized
to vote upon such other business as may properly come before the meeting.
|
|
For
|
Against
|
Abstain
|
Please sign exactly as your name(s) appear(s) hereon. When
signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign
personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name, by authorized
officer.
|
Investor Address Line 1
Investor Address Line 2
Investor Address Line 3
Investor Address Line 4
Investor Address Line 5
John Sample
1234 ANYWHERE STREET
ANY CITY, ON A1A 1A1
|
Signature (PLEASE SIGN WITHIN BOX)
|
Signature (Join Owners)
|
|
SHARES
CUSIP #
SEQUENCE #
|
Important Notice Regarding the Availability of Proxy
Materials for the Annual Meeting: The Annual Report, Notice & Proxy Statement is/are available at www.proxyvote.com .
FONAR CORPORATION
Annual Meeting of Stockholders
June 24, 2013 10:00 AM
This proxy is solicited by the
Board of Directors
The undersigned, a stockholder of Fonar Corporation (the
"Company"), hereby revoking any proxy heretofore given, does hereby appoint Raymond V. Damadian, Ronald G. Lehman, Luciano
Bonanni, Kurt Reimann, Daniel Culver and Ellen Yeske, and each of them, proxies with full power of substitution, for and in the
name of the undersigned to attend the Annual Meeting of the Stockholders of the Company to be held at the Double Tree Hotel, Wilmington
Downtown, 700 King Street, Wilmington, Delaware on June 24, 2013 at 10:00 a.m., local time, and at any adjournment(s) thereof,
and there to vote upon all matters specified in the notice of said meeting, as set forth herein, and upon such other business as
may properly and lawfully come before the meeting, all shares of stock of the Company which the undersigned would be entitled to
vote if personally present at said meeting.
THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED IN THE
MANNER DIRECTED HEREIN BY THE UNDERSIGNED STOCKHOLDER. IF NO DIRECTION IS GIVEN, SUCH SHARES WILL BE VOTED FOR PROPOSALS ONE THROUGH
THREE.
Continued and to be signed on
reverse side
ANNUAL REPORT
FONAR PRESIDENT’S
LETTER TO SHAREHOLDERS
May 2013
Dear Shareholders:
I am pleased to report to our shareholders
that business for FONAR is robust and healthy. Our prospects for the future are perhaps even more promising. Fiscal 2012 was an
outstanding year where we reported record profits from operations, net income doubling over the prior year and revenues advancing
at a healthy 19%. Indeed, the difficulties we faced due to the 2008 banking fiasco are now long behind us.
Fiscal 2013 promises to be even better.
At the conclusion of our second fiscal quarter at December 31, 2012, FONAR had 12 straight quarters of net income from operations
and most impressive the past six quarters each showed profitability greater than $1.5 million.
Our financial highlights include that
FONAR has earned $0.91 during fiscal 2012 and $0.43 for the first six months of fiscal 2013 of diluted net income per common share
available to common stockholders.
The Company stock, which is listed on
the NASDAQ Capital Markets under the symbol FONR, has had substantial interest by institutions. In fact, institutional ownership
for the company has grown from 3% at December 31, 2011 to over 21% one year later. This is a seven-fold increase in just one year!
This may be a contributing reason why the stock price has continued to move up.
I am very pleased with these results.
Our Company has always had great promise for its investors but now it has been achieving long sought goals.
A Brief Overview of FONAR
FONAR is the Original MRI Company –
the first-ever to produce an MRI scanner. With great pride, we call ourselves the inventor of the MRI scanner. We incorporated
in 1978 and introduced the first commercial MRI scanner (the QED 80) in 1980. We have installed nearly 300 recumbent-OPEN MRIs
and 150 FONAR UPRIGHT® Multi-Position™ MRIs in 29 states, Puerto Rico, and eleven foreign countries. The company, headquartered
on Long Island, New York, became a publicly traded company in 1981.
Our primary product is the FONAR UPRIGHT®
Multi-Position™ MRI (also known as the STAND-UP® MRI), the only whole-body MRI that performs Position™ Imaging
(pMRI™) and scans patients in numerous weight-bearing positions, i.e. standing, sitting, bending, in flexion and extension,
as well as the conventional lie-down position. The FONAR UPRIGHT® Multi-Position™ MRI often detects patients’ problems
that lie-down MRIs can’t.
Only the FONAR UPRIGHT® Multi-Position™
MRI Offers a Nearly Perfect Patient Experience
The FONAR UPRIGHT® Multi-Position™
MRI has a near-zero claustrophobic rejection rate by patients. Approximately 85% of patients are scanned sitting while they watch
a 42” flat-screen TV. It is not unusual for patients in need of an MRI scan to drive long distances to the nearest Upright®
MRI in order to avoid being scanned in one of our competitor’s highly claustrophobic “tube” or “tunnel”
MRIs. This alone is a major reason for the success of this scanner over the conventional recumbent-only MRI technology, but there
is much more to offer medically.
FONAR Plan to Cut Costs and Focus
on Revenue Producing Segments
FONAR has been able to withstand the
difficult era of the banking calamity by making some deep cost-saving cuts and by redirecting its resources to two of its main
divisions – the Field Service Division and the company’s MRI facility management subsidiary, Health Management Corporation
of America (HMCA). Together they have provided a regular, predictable stream of income, with HMCA, in particular, experiencing
steady growth from one year to the next.
The key to HMCA’s success is that
nearly every one of the diagnostic imaging centers it manages is equipped with the FONAR UPRIGHT® Multi-Position™ MRI,
also known as the STAND-UP® MRI. The clinical importance of Position-of-Symptoms MRI and Weight-Bearing MRI has been steadily
gaining momentum in the medical community. And, of course, the extraordinarily spacious, “non-claustrophobic”, patient
environment of the scanner has enormous appeal among patients everywhere. HMCA-managed MRI facilities completed roughly 30,000
MRI scans in 2009; 36,000 MRI scans in 2010; 41,000 in 2011; and 45,000 in 2012.
Key Acquisition Leads to An Estimated
Increase of Patient Throughput by 250%
On March 5 of this year, FONAR and its
subsidiary HMCA acquired a majority interest (50.5%) in a newly formed limited liability company, Health Diagnostics Management
(HDM). Prior to the acquisition, HMCA was managing 11 STAND-UP® MRI diagnostic centers – 8 in New York and 3 in Florida,
collectively completing 45,000 scans in 2012. In one giant step, HMCA grew by fourteen (14) MRI facilities under HMCA management
- 10 in New York and 4 in Florida, 12 of them equipped with STAND-UP® MRIs. Those 14 centers completed 68,000 MRI scans in
2012. Together the two groups of centers completed 113,000 scans in 2012, a strong indicator of the patient throughput run rate
that is expected for HMCA going forward.
Of course, I am delighted with this acquisition.
By combining the resources of HMCA and HDM, we will enjoy the benefits of 1) economies of scale, 2) shared administrative and technical
expertise and capabilities, and 3) joint marketing strategies. HMCA’s 11 STAND-UP® MRIs together with HDM’s 12
form a network of 23 STAND-UP® MRIs, the largest in the world.
But we’re not finished growing.
We will continue to pursue additional management contracts, primarily in New York and Florida. A new HMCA-managed center is expected
to open in New York by the end of the year.
FONAR UPRIGHT® MRI Opens a New
Medical Frontier With Cinematography of Upright CSF Flow
The FONAR
UPRIGHT® Multi-Position™ MRI imaging has a new and powerful imaging tool that makes motion pictures of CSF (cerebrospinal
fluid
)
flow as it moves in and out of the vertically positioned brain, i.e. as it flows out
of the lateral ventricles of the vertical weight-bearing brain, down through the Foramen of Monro into the 3rd ventricle, down
the Aqueduct of Sylvius into the 4th ventricle and down the full length of the spinal canal and back up into the vertical weight-bearing
brain. This new vertical position imaging technology, created and introduced by FONAR's UPRIGHT® Multi-Position™ MRI,
opens a new frontier in clinical medicine.
This cinematography of CSF flow in the
Upright position, in and out of the brain, has proven uniquely sensitive to the visualization of any impairments of CSF flow, often
indicating the etiology of cervical anatomy dislocation that might be contributing to the symptoms of the patient.
In football, for example, "U.S.-style
football sends more athletes to emergency rooms for neck injuries than ice hockey or soccer according to a new study" (WebMD,
Health News
, April 20, 2005). For the period 1990 to 1999, "there were an estimated 5,038 neck injuries from ice hockey,
19,341 from soccer, and 114,706 from American football." "The rates for total neck injuries and combined neck contusions,
sprains or strains were higher for (American) football than for ice hockey, or soccer in all years for which data were available"
(
Br. J. Sports Med
. 2005;39:189).
Recognizing that such neck injuries may
result in obstructions of the normal vertical cerebrospinal fluid (CSF) flow from the brain down the spinal column to the sacrum
and back into the brain, it is critical that symptomatic professional athletes, football players, in particular, have FONAR UPRIGHT®
Multi-Position™ MRI examinations of their head and neck and vertical cerebrospinal fluid (CSF) flow cinematography of the
cranio-cervical junction and cervical spine to assure that CSF is flowing up and down the spinal column normally and that there
are no obstructions to flow.
Normal Pressure Hydrocephalus (NPH)
and Ventriculomegaly
Cinematography of CSF flow allows visualization
of a neurologic syndrome called normal pressure hydrocephalus (NPH). It is determined when a measurement by lumbar puncture of
CSF pressure in the lumbar spinal canal is found to be normal. It is determined to be hydrocephalus when the ventriculomegaly is
observed on an MRI. However, this is a quandary. What explains the coexistence of these two diametrically opposed conditions? If
there is no measured increase in intracranial pressure (ICP), what accounts for the observed vertriculomegaly? Among the proposed
explanations for the normal measured pressure of NPH is the possibility that the CSF pressure measurement in the lumbar canal is
being obtained below a higher-up obstruction in the spinal canal (e.g. a cervical CSF flow obstruction) and is not therefore elevated,
while the CSF pressure above the obstruction (e.g. in the brain) is elevated but not readily measured. This dilemma is now addressable
by FONAR’s new UPRIGHT® CSF flow ciné technology, which can readily image the integrity of CSF flow throughout
the full length of the spinal canal and quantify it. Thus the CSF flow obstructions causing the ICP (intracranial pressure) increases
responsible for the hydrocephic ventriculomegalies can now be directly visualized so they can be therapeutically addressed surgically
or non-surgically.
A common current treatment of NPH is
the VP (Ventriculo-Peritoneal) shunt. While such shunts are effective in relieving many of the dire symptoms of NPH, their current
difficulty is their tendency to become obstructed within two years of installation (50%). This difficulty is addressable by the
FONAR UPRIGHT® Multi-Position™ MRI, since the vertical CSF flows of these VP shunts can now be visualized and monitored
by FONAR's UPRIGHT® Multi-Position™ CSF video technology, to enable a shunt maintenance program. Signs of any shunt flow
impairment can now be detected as soon as they occur, to assure that VP shunt flow is being optimally maintained.
A Case-Control Study of Cerebellar
Tonsillar Ectopia [Chiari] and Head/Neck Trauma [Whiplash]
We reported in July 2010 that the medical
journal “Brain Injury” published a significant study of 1200 neck pain patients comparing the FONAR UPRIGHT® Multi-Position™
MRI to a conventional recumbent MRI and the ability to diagnose whiplash trauma from a motor vehicle accident. Four groups, including
two control groups, were used and the reading radiologists were blinded as to who belonged to which group. Recumbent MRI images
were obtained in a conventional recumbent MRI and the upright images were obtained in the FONAR UPRIGHT® Multi-Position™
MRI aka The STAND-UP® MRI. The “Brain Injury” study showed that the fallen cerebellar tonsils (CTE) caused by motor
vehicle whiplash injuries were being missed 60% of the time where the patient was scanned recumbent-only in a conventional “lie-down
MRI” and not scanned upright. As a result of this study, the medical evidence indicated that the fallen cerebellar tonsils
of a whiplash injury patient can now be reliably visualized by using the FONAR UPRIGHT® Multi-Position™ MRI. I believe
that this study adds significant substance to the proposal that this needs to be the "new standard of care" for whiplash
injury patients.
Breakthrough in the Diagnoses of
Multiple Sclerosis
In February 2011, I scanned a patient
who had multiple sclerosis (MS). So I scanned her head and neck including CSF Flow studies in the Upright and recumbent positions.
I noticed that her MS lesions seemed to be directly connected to the CSF in the adjacent brain ventricles. I reviewed the literature
and then scanned seven other patients with MS. The first important observation was that all eight MS patients who were scanned,
as they arrived with no patient selectivity of any kind having been exercised, had prior histories of serious trauma to the neck.
On September 20, 2011, I and co-author,
FONAR scientist David Chu, PhD., published a paper titled “The Possible Role of Cranio-Cervical Trauma and Abnormal CSF Hydrodynamics
in the Genesis of Multiple Sclerosis," in the journal
Physiological Chemistry and Physics and Medical NMR
(Sept. 20,
2011, 41: 1-17).
We reported a possible breakthrough in
the etiology of multiple sclerosis (MS) based on observations of those eight patients and our unique UPRIGHT® Multi-Position™
(STAND-UP®) MRI. The findings revealed that the cause of multiple sclerosis may be biomechanical and related to earlier trauma
to the neck, which resulted in the obstruction of the flow of cerebrospinal fluid (CSF) produced in the central anatomic structures
of the brain known as the ventricles. Since the ventricles produce a large volume of CSF each day (500 cc), an obstruction can
result in increases in intracranial pressure (ICP) which in turn can result in leakage of the CSF into the surrounding brain tissue.
Since the CSF contains approximately 300 polypeptides, 9 of which are antigenic and could be the sources of the antigens known
to stimulate the auto-immune reaction (antigen-antibody complexing) responsible for generating the MS lesions seen in the MRIs
of the brain of MS patients.
The complete study in which the diagnostic
breakthrough was reported can be viewed at www.fonar.com/pdf/PCP41_damadian.pdf. To be found at www.fonar.com are images related
to the study.
Most
recently there is a published report (Magnano C., et al., "Cine Cerebrospinal Fluid Imaging in Multiple Sclerosis",
J.
Magn. Reson. Imaging
2012 Oct;36(4):825-34. doi: 10.1002/jmri. 23730. Epub 2012 Jun 25)
corroborating
our findings of the presence of CSF flow obstructions in MS patients. In their study of 67 MS patients, the authors reported significant
obstruction of CSF flow in the Aqueduct of Sylvius in 67 MS patients as well as the simultaneous heightening of CSF flow during
systole in these patients. In addition, there is also a newly published report of results that appears to confirm CSF "leakages"
as playing a significant role in the genesis of multiple sclerosis. As we had pointed out, the study reports a generalized increase
in the sodium content of the brain tissues of patients with multiple sclerosis (
Radiology
, July 17, 2012). This finding
would be consistent with the CSF "leakages" seen in MS and reported in
Physiol. Chem. Phys. & Med. NMR
, Sept.
20, 2011, 41: pp 1-17. The significant sodium content of "leaked" CSF (140mm/L) is likely to be the source of the elevated
sodium content that was observed in the brain tissues of the multiple sclerosis patients studied.
An Advancement of Image Guided Therapy
We used the UPRIGHT® MRI to view
the flow of cerebrospinal fluid in and out of the brain with the patients scanned Upright and also scanned lying down. The UPRIGHT®
MRI also revealed that these obstructions were the result of structural deformities of the cervical spine, induced by trauma earlier
in life. The findings are based on viewing the real-time flow of cerebrospinal fluid in a series of the eight randomly chosen patients
with multiple sclerosis. These invaluable dual observations have only been possible since the invention by FONAR of an MRI capable
of imaging the patient Upright.
One of the eight MS patients in the
study was treated by Dr. Scott Rosa, DC, BCAO, Trauma Imaging Foundation, Rock Hill, NY using his image guided (UPRIGHT® MRI),
patented, proprietary, non-invasive method. Her symptoms subsided. FONAR reported on the case study on November 2, 2011. It appears
that the biomechanical barriers seen on her images, i.e. cerebellar tonsillar ectopia (CTE), were responsible for the significant
CSF "leakages" visualized on her brain MRIs. The observed CSF "leakages" were directly connected to her MRI
visualized MS lesions, suggesting the possibility that the CSF "leakages" were playing a role in generating her MS lesions
.
Dr. Rosa eliminated the biomechanical barrier which allowed CSF to flow freely, and subsequently the patient’s symptoms subsided.
The patient is currently being maintained free of MS symptoms (vertigo and vomiting on recumbency) with continued care.
Accordingly, in the minds of the researchers
who performed the vertical position examinations of these MS patients, there now exists a genuine hope that if MS patients can
have their vertical position CSF flow and intracranial pressure (ICP) monitored and restored to normal, there is the prospect that
these multiple sclerosis patients can be improved.
It is exciting that our FONAR UPRIGHT®
MRI may now be responsible for helping out patients with severe illness and the prospect of being able to deliver these benefits
to the patient non-invasively.
The Cranio-Cervical Syndrome (CCS)
One deficiency of the current universal
MRI scanner protocols for imaging the neck came to our attention in the course of these UPRIGHT® positional studies of patients.
Current MRI protocols of the neck do not provide axial images of the cervical spine above the C2/C3 cervical junction, i.e. axial
cuts of the cranio-cervical junction (CCJ) that visualize the axial positioning of C-1 and C-2. These key axial images of the cranio-cervical
junction are therefore not available for two of the seven vertebra of the cervical spine in a conventional MR scan of the cervical
spine. The FONAR UPRIGHT® Multi-Position™ MRI has therefore added this key cranio-cervical junction (CCJ) scan to its
cervical spine scanning protocol. The C1/C2 junction provides for a 70% rotation of the head and neck while the cerebral C1 junction
only enables a 40% rotation. The C1/C2 rotation of the skull enabled by the rotary stylus or dens, provided by C-2 (the Axis) is
further enabled by the rotation enabling alar and transverse ligaments that are increasingly being recognized as key structures
in cranio-cervical mobility, which when traumatized can result in cervical junction malalignment and the obstruction of CSF flow.
We have named the syndrome resulting from these cervical malalignments the Cranio-Cervical Syndrome (CCS).
This past April 6
th
we held
in Manhattan, Symposium 2013 "The Cranio-Cervical Syndrome (CCS): The Vulnerability of the Human Neck and Its Impact on Cerebrospinal
Fluid (CSF) Flow." Its principal purpose was to bring the existence of this Cranio-Cervical Syndrome and its pandemic dimension
["1.2 million whiplash injuries per year per 315 million U. S. population" - U.S. Census Bureau Jan. 2013: Pub Med Central
(PMC) – National Institutes of Health:
(
www.ncbi.nlm.nih.gov/pmc/articles/pmc2684148
)]
to the attention of the medical community.
The scheduled speakers were myself and:
|
·
|
William G. Bradley, Jr, MD, PhD, FACR, Professor and Chair, Department of Radiology, University
of California San Diego and Author of “Magnetic Resonance Imaging,” Mosby, Principal Textbook of MRI
|
|
·
|
Scott Rosa, DC, BCAO, Executive Director Trauma Imaging Foundation, Chairman of Research, Upper
Cervical Council, Vice President, R. W. Sweat Research Foundation
|
|
·
|
Joseph C. Maroon, MD, FACS, Heindl Scholar, Professor and Vice Chairman, Department of Neurosurgery,
University of Pittsburgh Medical Center, Team Neurosurgeon Pittsburgh Steelers
|
|
·
|
Francis W. Smith, MD, Consultant Radiologist, Grampian University Hospitals NHS Trust, Scotland,
UK
|
|
·
|
Noam Alperin, PhD, VC for Research, Department of Radiology, Miller School of Medicine, University
of Miami
|
|
·
|
And last, but not least, Garo Yepremian, President – The Garo Yepremian Foundation, 2 - Time
NFL Super Bowl Champion with the Miami Dolphins
|
|
·
|
In addition, an unscheduled guest presented. Joel I. Franck, MD, Neurosurgery, Bay Neurosurgical
& Spinal Institute, reported to have treated, often surgically, approximately 50 patients with Cranio-Cervical Syndrome.
|
Symposium 2013 was recorded by video
and audio. Soon the conference will be able to be accessed on the Internet for the benefit of the medical community and its patients.
UPRIGHT® Multi-Position™
MRI Sales and Installations
The Company continues to market its FONAR
UPRIGHT® Multi-Position™ MRI. One scanner sale that occurred in August of last year has now been installed in Texarkana,
TX. Other installations during the past year occurred in Milwaukee, WI and Hagerstown, MD. Soon, installations in London, UK, St.
Louis, MO, and Wantagh, NY will be completed.
I am committed to seeing to it that the
advantages of this new FONAR UPRIGHT® technology be brought to the benefit of as many persons in need of it, as quickly as
possible.
Conclusion
A result of FONAR's multiple sclerosis
findings and the new understanding of the role that cervical trauma plays in the etiology of disease, it is imperative to certify
that the sustained neck or head injuries of professional athletes such as NFL football players, whiplash patients and others with
severe neck trauma, have not resulted in any obstructions of CSF flow or heightened ICP, which would eventually lead to the symptomatology
we have reported as related to the Cranio-Cervical Syndrome. This in turn will lead to a resurgence of FONAR UPRIGHT® Multi-Position™
MRI sales.
In conclusion, the FONAR UPRIGHT®
Multi-Position™ MRI is a truly unique technology producing exquisite images in all positions of the body. Therefore, in addition
to providing all the routine scans of the conventional lie-down-only MRI, it not only yields a whole new treasure of new medical
applications in such calamitous medical categories as multiple sclerosis, and other dementia, but it also possesses the strong
potential to provide fresh new insights into the debilitating chronic consequences of sports injuries, the current epidemic of
automobile whiplash injuries (approximately 1 million/year in the U.S.), low back injuries, pediatric disabilities and pathologies
in need of pediatric imaging, and many more yet to be unearthed.
The Company has installed 157 UPRIGHT®
Multi-Position™ MRI scanners and they have performed approximately 2.75 million UPRIGHT® MRI scans. We continue to help
thousands upon thousands of patients across the country, even across the globe, with the extraordinary diagnostic power and unmatched
comfort of the FONAR UPRIGHT®, Weight-Bearing, Multi-Position™ MRI. Behind the scenes we have maintained our product
for our users, improved it, and discovered exciting new applications that only our product can provide.
I remain grateful to our stockholders,
customers and employees for their loyal support.
Sincerely,
Raymond V. Damadian
President and Chairman
SECURITIES AND EXCHANGE
COMMISSION WASHINGTON, D.C. 20549
_____________________
FORM 10-K/A
_____________________
[X] ANNUAL REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [Fee
Required]
For the fiscal year ended
June 30, 2012
OR
[ ] TRANSITION REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES AND EXCHANGE
ACT OF 1934 [No Fee Required]
For the transition period
from _____________ to _____________
Commission File No.
0-10248
___________________________
FONAR
CORPORATION
(Exact name of registrant
as specified in its charter)
DELAWARE
|
|
11-2464137
|
(State of
incorporation)
|
|
(IRS Employer
Identification
Number)
|
110 Marcus Drive,
Melville, New York
|
|
11747
|
Address of principal
executive
offices)
|
|
(Zip
Code)
|
(631)
694-2929
|
(Registrant's
telephone number, including area code)
|
____________________________________________________
Securities registered
pursuant to Section 12(b) of the Act:
Common Stock, par value
$.0001 per share
Securities registered
pursuant to Section 12(g) of the Act:
None
________________________________________________________________
Indicate by check mark if
the registrant is a well-known seasoned issuer, as defined in Rule 405 of the
Securities Act. Yes ___ No _X_
Indicate by check mark if
the registrant is not required to file reports pursuant to Section 13 or Section
15(d) of the Act. Yes ___ No _X_
Indicate by check mark
whether the registrant (1) has filed all reports required to be filed by Section
13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90
days. Yes _X_ No ___
Indicate by check mark
whether the registrant (1) has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this
chapter) during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such files).
Yes __X___ No
____
Indicate by check mark if
disclosure of delinquent filers, pursuant to Item 405 of Regulation S-K,
§229.405 of this Chapter, is not contained, and will not be contained, to the
best of the registrant’s knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this 10-K or any amendment
to the Form 10-K. [X]
Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See definitions of “large
accelerated filer”, “accelerated filer and “smaller reporting company” in Rule
12b-2 of the Exchange Act. (Check one):
Large accelerated filer
___ Accelerated filer ____ Non-accelerated filer ____ Smaller reporting company
_X_
(Do not check if a smaller
reporting company)
Indicate by check mark
whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act).
Yes ___ No _X_
The aggregate market value
of the shares of Common Stock held by non-affiliates as of December 31, 2011
based on the closing price of $1.70 per share on such date as reported on the
NASDAQ System, was approximately $9.6 million. The other outstanding classes do
not have a readily determinable market value.
As of September 6, 2012,
5,901,262 shares of Common Stock, 158 shares of Class B Common Stock, 382,513
shares of Class C Common Stock and 313,438 shares of Class A Non-voting
Preferred Stock of the registrant were outstanding.
DOCUMENTS INCORPORATED BY
REFERENCE
None
FONAR CORPORATION AND
SUBSIDIARIES
DOCUMENTS INCORPORATED BY
REFERENCE
None
REASON
FOR AMENDMENT: Adding XBRL Files
PART I
ITEM 1.
BUSINESS
GENERAL
Fonar Corporation,
sometimes referred to as the "Company" or "Fonar", is a Delaware corporation
which was incorporated on July 17, 1978. Our address is 110 Marcus Drive,
Melville, New York 11747 and our telephone number is 631-694-2929. Fonar also
maintains a WEB site at www.fonar.com. Fonar provides copies of its filings with
the Securities and Exchange Commission on Forms 10-K, 10-Q and 8-K and
amendments to these reports to stockholders on request.
We conduct our business in
two segments. Our medical equipment segment is conducted directly through Fonar.
Our physician management and diagnostic services segment is conducted through
our subsidiary Health Management Corporation of America, which has assigned its
assets and liabilities for a controlling interest in a limited liability
company, Imperial Management Services, LLC. This new entity includes outside
investors.
MEDICAL EQUIPMENT
SEGMENT
Fonar is engaged in the
business of designing, manufacturing, selling and servicing magnetic resonance
imaging, also referred to as "MRI" or "MR" scanners, which utilize MRI
technology for the detection and diagnosis of human disease, abnormalities,
other medical conditions and injuries. Fonar’s founders built the first scanner
in 1977 and Fonar introduced the first commercial MRI scanner in 1980. Fonar is
also the originator of the iron-core non-superconductive and permanent magnet
technology.
Fonar’s iron frame
technology made Fonar the originator of "open" MRI scanners. We introduced the
first "open" MRI in 1980. Since that time we have concentrated on further
application of our “open” MRI, introducing most recently the Upright®
Multi-Position™” MRI scanner (also referred to as the “Upright®” or “Stand-Up®”
MRI scanner) and the Fonar 360™ MRI scanner.
The product we are now
most vigorously promoting is our Upright® MRI. Our patented Upright® MRI is
unique in the industry in that it allows patients to be scanned in fully
weight-bearing conditions, such as standing, sitting or bending in any position
that causes symptoms. This means that an abnormality or injury, such as a
slipped disk can be visualized where it may not have been with the patient lying
down. We have introduced the name “Upright®” as an alternative to “Stand-UP®”
because of the multiplicity of positions in which the patient may be scanned
where the patient is not standing.
PHYSICIAN MANAGEMENT AND
DIAGNOSTIC SERVICES SEGMENT
Health Management
Corporation of America, which we sometimes refer to as "HMCA", was formed by
Fonar in March 1997 as a wholly-owned subsidiary in order to enable us to expand
into the business of providing comprehensive management services to medical
providers. HMCA provides management services, administrative services, billing
and collection services, office space, equipment, repair, maintenance service
and clerical and other non-medical personnel to medical providers.
The Company completed a
private placement of equity and succeeded in raising $6,000,000 by May 2, 2011.
The offering consisted of Preferred Class A membership interests in a newly
formed limited liability company, Imperial Management Services, LLC
(“Imperial”). Class B membership interests, all of which were retained by the
Company’s subsidiary, HMCA, hold a 75% equity interest in Imperial. The Class A
membership interests are entitled to receive a dividend of 18% per annum of
their capital contributions to the limited liability company. HMCA contributed
all of its assets, together with its liabilities, to Imperial as HMCA’s capital
contribution. The Imperial operating agreement provides for the Class A members
to receive priority distributions until their original capital contributions are
returned. As of June 30, 2012, Imperial manages 11 diagnostic imaging facilities
located in states of New York and Florida. One fifth of the Class A membership
interests were redeemed during fiscal 2012 (equivalent to 5% of the A and B
membership interests in the aggregate).
On October 1, 2010, the
Company purchased 100% of the stock of Fair Haven Services Inc., an entity
wholly owned by Raymond Damadian. The entity is in the business of leasing
medical equipment to various unrelated PC’s. The Company also holds a 50%
controlling interest in two entities from unrelated parties that provides
management services to two diagnostic centers in the New York Metropolitan
area.
See Note 19 to the
Consolidated Financial Statements for separate financial information regarding
our medical equipment and physician and diagnostic management services
segments.
FORWARD LOOKING
STATEMENTS.
Certain statements made in
this Annual Report on Form 10-K are "forward-looking statements", within the
meaning of the Private Securities Litigation Reform Act of 1995, regarding the
plans and objectives of Management for future operations. Such statements
involve known and unknown risks, uncertainties and other factors that may cause
our actual results, performance or achievements to be materially different from
any future results, performance or achievements expressed or implied by such
forward-looking statements. These forward-looking statements are based on
current expectations that involve numerous risks and uncertainties. Our plans
and objectives are based, in part, on assumptions involving the expansion of
business. These assumptions involve judgments with respect to, among other
things, future economic, competitive and market conditions and future business
decisions, all of which are difficult or impossible to predict accurately and
many of which are beyond our control. Although we believe that our assumptions
underlying the forward-looking statements are reasonable, any of the assumptions
could prove inaccurate and, therefore, there can be no assurance that the
forward-looking statements included in this Annual Report will prove to be
accurate. In light of the significant uncertainties inherent in our
forward-looking statements, the inclusion of such information should not be
regarded as a representation by us or any other person that our objectives and
plans will be achieved.
RECENT DEVELOPMENTS AND
OVERVIEW.
Our products and
works-in-progress are intended to significantly improve our competitive
position. Our current products are the Upright® MRI and the Fonar
360™.
The Upright® MRI permits,
for the first time, MRI diagnoses to be made in the weight-bearing state. The
Upright® MRI is the only MRI scanner that allows patients to be scanned while
standing, sitting, bending or lying down. This means that an abnormality or
injury, such as a slipped disk, will be able to be scanned under full
weight-bearing conditions, which is more often than not the position in which
the patient experiences pain. An adjustable bed allows patients to stand, sit or
lie on their backs, sides or stomachs. The Upright® MRI may also be useful for
MRI-guided interventional procedures.
An important application
of the Fonar Upright® technology is in the evaluation and diagnosis of patients
with the Arnold-Chiari syndrome believed to affect from 200,000 to 500,000
Americans. In this syndrome there is brain stem compression and entrapment of
the brain at the base of the skull in the foramen magnum, which is the circular
bony opening at the base of the skull where the spinal cord exits the skull. The
brain structure “entrapped” in Chiari Syndrome are the lowest lying structures
of the brain, the tonsils of the cerebelium. The Chiari Syndrome is therefore
alternately named Cerebellar Ectopia (CTE) indicating the displacement (ectopia)
of these Cerebellar tonsils in this syndrome. Classic symptoms of the Chiari
Syndrome include the “drop attack,” where the erect patient unexpectedly
experiences an explosive rush or nervous discharge at the base of the brain
which rushes down the body to the extremities, causing the patient to collapse
in a temporary neuromuscular paralysis which then subsides while the patient is
lying in a horizontal position.
The Fonar Upright® MRI has
demonstrated its key value on two current patients with Chiari Syndrome showing
that the conventional lie-down MRI scanners cannot make an adequate evaluation
where the patient’s pathology is most visible and where symptoms are most acute
when the patient is upright. A recent publication in the Journal “Brain Injury”
(Brain Injury 2010, 24 (7-8) 988-994) of 1,200 neck pain patients reported that
the fallen cerebellar tonsils of the brain (CTE) were missed 75% of the time
when the patient was scanned only in the recumbent position. It is critical to
have an image of the patient in an upright position so that the neurosurgeons
can fully evaluate the extent of the brain stem compression which is occurring
so they can choose the most appropriate surgical approach for the operative
repair.
The Upright® is emerging
as the MRI of choice for diagnosing spinal pathology. In September, 2006, FONAR
sold an Upright® MRI scanner to the largest orthopedic hospital in the
Netherlands, the St. Maartenskliniek. St. Maartenskliniek has over 300
in-patient beds and an extensive outpatient clinic program that diagnoses and
treats 25,000 patients with orthopedic problems annually. In placing the order,
St. Maartenskliniek announced from the point of view of their internationally
recognized “Spine Center” that “once Fonar made available upright weight-bearing
MRI imaging technology, owning one for the St. Maartenskliniek “Spine Center”
was not optional but mandatory. For our hospital to continue to engage in spine
surgery without it, once this new technology became available, was unacceptable.
Once the means were available to make certain we were getting the complete
picture of the patient’s spine pathology before undertaking surgery, so that we
could be certain we were not performing surgery based on a wrongdiagnosis and
running the risk of doing the wrong surgery, we did not regard the utilization
of this new technology, from our patients’ perspective, as optional. It was
mandatory.”
In February 2011, FONAR
sold an UPRIGHT® MRI to a neuroscience spine institute in the Northeast. The
group that purchased the MRI said they wanted the best diagnostic device
available to allow them to be a “center of excellence for the spine.” They had
considered other state-of-the-art MRI scanners including those with field
strengths of 1.5 and 3.0 Tesla, but those were single-position (recumbent only)
and not weight-bearing systems. The buyers firmly believed that in order for
them to be a “center of excellence for the spine,” it was crucial for them to
have an MRI that could evaluate the spine in its full range of dynamic
weight-bearing positions.
In June 2011, FONAR sold
an Upright® MRI to another medical practice dedicated to being a “center of
excellence for the spine.” Hoorman M. Melamed, MD, FAOOS, a board-certified
orthopaedic spine surgeon, and a principal at the Bakersfield UPRIGHT MRI
Center, said, “Selection of the FONAR UPRIGHT® Multi-Position™ MRI for our group
was a very careful and deliberate decision. We recognize that the UPRIGHT® MRI
offers capabilities beyond that of a recumbent-only MRI. The UPRIGHT® MRI allows
for scanning patients weight-bearing and the dynamic positions of flexion and
extension. This allows us to see and evaluate the spine under load of a
patient’s pathology thus enabling us to avoid underestimating a patient’s
pathology and therefore obtaining a better diagnosis.”
Another milestone in the
utilization of the FONAR Upright® MRI was the publication in the medical journal
"Brain Injury" (July 2010) of a study of 1,200 neck pain patients. The study was
published by 10 authors from distinguished universities in the United States and
around the world. The study reported that Cerebellar Tonsil Herniation (CTE) was
missed 75% of the time when the patient was scanned recumbent instead of
upright. At the current rate of 1,000,000 automobile whiplash injuries in the
U.S. per year, 600,000 patients each year would have the pathology responsible
for their symptoms go undetected if they were examined solely in a conventional
recumbent-only MRI.
We are vigorously
promoting sales of the Upright® MRI which we regard as our most promising
product. Revenues recognized from the sale of Upright® MRI scanners increased in
fiscal 2012 by 18.5% over fiscal 2011 from approximately $5.3 million in fiscal
2011 to approximately $6.3 million in fiscal 2012 under present market
conditions. The following chart shows the revenues attributable to our different
model scanners for the fiscal years ended June 30, 2011 and June 30, 2012. Note
that we recognize revenue on a percentage of completion basis. Accordingly,
revenue is recognized as each sub-assembly of a scanner is manufactured.
Consequently the revenues for a fiscal period do not necessarily relate to
orders placed in that period or payments received.
Model
|
|
Revenues
Recognized
|
|
|
Fiscal
2011
|
|
Fiscal
2012
|
|
Upright®
|
|
|
$
|
5,345,932
|
|
|
$
|
6,335,198
|
|
|
Fonar 360™
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
Other
|
|
|
$
|
1,336,365
|
|
|
$
|
587,267
|
|
“Other” revenue includes
upgrades and deinstallations of scanners.
Although the Fonar 360™
has not been sold in the past two fiscal years, it remains part of Fonar’s
product line. At the present time the Upright® MRI scanner is the main focus of
Fonar’s manufacturing activities.
The Fonar 360™ includes
the Open Sky™ MRI. We received our first order for a Fonar 360™ scanner in the
first quarter of fiscal 2005. The magnet frame is incorporated into the floor,
ceiling and sidewalls of the scan room and is open. Consequently, physicians and
family members can walk inside the magnet to approach the patient. The Open Sky™
version of the Fonar 360™ is decoratively designed so that it is incorporated
into the panoramic landscape that decorates the walls of the scan room. The
ability of the Fonar 360™ to give physicians direct 360 degree access to
patients and the availability of MRI compatible interventional instruments such
as needles, catheters, probes, scalpels and forceps, will also enable the Fonar
360™ to be used for image guided interventions.
Fonar’s showcase
installation of the first Fonar 360™ MRI scanner was completed at the Oxford
Nuffield Orthopedic Center in Oxford, United Kingdom. Oxford-Nuffield had two
objectives in the choice of the Fonar 360™ MRI. The first was to have an open
mid-field MRI imaging scanner to meet their medical imaging needs. The second
was to have an open scanner that would enable direct image guided surgical
intervention. The Oxford-Nuffield scanner is carrying a full diagnostic imaging
load daily.
Additionally, development
of the works in progress Fonar 360™ MRI image guided interventional technology
is actively progressing. Fonar software engineers have completed and installed
their 2nd generation tracking software at Oxford-Nuffield which is designed to
enable the surgeons to insert needles into the patient and accurately advance
them under direct visual image guidance to the target tissue, such as a tumor,
so that therapeutic agents can be injected.
Health Management
Corporation of America (“HMCA”), a subsidiary of Fonar, currently is managing 11
diagnostic imaging centers located in New York and Florida.
All these centers, are
equipped with Upright® MRI scanners. HMCA has intensified its marketing efforts,
including the hiring of additional marketers and supervisory personnel. HMCA’s
objective is to increase HMCA’s revenues not only for HMCA’s sake of promoting
HMCA’s profitability but to provide sufficient revenues to support both segments
of our business during times when MRI scanner sales are weak.
MEDICAL EQUIPMENT
SEGMENT
PRODUCTS
Fonar’s principal product
is the Upright® MRI.
The Upright® MRI is a
whole-body open MRI system that enables positional MRI (pMRI®) applications,
such as weight-bearing MRI studies. Operating at a magnetic field strength of
0.6 Tesla, the scanner is a powerful, diagnostically versatile and
cost-effective open MRI that provides a broad range of clinical capabilities and
a complete set of imaging protocols. Patients can be scanned standing, bending,
sitting, upright at an intermediate angle or in any of the conventional
recumbent positions. This multi-positional MRI system accommodates an
unrestricted range of motion for flexion, extension, lateral bending, and
rotation studies of the cervical (upper)and lumbar (lower) spine. Previously
difficult patient scanning positions can be achieved using the system’s
MRI-compatible, three-dimensional, motorized patient handling system. Patients,
lying horizontally, are placed into the magnet in the conventional manner. The
system’s lift and tilt functions then deliver the targeted anatomical region to
the center of the magnet. The ceiling and floor are recessed to accommodate the
full vertical travel of the table. True image orientation is assured, regardless
of the rotation angle, via computer read-back of the table’s position. Spines
and extremities can be scanned in weight-bearing states; brains can be scanned
with patients either standing or sitting.
This capability of the
Fonar Upright® technology has demonstrated its key value on patients with the
Arnold-Chiari Syndrome (CTE), which is believed to affect 200,000 to 500,000
Americans. In this syndrome, brain stem compression and subsequent severe
neurological symptoms occur in these patients, when because of weakness in the
support tissues within the skull, the brain stem descends and is compressed at
the base of the skull in the foramen magnum, which is the circular bony opening
at the base of the skull where the spinal cord exits the skull. Conventional
lie-down MRI scanners cannot make an adequate evaluation of the pathology since
the patient’s pathology is most visible and the symptoms most acute when the
patient is scanned in the upright weight-bearing position.
The Upright® MRI has also
demonstrated its value for patients suffering from scoliosis. Scoliosis patients
have been typically subjected to routine x-ray exams for years and must be
imaged upright for an adequate evaluation of their scoliosis. Because the
patient must be standing for the exam, an x-ray machine has been the only
modality that could provide that service. The Upright® MRI, is the only MRI
scanner which allows the patient to stand during the MRI exam. Fonar has
developed a new RF receiver and scanning protocol that for the first time allows
scoliosis patients to obtain diagnostic pictures of their spines without the
risks of x-rays. A recent study by the National Cancer Institute (2000)of 5,466
women with scoliosis reported a 70% increase in breast cancer resulting from
24.7 chest x-rays these patients received on the average in the course of their
scoliosis treatment.
The Upright® MRI is
exceptionally open, making it the most non-claustrophobic whole-body MRI
scanner. Patients can walk into the magnet, stand or sit for their scans and
then walk out. From the patient’s point of view, the magnet’s front-open and
top-open design provides an unprecedented degree of comfort because the scanner
allows the patient an unobstructed view of the scanner room from inside the
magnet, and there is nothing in front of one’s face or over one’s head. The only
thing in front of the patient’s face during the scan is a very large (42”)
panoramic TV (included with the scanner) mounted on the wall. The bed is tilted
back five degrees to stabilize a standing patient. Special coil fixtures, a
patient seat, Velcro straps, and transpolar stabilizing bars are available to
keep the patient comfortable and motionless throughout the scanning
process.
Full-range-of-motion
studies of the joints in virtually any direction are possible, an especially
promising feature for sports injuries. Full Range of Motion cines, or movies, of
the lumbar spine will be achieved under full body weight.
The Upright® MRI will also
be useful for MRI guided interventional procedures as the physician would have
unhindered access to the patient with no restrictions in the vertical
direction.
This easy-entry,
mid-field-strength scanner should be ideal for trauma centers where a quick MRI
screening within the first critical hour of treatment will greatly improve
patients' chances for survival and optimize the extent of recovery.
The Fonar 360™ is an
enlarged room sized magnet in which the floor, ceiling and walls of the scan
room are part of the magnet frame. This is made possible by Fonar’s patented
Iron-Frame™ technology which allows our engineers to control, contour and direct
the magnet’s lines of flux in the patient gap where wanted and almost none
outside of the steel of the magnet where not wanted. Consequently, this scanner
allows 360 degree access to the patient, and physicians and family members are
able to enter the scanner and approach the patient.
The Fonar 360™ is
presently marketed as a diagnostic scanner and is sometimes referred to as the
Open Sky™ MRI. In its Open Sky™ capacity, the Fonar 360™ serves as an open
patient-friendly scanner which allows 360 degree access to the patient on the
scanner bed.
To optimize the
patient-friendly character of the Open Sky™ MRI, the walls, floor, ceiling and
magnet poles are decorated with landscape murals. The patient gap is twenty
inches and the magnetic field strength is 0.6 Tesla.
We also expect to enable
the Fonar 360™ to function as an MRI guided interventional scanner, for the
purpose of performing intra-operative, interventional and therapeutic procedures
with MR compatible instrumentation. In this capacity, the enlarged room sized
magnet and 360 degree access to the patient afforded by the Fonar 360™ would
permit full-fledged support teams to walk into the magnet and perform MRI guided
interventions on the patient inside the magnet. Most importantly, the
exceptional quality of the MRI image and its exceptional capacity to exhibit
tissue detail on the image, by virtue of the nuclear resonance signal’s
extraordinary capacity to create image contrast, can then be obtained very near
real time to guide the physician during the MRI guided intervention. Thus MRI
compatible instruments, needles, catheters, endoscopes and the like can be
introduced directly into the human body and guided to the malignant lesion or
other pathology by means of the MRI image. Surgically inoperable lesions could
be accessed through MRI guided catheters and needles making it possible to
deliver the treatment agent directly to the targeted tissue.
The first Fonar 360™ MRI
scanner, installed at the Oxford-Nuffield Orthopedic Center in Oxford, United
Kingdom, is now carrying a full diagnostic imaging caseload. In addition,
however, development of the works in progress Fonar 360™ MRI image guided
interventional technology is actively progressing. Fonar software engineers have
completed and installed their 2nd generation tracking software at
Oxford-Nuffield which is designed to enable the surgeons to insert needles into
the patient and accurately advance them, under direct visual image guidance, to
the target tissue, such as a tumor, so that therapeutic agents can be
injected.
With current treatment
methods, such as chemotherapy taken by mouth, the therapy must always be
restricted in the doses that can be applied to the malignant tissue because of
the adverse effects on the healthy tissues. Thus chemotherapies must be limited
at the first sign of toxic side effects. The same is the case with radiation
therapy. Fonar expects that with the Fonar 360™ treatment agents may be
administrated directly to the malignant tissue through small catheters or
needles, thereby allowing much larger doses of chemotherapy, x-rays, laser
ablation, microwave and other anti-neoplastic agents to be applied directly and
exclusively to the malignant tissue with more effective results. Since the
interventional procedure of introducing a treatment needle or catheter under
image guidance will be minimally invasive, the procedure can be readily repeated
should metastases occur elsewhere, with minimum impact on the patient beyond a
straightforward needle injection. The presence of the MRI image during treatment
would enable the operator to make assessments during treatment whether the
treatment is being effective.
In addition to the patient
comfort and new applications, such as MRI directed interventions, made possible
by our scanners’ open design, the Upright® and Fonar 360™ scanners are designed
to maximize image quality through an optimal combination of signal-to-noise
(S/N) and contrast-to-noise (C/N) ratios. The technical improvements realized in
these scanners’ design over their predecessors also include increased
image-processing speed and diagnostic flexibility.
MRI directed interventions
are made possible by the scanners’ ability to supply images to a monitor
positioned next to the patient, enabling the operator to view in process an
interventional procedure from an unlimited number of angles. The openness of
Fonar’s scanners would enable a physician to perform a wide range of
interventional procedures inside the magnet.
In the case of breast
imaging the access by a physician permits an image guided biopsy to be performed
easily which is essential once suspicious lesions are spotted by any diagnostic
modality. In addition to being far superior to x-ray in detecting breast lesions
because of the MRI’s ability to create the soft tissue contrast needed to see
them, where x-ray is deficient in its ability to generate the needed contrast
between cancer and normal tissue, there is not the painful compression of the
breast characteristic of X-ray mammography.
The Upright® MRI and Fonar
360™ scanners share much of the same fundamental technology and offer the same
speed, precision and image quality. Fonar’s scanners initiated the new market
segment of high-field open MRI. High-field open MRIs operate at significantly
higher magnetic field strengths and, therefore, produce more of the MRI
image-producing signal needed to make high-quality MRI images (measured by
signal-to-noise ratios, S/N).
The Upright® MRI and Fonar
360™ scanners utilize a 6000 gauss (0.6 Tesla field strength) iron core
electromagnet. The greater field strength of the 6000 gauss magnet, as compared
to lower field open MRI scanners that operate at 3,000 gauss (0.3 Tesla) when
enhanced by the electronics already utilized by Fonar’s scanners, produces
images of higher quality and clarity. Fonar’s 0.6 Tesla open scanner magnets are
among the highest field "open MRI" magnets in the industry.
The Upright® MRI and Fonar
360™ scanners are designed to maximize image quality through an optimal
combination of signal-to-noise (S/N) and contrast-to-noise (C/N) ratios. The
technical improvements realized in the scanners’ design over their lower field
predecessors also include increased image-processing speed and diagnostic
flexibility.
Several technological
advances have been engineered into the Upright® MRI and Fonar 360™ scanners for
extra improvements in S/N, including: new high-S/N Organ Specific(TM) receiver
coils; new advanced front-end electronics featuring high-speed,
wide-dynamic-range analog-to-digital conversion and a miniaturized
ultra-low-noise pre-amplifier; high-speed automatic tuning, bandwidth-optimized
pulse sequences, multi-bandwidth sequences, and off-center FOV imaging
capability.
In addition to the
signal-to-noise ratio, however, the factor that must be considered when it comes
to image quality is contrast, the quality that enables reading physicians to
clearly distinguish adjacent, and sometimes minute, anatomical structures from
their surroundings. This quality is measured by contrast-to-noise ratios (C/N).
Unlike S/N, which increases with increasing field strength, relaxometry studies
have shown that C/N peaks in the mid-field range and actually falls off
precipitously at higher field strengths. The Upright® MRI and Fonar 360™
scanners operate squarely in the optimum C/N range.
The Upright® MRI and Fonar
360™ provide various features allowing for versatile diagnostic capability. For
example, SMART™ scanning allows for same-scan customization of up to 63 slices,
each slice with its own thickness, resolution, angle and position. This is an
important feature for scanning parts of the body that include small-structure
sub-regions requiring finer slice parameters. There is also Multi-Angle Oblique™
(MAO) imaging, and oblique imaging.
The console for these
scanners includes a mouse-driven, multi-window interface for easy operation and
a 19-inch, 1280 x 1024-pixel, 20-up, high-resolution image monitor with features
such as electronic magnifying glass and real-time, continuous zoom and
pan.
The predecessors of the
Upright® MRI and Fonar 360™ were FONAR’s QUAD™ scanner, Ultimate™ 7000 scanner
and Beta™ scanner. The Beta™ 3000 scanner utilized a permanent magnet. The Beta™
3000M scanner utilized an iron core electromagnet. All of our current and
earlier model scanners create cross-sectional images of the human
body.
During fiscal 2012, sales
of our Upright® MRI scanners accounted for approximately 16.1% of our total
revenues and 33.9% of our medical equipment revenues, as compared to 16.1% of
total revenues and 30% of medical equipment revenues in fiscal 2011. These
results reflect the decrease in our sales of scanners.
During fiscal 2012 and
fiscal 2011, we had no revenues attributable to sales of our Fonar 360™
scanner.
Our principal selling,
marketing and advertising efforts have been focused on the Upright® MRI, which
we believe is a particularly unique product, being the only MRI scanner which is
both open and allows for weight-bearing imaging. Since we perceive that the
Upright® MRI is successfully penetrating the market and enabled us to achieve
profitability in fiscal 2011 and 2012, we expect to continue our focus on the
Upright® MRI in the immediate future. We are optimistic that in the long run the
Fonar 360™ and our other products and works in progress will also contribute to
increased product sales.
The materials and
components used in the manufacture of our products (circuit boards, computer
hardware components, electrical components, steel and plastic) are generally
available at competitive prices. We have not had difficulty acquiring such
materials.
WORKS-IN-PROGRESS
All of our products and
works-in-progress seek to bring to the public MRI products that are expected to
provide important advances against serious disease.
MRI takes advantage of the
nuclear resonance signal elicited from the body's tissues and the exceptional
sensitivity of this signal for detecting disease. Much of the serious disease of
the body occurs in the soft tissue of vital organs. The principal diagnostic
modality currently in use for detecting disease, as in the case of x-ray
mammography, are diagnostic x-rays. X-rays discriminate soft tissues, such as
healthy breast tissue and cancerous tissue poorly, because the x-ray particle
traverses the various soft tissues almost equally thereby causing target films
to be nearly equally exposed by x-rays passing through adjacent soft tissues and
creating healthy and cancerous shadows on the film that differ little in
brightness. The image contrast in x-ray between cancerous and healthy breast
tissue is poor, making the detection of breast cancers by the x-ray mammogram
less than optimal and forcing the mammogram to rely on the presence or absence
of microscopic stones called “microcalcifications” instead of being able to
“see” the breast cancer itself. If microcalcifications are not present to
provide the missing contrast, then the breast cancer goes undetected. They
frequently are not present. The maximum contrast available by x-ray with which
to discriminate disease is 4%. Brain cancers differ from surrounding healthy
brain by only 1.6% while the contrast in the brain by MRI is 25 times greater at
40%. X-ray contrasts among the body’s soft tissues are maximally 4%. Their
contrast by MRI is 32.5 times greater (130%).
The soft tissue contrasts
with which to distinguish cancers on images by MRI are up to 180%. In the case
of cancer these contrasts can be even more marked making cancers readily visible
and detectable anywhere in the body. This is because the nuclear resonance
signals from the body's tissues differ so dramatically. Liver cancer and healthy
liver signals differ by 180% for example. Thus there is some urgency to bring to
market an MRI based breast scanner that can overcome the x-ray limitation and
assure that mammograms do not miss serious lesions. The added benefit of MRI
mammography relative to x-ray mammography is the elimination of the need for the
patient to disrobe and the painful compression of the breast typical of the
x-ray mammogram. The patient is scanned in her street clothes in MRI
mammography. Moreover MRI mammogram scans the entire chest wall including the
axilla for the presence of nodes which the x-ray mammogram cannot
reach.
We view our Upright® MRI
as having the potential for being an ideal breast examination machine as it
permits the patient to be seated for the examination, which would allow easy
access for an MRI guided breast biopsy when needed. The Fonar 360™ MRI scanner
would also be ideal for breast examinations.
PRODUCT
MARKETING
The principal markets for
the Company's scanners are private diagnostic imaging centers and
hospitals.
Our internal sales force
handles the domestic market. We continue to use independent manufacturer’s
representatives and distributors for foreign markets. None of Fonar’s
competitors are entitled to make the Fonar Upright® MRI scanner.
Fonar’s Website includes
interactive product information for reaching customers.
Fonar has targeted
orthopedic surgeons and neurosurgeons, particularly spine surgeons, as important
markets for the Upright® MRI. Accordingly, Fonar has exhibited at annual
meetings of The American Academy of Orthopaedic Surgeons (AAOS); the North
American Spine Society (NASS); the American Association of Neurological Surgeons
(AANS); and the Congress of Neurological Surgeons (CNS).
Fonar’s success in
targeting surgeons was most evident in the sale, in September 2006, of an
Upright® MRI scanner to the largest orthopedic hospital in the Netherlands, the
St. Maartenskliniek in Nijmegen. In addition to being a key sale to a
prestigious hospital, the medical conclusions reached and stated by the buyer
and the buyer’s intention to conduct research and publish articles concerning
the Upright® technology, are a vital component to Fonar’s objective to prove to
the medical community at large, insurers, governmental agencies and others the
benefits, if not the necessity of Upright® scanning. A Director of St.
Maartenskliniek and the Chairman of Spine Surgery stated that “We at St.
Maartenskliniek, the biggest orthopedic hospital in the Netherlands, are very
much looking forward to this new technology from Fonar which will enable us to
evaluate the spine anatomy in the fully weight-bearing state and in multiple
positions. We expect these new multi-position capabilities to lead to more
accurate diagnosis and better surgery outcomes for patients. Once our active
research program has discovered the benefits of this new Fonar technology for
patients, we intend to publish the results in a lot of peer reviewed scientific
journals.” The Chairman stated further “that once Fonar made available upright
weight-bearing MRI imaging technology, owning one for the St. Maartenskliniek
“Spine Center” was not optional but mandatory. For our hospital to continue to
engage in spine surgery without it, once this new technology became available,
was unacceptable”.
Recognition of the
importance of Fonar Upright® MRI continues to grow. Medserena, of Germany,
announced in August, 2010 the purchase of its fourth Upright® Multi-Position™
MRI. CEO Matthais Schulz said, “The large number of requests coming from our
physicians in Germany are arising because of the special medical need for
FONAR’s unique technology. This is in spite of an intensely active MRI market in
Germany, where there are already many conventional lie-down MRIs
installed.”
Even high-field 3.0 Tesla
MRI scanners cannot overshadow the importance of Fonar’s unique technology. In
August, 2010, a distinguished board-certified radiologist in Florida, the
owner/operator of two multi-modality imaging centers equipped with MRIs, ordered
a Fonar Upright® MRI. He initially considered purchasing a 3.0 Tesla lie-down
MRI, but decided instead to buy the Fonar Upright® Multi-Position™ MRI when he
became aware of its many unique imaging capabilities.
Fonar’s advertising
strategy has been designed to reach key purchasing decision makers with
information concerning our flagship product, the Upright® MRI. This has led to
many inquiries and to some sales of the Upright® MRI scanner and is intended to
increase Fonar’s presence in the medical market. Fonar’s advertising has been
directed at four target audiences: neurosurgeons, orthopaedic surgeons,
radiologists and physicians in general.
|
1)
|
Neurosurgeons and Orthopaedic Surgeons:
These are the surgeons who can most benefit from the superior diagnostic
benefits of the Fonar Upright® MRI with its Multi-Position® diagnostic
ability. Advertisements to them have appeared in the journal Spine, The
Journal of Neurosurgery, and the Journal of the American Academy of
Orthopedic Surgery.
|
|
2)
|
Radiologists: This segment of the campaign
is aimed at the physicians who now have a new modality to offer their
referring physicians. Our advertisements directed to them have appeared in
Radiology and Diagnostic Imaging.
|
|
3)
|
All Physicians: These advertising efforts
have been directed to the total physician audience, so that the vast
number of doctors who send patients for MRI’s are aware of the diagnostic
advantages of the Fonar Upright® Multi-Position® MRI. Advertisements
directed to this audience have appeared in the Journal of the American
Medical Association.
|
This advertising has
featured a series of compelling messages. One advertisement pointed out that the
AMA book, Guides to the Evaluation of Permanent Impairment, indicates that
diagnosis must be performed upright in flexion and extension. Another
advertisement was educational and headlined, “Discover the power of Upright
Imaging”. Fonar realizes that peer-to-peer communications is the most powerful
way to speak to physicians. Consequently, testimonials from surgeons and
radiologists have been used to promote our Upright® MRI scanner. The first such
advertisement featured five surgeons and two radiologists, explaining the
Multi-Position® diagnostic benefits of the Fonar Upright® MRI scanner to them.
Another advertisement featured a leading radiologist, telling why he bought 12
Fonar Upright® MRI scanners and planned to buy more.
Also, our advertising for
HMCA also serves as advertising for Fonar MRI scanners. We have increased
internet awareness of our product by driving patient traffic to the Upright®
scanning centers we manage by installing Websites for every location. These
websites and advertising give prospective customers of Upright® MRI scanners a
view of operating Upright® MRI centers and the benefits of using an Upright® MRI
scanner. The success of HMCA-managed sites not only increases management fees to
HMCA but encourages new sales for Fonar as well.
To meet the demand for
high-field open MRI scanners, Fonar plans to devote its principal efforts to
marketing the Upright® MRI. The Upright® MRI is the only scanner in the industry
that has the unique capability of scanning patients under weight-bearing
conditions and in various positions of pain or other symptoms. In addition we
will continue to market our Fonar 360™ MRI scanners. Utilizing a 6000 gauss (0.6
Tesla field strength) iron core electromagnet, the Upright® MRI and Fonar 360™
scanner magnets are among the highest field "Open MRI" scanners in the
industry.
The Upright® MRI is also
suited to fill a demand for better diagnoses of scoliosis patients, who must be
standing for the exam. Scoliosis patients are typically subjected to routine
x-ray exams for years. In the past, an x-ray machine was the only modality that
could provide that service. Typical MRI scanners cannot provide this service
because the patient cannot stand up inside of them. The Fonar Upright™ MRI
scanner is the only MRI scanner which allows the patient to stand during the
exam. The Fonar Upright® Scanner avoids radiation of the x-ray machines
currently used for scoliosis, which have been reported by the National Cancer
Institute to cause a 70% increase in the risk of breast cancer. Other important
new applications are Upright® imaging of the pelvic floor and abdomen to image
prolapses and inguinal hernias. Fonar has also developed the first non-invasive
method to image the prostate: the patient simply sits on a flat, seat-like
coil.
We also will seek to
introduce new MRI applications for our scanners such as MRI-directed
interventions.
Our areas of operations
are principally in the United States. During the fiscal year ended June 30,
2012, 6.2% of the Company's revenues were generated by foreign sales, as
compared to 8.5% for fiscal 2011.
We are seeking to promote
foreign sales and have sold scanners in various foreign countries. Foreign
sales, however, have not yet proved to be a significant source of
revenue.
SERVICE AND UPGRADES FOR
MRI SCANNERS
Our customer base of
installed scanners has been and will continue to be an additional source of
income, independent of direct sales.
Income is generated from
the installed base in two principal areas namely, service and upgrades. Service
and maintenance revenues from our external installed base were approximately
$11.8 million in fiscal 2012 and $11.1 million in fiscal 2011. We expect service
revenues to increase as warranties expire on previously sold scanners, and the
customers then enter into service contracts.
We also anticipate that
our new scanners will result in upgrades income in future fiscal years. The
potential for upgrades income, particularly in the form of new patient
supporting upright imaging fixtures and receiver coils, originates in the
versatility and productivity of the new Upright® Imaging technology. New medical
uses for MRI technology are constantly being discovered and are anticipated for
the Upright® Imaging technology as well. New features can often be added to the
scanner by the implementation of little more than versatile new software
packages. For example, software can be added to existing MRI angiography
applications to synchronize angiograms with the cardiac cycle. By doing so the
dynamics of blood vessel filling and emptying can be visualized with movies.
Such enhancements are attractive to end users because they extend the useful
life of the equipment and enable the user to avoid obsolescence and the expense
of having to purchase new equipment.
RESEARCH AND
DEVELOPMENT
During the fiscal year
ended June 30, 2012, we incurred expenditures of $1,242,656, none of which was
capitalized, on research and development, as compared to $1,507,290, $67,258 of
which was capitalized, during the fiscal year ended June 30, 2011.
Research and development
activities have focused principally, on the development and enhancement of the
Upright® and Fonar 360™ MRI scanners. The Upright® MRI and Fonar 360™ involve
significant software and hardware development as the new products represent
entirely new hardware designs and architecture requiring a new operating
software. Our research activity includes developing a multitude of new features
for upright scanning made possible by the new high speed data processing power
of Fonar’s newest scanners. In addition, the Company’s research and development
efforts include the development of new software, such as its Sympulse™ software
and hardware upgrade and the designing and continuing introduction of new
receiver surface coils for the Upright® MRI.
Research and development
activities have focused principally on software improvements to the user
interface of the MRI scanner. The Windows-based Sympulse™ platform controls all
of the functions of the UPRIGHT® scanner except those of the versatile,
multi-position patient table. Separate, dedicated, motion-control software is
used to maneuver the UPRIGHT® bed, and development of this software is ongoing
as well. The same Sympulse™ platform running identical software underpins the
operation of other FONAR MRI scanners, including the FONAR 360™ and older units
such as the Quad 12000™.
In December 2010 FONAR
completed and shipped Release 8.0. The signature feature of Release 8.0 is the
Centering Cursor, which enables the technologist to position the target anatomy
precisely at the center of the magnet by means of a cursor that can be
translated on scout or localizer images. The location of the Centering Cursor is
communicated directly to the patient table with a click of the mouse. Because
the UPRIGHT® bed enjoys three degrees of freedom in its motion, unlike
conventional recumbent MRI scanners that have but one (in and out), the anatomy
of interest can be scanned at magnet isocenter, where the magnetic field is most
uniform. This is critical for the successful implementation of chemical-shift
sensitive fat suppression techniques, such as direct fat saturation and the
Dixon method.
While software
improvements to the user interface are important in their own right, significant
value is added to the MRI scanner by the modification of existing protocols for
examining various parts of the body, and the development of new protocols that
utilize new underlying capabilities of the pulse sequence software.
For example, in Release
8.0, the Dixon method of fat suppression was extended from gradient echo
sequences to fast spin echo and spin echo sequences. This is particularly
important for musculoskeletal imaging because it enables technologists to meet
the demand of radiologists for true proton density-, T1-, and T2-weighted
imaging with fat suppression. Protocols employing this new technique were
released together with the user interface software in a bundled package. Over
time, FONAR users have become accustomed to the steady improvement in clinical
protocols that accompany new software releases. More significantly, in recent
years we have seen increasing adoption of FONAR-standard clinical protocols over
those developed on site. This is a testament to the superior image quality they
produce in attractively short scan times.
The development of
clinically practical scan protocols and software depends on close contact
between research and development scientists and engineers and end users. That
close contact is facilitated in part by the subsidiary relationship with
HMCA-IMPERIAL and the scanning centers it manages. In addition to that
collaboration, R&D staff have pursued a variety of novel and UPRIGHT®
MRI-specific research projects that, it is anticipated, will ultimately lead to
new applications that are made available to existing customers as upgrade
add-ons to their machines.
For example, a multi-year
collaboration with faculty and graduate students at the University of Delaware
has led to the development of an open-geometry low-impedance quadrature knee
coil that is ideally suited to the weight-bearing examination of the knee, and
the study of a variety of pathologies such as patellofemoral pain syndrome and
osteoarthritis. This work is described in doctoral dissertations and papers that
have been presented at conferences and submitted for publication.
Two independent
collaborations with plastic surgeons specializing in breast implantation have
yielded insights into the way in which various types of implants coexist with
surrounding tissues in the cosmetically significant upright seated or standing
posture. One or more publications authored by these outside users are in
progress.
A receiver coil and
scanning protocols designed for rapid, x-ray free MRI evaluation of patients
with scoliosis has already been made available to FONAR customers. FONAR image
display software that enables the technologist to reformat the axial 3D data set
into a coronal plane that follows the lordotic curve of the spine is enabled
upon purchase of the coil. Papers describing this work have already been
published.
Another important
development is “Correlated Slice Profile” (CSP™) Imaging which can be done for
most spine patients. The patient having the spine scan is scanned in the four
positions of Upright®-neutral, Upright®-flexion, Upright®-extension, and
traditional recumbent. At the conclusion of the scan, the MRI technologist
selects a center-slice sagittal view from each of the four positions. The four
image positions are then displayed side by side. In this way, one can quickly
comprehend how a patient’s pathology changes from position to position within
the same anatomic slice. This multi-position weight-bearing imaging of the spine
enables the patient’s physician to see all of the patient’s symptom-generating
pathology so they can be correctly addressed therapeutically or surgically (if
necessary).
BACKLOG
Our backlog of unfilled
orders at September 14, 2012 was approximately $7.4 million, as compared to $9.4
million at September 20, 2011. It is expected that a substantial portion of the
existing backlog of orders will be filled within the 2013 fiscal year. Our
contracts generally provide that if a customer cancels an order, the customer's
initial down payment for the MRI scanner is nonrefundable.
PATENTS AND
LICENSES
We currently have numerous
patents in effect which relate to the technology and components of the MRI
scanners. We believe that these patents, and the know-how we have developed, are
material to our business.
One of our patents, issued
in the name of Dr. Damadian and licensed to Fonar, was United States patent No.
3,789,832, Apparatus and Method for Detecting Cancer in Tissue, also referred to
as the "1974 Patent". The development of our MRI scanners have been based upon
the 1974 Patent, and we believe that the 1974 Patent was the first of its kind
to utilize MR to scan the human body and to detect cancer. The 1974 Patent was
extended beyond its original 17-year term and expired in February,
1992.
We have significantly
enhanced our patent position within the industry and now possesses a substantial
patent portfolio which provides us, under the aegis of United States patent law,
"the exclusive right to make, use and sell" many of the scanner features which
Fonar pioneered and which are now incorporated in most MRI scanners sold by the
industry. As of June 30, 2012, 182 patents had been issued to Fonar, and
approximately 19 patents were pending. A number of Fonar’s existing patents
specifically relate to protecting Fonar’s position in the high-field iron frame
open MRI market. The patents further enhance Dr. Damadian's pioneer patent, the
1974 Patent, that initiated the MRI industry and provided the original invention
of MRI scanning. The terms of the patents in Fonar’s portfolio extend to various
times.
We also have patent
cross-licensing agreements with other MRI manufacturers.
PRODUCT
COMPETITION
MRI SCANNERS
A majority of the MRI
scanners in use in hospitals and outpatient facilities and at mobile sites in
the United States are based on high field air core magnet technology while the
balance are based on open iron frame magnet technology. Fonar’s open iron frame
MRI scanners are competing principally with high-field air core scanners.
Fonar’s open MRI scanners, however, utilizing a 6,000 gauss or 0.6 Tesla field
strength, iron core electromagnet, were the first "open" MR scanners at high
field strength.
Fonar believes that its
MRI scanners have significant advantages as compared to the high-field air core
scanners of its competitors. These advantages include:
1. There is no expansive
fringe magnetic field. High field air core scanners require a more expensive
shielded room than is required for the iron frame scanners. The shielded room
required for the iron frame scanners is intended to prevent interference from
external radio frequencies.
2. They are more open and
quiet.
3. They can scan the
trauma victim, the cardiac arrest patient, the respirator-supported patient, and
premature and newborn babies. This is not possible with high- field air core
scanners because their magnetic field interferes with conventional life-support
equipment.
The principal competitive
disadvantage of our products is that they are not “high field strength”, 1.0
Tesla +, magnets. As a general principle, the higher field strength can produce
a faster scan. In some parts of the body a faster scan can be traded for a
clearer picture. Although we believe that the benefits of “openness” provided by
our scanners compensate for the lower field strength, certain customers will
still prefer the higher field strength.
Fonar faces competition
within the MRI industry from such firms as General Electric Company, Philips
N.V., Toshiba Corporation, Hitachi Corporation and Siemens A.G. Most competitors
have marketing and financial resources more substantial than those available to
us. They have in the past, and may in the future, heavily discount the sales
price of their scanners. Such competitors sell both high field air core
superconducting MRI scanners and iron frame products. Fonar’s original iron
frame design, ultimately imitated by Fonar’s competitors to duplicate Fonar’s
origination of “Open” MRI magnets, gave rise to current patient protected
Upright® MRI technology with the result that Fonar today is the unique and only
supplier of the highest field MRI magnets (.6 Tesla) that are not
superconducting, do not use liquid helium and are not therefore susceptible to
explosion.
The iron frame, because it
could control the magnetic lines of force and place them where wanted and remove
them from where not wanted, such as in the Fonar 360™ where physicians and staff
are standing, provide a much more versatile magnet design than is possible with
air core magnets. Air core magnets contain no iron but consist entirely of turns
of current carrying wire.
For an 11 year period from
1983-1994, Fonar's large competitors, with one exception, generally rejected
Fonar's "open" design but by now all have added the iron frame "open" magnet to
their MRI product lines. One reason for this market shift, in addition to
patient claustrophobia, is the awareness that the open magnet designs permit
access to the patient to perform MRI guided procedures, a field which is now
growing rapidly and is called "interventional MRI."
The Fonar 360™ scanner
explicitly addresses this growing market reception of MRI guided interventions,
and the first of these scanners was sold to a hospital in England. Fonar's
Upright® magnet also addresses the growing market reception of MRI guided
interventions. Although not enabling a full interventional theater as the Fonar
360™ does, the iron frame Upright® MRI design permits ready access to the
patient and enables a wide range of interventional procedures such as biopsies
and needle or catheter delivered therapies to be performed under MRI image
guidance. The "tunnel" air core superconductive scanners do not permit access to
the patient while the patient is inside the scanner.
Fonar expects to be the
leader Upright® Multi-Position MRI for providing dynamic visualization of body
parts such as the spine and other joints as well as dynamic visualization of the
heart in its upright position when it is sustaining its full normal
physiological load. No companies possess the patented Upright® MRI technology or
the Fonar 360™’s 360° full access interventional technology.
OTHER IMAGING
MODALITIES
Fonar’s MRI scanners also
compete with other diagnostic imaging systems, all of which are based upon the
ability of energy waves to penetrate human tissue and to be detected by either
photographic film or electronic devices for presentation of an image on a
television monitor. Three different kinds of energy waves - X-ray, gamma and
sound - are used in medical imaging techniques which compete with MRI medical
scanning, the first two of which involve exposing the patient to potentially
harmful radiation. These other imaging modalities compete with MRI products on
the basis of specific applications.
X-rays are the most common
energy source used in imaging the body and are employed in three imaging
modalities:
1. Conventional X-ray
systems, the oldest method of imaging, are typically used to image bones and
teeth. The image resolution of adjacent structures that have high contrast, such
as bone adjacent to soft tissue, is excellent, while the discrimination between
soft tissue organs is poor because of the nearly equivalent penetration of
x-rays.
2. Computerized
Tomography, also referred to as "CT", systems couple computers to x-ray
instruments to produce cross-sectional images of particular large organs or
areas of the body. The CT scanner addresses the need for images, not available
by conventional radiography, that display anatomic relationships spatially.
However, CT images are generally limited to the transverse plane and cannot
readily be obtained in the two other planes, sagittal and coronal. Improved
picture resolution is available at the expense of increased exposure to x-rays
from multiple projections. Furthermore, the pictures obtained by this method are
computer reconstructions of a series of projections and, once diseased tissue
has been detected, CT scanning cannot be focused for more detailed pictorial
analysis or obtain a chemical analysis.
3. Digital radiography
systems add computer image processing capability to conventional x-ray systems.
Digital radiography can be used in a number of diagnostic procedures which
provide continuous imaging of a particular area with enhanced image quality and
reduced patient exposure to radiation.
Nuclear medicine systems,
which are based upon the detection of gamma radiation generated by radioactive
pharmaceuticals introduced into the body, are used to provide information
concerning soft tissue and internal body organs and particularly to examine
organ function over time.
Ultrasound systems emit,
detect and process high frequency sound waves reflected from organ boundaries
and tissue interfaces to generate images of soft tissue and internal body
organs. Although the images are substantially less detailed than those
obtainable with x-ray methods, ultrasound is generally considered harmless and
therefore has found particular use in imaging the pregnant uterus.
X-ray machines, ultrasound
machines, digital radiography systems and nuclear medicine compete with the MRI
scanners by offering significantly lower price and space requirements. However,
Fonar believes that the quality of the images produced by its MRI scanners is
generally superior to the quality of the images produced by those other
methodologies.
GOVERNMENT
REGULATION
FDA Regulation
The Food and Drug
Administration in accordance with Title 21 of the Code of Federal Regulations
regulates the manufacturing and marketing of Fonar’s MRI scanners. The
regulations can be classified as either pre-market or post-market. The
pre-market requirements include obtaining marketing clearance, proper device
labeling, establishment registration and device listing. Once the products are
on the market, Fonar must comply with post-market surveillance controls. These
requirements include the Quality Systems Regulation, or “QSR”, also known as
Current Good Manufacturing Practices or CGMPs, and Medical Device Reporting,
also referred to as MDR regulations. The QSR is a quality assurance requirement
that covers the design, packaging, labeling and manufacturing of a medical
device. The MDR regulation is an adverse event-reporting program.
Classes of
Products
Under the Medical Device
Amendments of 1976 to the Federal Food, Drug and Cosmetic Act, all medical
devices are classified by the FDA into one of three classes. A Class I device is
subject only to general controls, such as labeling requirements and
manufacturing practices; a Class II device must comply with certain performance
standards established by the FDA; and a Class III device must obtain pre-market
approval from the FDA prior to commercial marketing.
Fonar’s products are Class
II devices. Class I devices are subject to the least regulatory control. They
present minimal potential for harm to the user and are often simpler in design
than Class II or Class III devices. Class I devices are subject to "General
Controls" as are Class II and Class III devices. General Controls
include:
1. Establishment
registration of companies which are required to register under 21 CFR Part
807.20, such as manufacturers, distributors, re-packagers and
re-labelers.
2. Medical device listing
with FDA of devices to be marketed.
3. Manufacturing devices
in accordance with the Current Good Manufacturing Practices Quality System
Regulation in 21 CFR Part 820.
4. Labeling devices in
accordance with labeling regulations in 21 CFR Part 801 or 809.
5. Submission of a
Premarket Notification, pursuant to 510(k), before marketing a
device.
Class II devices are those
for which general controls alone
are insufficient to assure
safety and effectiveness, and existing methods are available to provide such
assurances. In addition to complying with general controls, Class II devices are
also subject to special controls. Special controls may include special labeling
requirements, guidance documents, mandatory performance standards and
post-market surveillance.
We received approval to
market our Beta™ 3000 and Beta™ 3000M scanners as Class III devices on September
26, 1984 and November 12, 1985. On July 28, 1988, the Magnetic Resonance
Diagnostic Device which includes MR Imaging and MR Spectroscopy was reclassified
by the FDA to Class II status. Consequently, Fonar’s products are now classified
as Class II products. On July 26, 1991, Fonar received FDA clearance to market
the Ultimate™ Magnetic Resonance Imaging Scanner as a Class II device. Fonar
received FDA clearance to market the QUAD™ 7000 in April 1995 and the QUAD™
12000 in November 1995. On March 16, 2000, Fonar received FDA clearance to
market the Fonar 360™ for diagnostic imaging, the Open Sky™ version, and on
October 3, 2000 received FDA clearance for the Upright® MRI.
Premarketing
Submission
Each person who wants to
market Class I, II and some III devices intended for human use in the U.S. must
submit a 510(k) to FDA at least 90 days before marketing unless the device is
exempt from 510(k) requirements. A 510(k) is a pre-marketing submission made to
FDA to demonstrate that the device to be marketed is as safe and effective, that
is, substantially equivalent, SE, to a legally marketed device that is not
subject to pre-market approval, PMA. Applicants must compare their 510(k) device
to one or more similar devices currently on the U.S. market and make and support
their substantial equivalency claims.
The FDA is committed to a
90-day clearance after submission of a 510(k), provided the 510(k) is complete
and there is no need to submit additional information or data.
The 510(k) is essentially
a brief statement and description of the product. As Fonar’s scanner products
are Class II products, there are no pre-market data requirements and the process
is neither lengthy nor expensive.
An investigational device
exemption, also referred to as IDE, allows the investigational device to be used
in a clinical study pending FDA clearance in order to collect safety and
effectiveness data required to support the Premarket Approval, also referred to
as PMA, application or a Premarket Notification pursuant to 510(k), submission
to the FDA. Clinical studies are most often conducted to support a
PMA.
For the most part,
however, we have not found it necessary to utilize IDE’s. The standard 90 day
clearance for our new MRI scanner products classified as Class II products makes
the IDE unnecessary, particularly in view of the time and effort involved in
compiling the information necessary to support an IDE.
Quality System
Regulation
The Quality Management
System is applicable to the design, manufacture, administration of installation
and servicing of magnetic resonance imaging scanner systems. The FDA has
authority to conduct detailed inspections of manufacturing plants, to establish
Good Manufacturing Practices which must be followed in the manufacture of
medical devices, to require periodic reporting of product defects and to
prohibit the exportation of medical devices that do not comply with the
law.
Medical Device Reporting
Regulation
Manufacturers must report
all MDR reportable events to the FDA. Each manufacturer must review and evaluate
all complaints to determine whether the complaint represents an event which is
required to be reported to FDA. Section 820.3(b) of the Quality Systems
regulation defines a complaint as, "any written, electronic or oral
communication that alleges deficiencies related to the identity, quality,
durability, reliability, safety, effectiveness, or performance of a device after
it is released for distribution."
A report is required when
a manufacturer becomes aware of information that reasonably suggests that one of
their marketed devices has or may have caused or contributed to a death, serious
injury, or has malfunctioned and that the device or a similar device marketed by
the manufacturer would be likely to cause or contribute to a death or serious
injury if the malfunction were to recur.
Malfunctions are not
reportable if they are not likely to result in a death, serious injury or other
significant adverse event experience.
A malfunction which is or
can be corrected during routine service or device maintenance still must be
reported if the recurrence of the malfunction is likely to cause or contribute
to a death or serious injury if it were to recur.
We have established and
maintained written procedures for implementation of the MDR regulation. These
procedures include internal systems that:
* provide for timely and
effective identification, communication and evaluation of adverse
events;
* provide a standardized
review process and procedures for determining whether or not an event is
reportable; and
*
provide procedures
to insure the timely transmission of complete reports.
These procedures also
include documentation and record keeping requirements for:
* information that was
evaluated to determine if an event was reportable;
* all medical device
reports and information submitted to the FDA;
* any information that was
evaluated during preparation of annual certification reports; and
* systems that ensure
access to information that facilitates timely follow up and inspection by
FDA.
FDA Enforcement
FDA may take the following
actions to enforce the MDR regulation:
FDA-Initiated or Voluntary
Recalls
Recalls are regulatory
actions that remove a hazardous, potentially hazardous, or a misbranded product
from the marketplace. Recalls are also used to convey additional information to
the user concerning the safe use of the product. Either FDA or the manufacturer
can initiate recalls.
There are three
classifications, i.e., I, II, or III, assigned by the Food and Drug
Administration to a particular product recall to indicate the relative degree of
health hazard presented by the product being recalled.
Class I
Is a situation in which
there is a reasonable probability that the use of, or exposure to, a violative
product will cause serious adverse health consequences or death.
Class II
Is a situation in which
use of, or exposure to, a violative product may cause temporary or medically
reversible adverse health consequences or where the probability of serious
adverse health consequences is remote.
Class III
Is a situation in which
use of, or exposure to, a violative product is not likely to cause adverse
health consequences.
Fonar has initiated five
voluntary recalls. Four of the recalls were Class II and one was Class III. The
recalls involved making minor corrections to the product in the field.
Frequently, corrections which are made at the site of the device are called
field corrections as opposed to recalls.
Civil Money
Penalties
The FDA, after an
appropriate hearing, may impose civil money penalties for violations of the
FD&C Act that relate to medical devices. In determining the amount of a
civil penalty, FDA will take into account the nature, circumstances, extent, and
gravity of the violations, the violator's ability to pay, the effect on the
violator's ability to continue to do business, and any history of prior
violations. The civil money penalty may not exceed $15,000 for each violation
and may not exceed $1,000,000 for all violations adjudicated in a single
proceeding, per person.
Warning Letters
FDA issues written
communications to a firm, indicating that the firm may incur more severe
sanctions if the violations described in the letter are not corrected. Warning
letters are issued to cause prompt correction of violations that pose a hazard
to health or that involve economic deception. The FDA generally issues the
letters before pursuing more severe sanctions.
Seizure
A seizure is a civil court
action against a specific quantity of goods which enables the FDA to remove
these goods from commercial channels. After seizure, no one may tamper with the
goods except by permission of the court. The court usually gives the owner or
claimant of the seized merchandise approximately 30 days to decide a course of
action. If they take no action, the court will recommend disposal of the goods.
If the owner decides to contest the government's charges, the court will
schedule the case for trial. A third option allows the owner of the goods to
request permission of the court to bring the goods into compliance with the law.
The owner of the goods is required to provide a bond or, security deposit, to
assure that they will perform the orders of the court, and the owner must pay
for FDA supervision of any activities by the company to bring the goods into
compliance.
Citation
A citation is a formal
warning to a firm of intent to prosecute the firm if violations of the FD&C
Act are not corrected. It provides the firm an opportunity to convince FDA not
to prosecute.
Injunction
An injunction is a civil
action filed by FDA against an individual or company. Usually, FDA files an
injunction to stop a company from continuing to manufacture, package or
distribute products that are in violation of the law.
Prosecution
Prosecution is a criminal
action filed by FDA against a company or individual charging violation of the
law for past practices.
Foreign and Export
Regulation
We obtain approvals as
necessary in connection with the sales of our products in foreign countries. In
some cases, FDA approval has been sufficient for foreign sales as well. Our
standard practice has been to require either the distributor or the customer to
obtain any such foreign approvals or licenses which may be required.
Legally marketed devices
that comply with the requirements of the Food Drug & Cosmetic Act require a
Certificate to Foreign Government issued by the FDA for export. Other devices
that do not meet the requirements of the FD&C Act but comply with the laws
of a foreign government require a Certificate of Exportability issued by the
FDA. All products which we sell have FDA clearance and would fall into the first
category.
Foreign governments have
differing requirements concerning the import of medical devices into their
respective jurisdictions. The European Union, also referred to as EU, made up of
27 individual countries, has some essential requirements described in the EU’s
Medical Device Directive, also referred to as MDD. In order to export to one of
these countries, we must meet the essential requirements of the MDD and any
additional requirements of the importing country. The essential requirements are
similar to some of the requirements mandated by the FDA. In addition the MDD
requires that we enlist a Notified Body to examine and assess our documentation,
a Technical Construction File, and verify that the product has been manufactured
in conformity with the documentation. The notified body must carry out or
arrange for the inspections and tests necessary to verify that the product
complies with the essential requirements of the MDD, including safety
performance and Electromagnetic Compatibility, also referred to as EMC. Also
required is a Quality System, ISO-9001, assessment by the Notified Body. We were
approved for ISO 9001 certification for its Quality Management System in April,
1999.
We received clearances to
sell the Fonar 360™ and Upright® MRI scanners in the EU in May, 2002.
Other countries require
that their own testing laboratories perform an evaluation of our devices. This
requires that we must bring the foreign agency’s personnel to the USA to perform
the evaluation at our expense before exporting.
Some countries, including
many in Latin America and Africa, have very few regulatory
requirements.
To date, Fonar has been
able to comply with all foreign regulatory requirements applicable to its export
sales.
HEALTH MANAGEMENT
CORPORATION OF AMERICA
IMPERIAL MANAGEMENT
SERVICES, LLC
PHYSICIAN AND DIAGNOSTIC
SERVICES MANAGEMENT BUSINESS
Health Management
Corporation of America, formed under the name U.S. Health Management Corporation
and referred to as "HMCA", was organized by FONAR in March 1997. HMCA was formed
as a wholly-owned subsidiary which engages in the business of providing
comprehensive management services to diagnostic imaging facilities. The services
we provide include development, administration, leasing of office space,
facilities and equipment, provision of supplies, staffing, training and
supervision of non-medical personnel, legal services, accounting, billing and
collection and the development and implementation of practice growth and
marketing strategies.
Subsequently, in May 2011,
HMCA contributed all of its assets, liabilities and business to Imperial which
is controlled but not wholly-owned by HMCA. Imperial is continuing the business
of HMCA utilizing the same facilities, equipment and personnel as HMCA. This
transaction did not result in a change of control or policy, but was solely a
means to raise capital. To avoid confusion in making comparisons and to show the
continuity of the business, our physician management and diagnostic services
segment is sometimes referred to as “HMCA-IMPERIAL” for both periods before and
after May 2, 2011.
HMCA-IMPERIAL currently
manages 11 MRI facilities. In April 2003, HMCA-IMPERIAL sold the portion of its
business which managed primary care medical practices, and in July 2005,
HMCA-IMPERIAL sold the portion of its business engaged in the management of
physical therapy and rehabilitation practices. This was the result of
HMCA-IMPERIAL’s decision to focus on management of MRI facilities, the business
in which HMCA-IMPERIAL is most experienced. For the 2011 fiscal year, the
revenues HMCA-IMPERIAL recognized from the MRI facilities increased to $15.3
million, and in fiscal 2012 the revenues recognized from the MRI facilities
further increased to $20.7 million.
HMCA-IMPERIAL GROWTH
STRATEGY
HMCA-IMPERIAL’s growth
strategy focuses on upgrading and expanding the existing facilities it manages
and expanding the number of facilities it manages for its clients. Our most
important effort in this regard has been to promote and facilitate the
replacement of existing MRI scanners with new Fonar Upright® MRI scanners.
Presently, we have Upright® MRI scanners at all of the MRI facilities we
manage.
On May 1, 2010,
HMCA-IMPERIAL purchased a 15.2% interest from an unrelated party of an entity
that provides management services to a diagnostic center in the New York
Metropolitan area. On January 1, 2011, the Company purchased an additional 34.8%
interest by the issuance of a promissory note of $400,000.
HMCA-IMPERIAL recently
added an eleventh Upright® MRI facility that it manages in Westchester County,
New York.
In connection with its
focus on managing only MRI facilities, HMCA-IMPERIAL sold its business of
managing physical therapy and rehabilitation practices on July 28, 2005 to
Health Plus Management Services, L.L.C.
PHYSICIAN AND DIAGNOSTIC
MANAGEMENT SERVICES
HMCA-IMPERIAL's services
to the facilities it manages encompass substantially all of their business
operations. Each facility is controlled, however, by the physician owner, not
HMCA-IMPERIAL, and all medical services are performed by the physicians and
other medical personnel under the physician-owner’s supervision. HMCA-IMPERIAL
is the management company and performs services of a non-professional nature.
These services include:
1. Offices and Equipment.
HMCA-IMPERIAL identifies, negotiates leases for and/or provides office space and
equipment to its clients. This includes technologically sophisticated medical
equipment. HMCA-IMPERIAL also provides improvements to leaseholds, assistance in
site selection and advice on improving, updating, expanding and adapting to new
technology.
2. Personnel.
HMCA-IMPERIAL staffs all the non-medical positions of its clients with its own
employees, eliminating the client's need to interview, train and manage
non-medical employees. HMCA-IMPERIAL processes the necessary tax, insurance and
other documentation relating to employees.
3. Administrative.
HMCA-IMPERIAL assists in the scheduling of patient appointments, purchasing of
office and medical supplies and equipment and handling of reporting, accounting,
processing and filing systems. It prepares and files the physician portions of
complex forms to enable its clients to participate in managed care programs and
to qualify for insurance reimbursement. HMCA-IMPERIAL assists the clients to
implement programs and procedures to ensure full and timely regulatory
compliance and appropriate cost reimbursement under no-fault insurance and
Workers' Compensation guidelines, as well as compliance with other applicable
governmental requirements and regulations, including HIPAA and other privacy
requirements.
4. Billing and
Collections. HMCA-IMPERIAL is responsible for the billing and collection of
revenues from third-party payors including those governed by No-Fault and
Workers' Compensation statutes. HMCA-IMPERIAL is presently using a third party
to perform its billing and collection services for its clients’ No-Fault and
Workers’ Compensation scanning business.
5. Cost Saving Programs.
Based on available volume discounts, HMCA-IMPERIAL seeks to assist in obtaining
favorable pricing for office and medical supplies, equipment, contrast agents,
such as gadolinuim, and other inventory for its clients.
6. Diagnostic Imaging and
Ancillary Services. HMCA-IMPERIAL can offer access to diagnostic imaging
equipment through diagnostic imaging facilities it manages. The Company may
expand the ancillary services offered in its network to include CT-scans and
x-rays, if it is determined that such additions may be useful to
clients.
7. Marketing Strategies.
HMCA-IMPERIAL is responsible for developing and proposing marketing plans for
its clients.
8. Expansion Plans.
HMCA-IMPERIAL assists the clients in developing expansion plans including the
opening of new or replacement facilities where appropriate.
HMCA-IMPERIAL advises
clients on all aspects of their businesses, including expansion where it is a
reasonable objective, on a continuous basis. HMCA-IMPERIAL’s objective is to
free physicians from as many non-medical duties as is practicable. Practices can
treat patients more efficiently if the physicians can spend less time on
business and administrative matters and more time practicing
medicine.
HMCA-IMPERIAL provides its
services pursuant to negotiated contracts with its clients. While HMCA-IMPERIAL
believes it can provide the greatest value to its clients by furnishing the full
range of services appropriate to that client, HMCA-IMPERIAL would also be
willing to enter into contracts providing for a more limited spectrum of
management services.
The facilities enter into
contracts with third party payors, including managed care companies. Neither
HMCA-IMPERIAL’s clients nor HMCA-IMPERIAL participate in any capitated plans or
other risk sharing arrangements. Capitated plans are those HMO programs where
the provider is paid a flat monthly fee per patient.
As of June 22, 2007, Dr.
Robert Diamond purchased the stock of the professional corporations owning eight
New York sites managed by HMCA-IMPERIAL, previously owned by Dr. Raymond V.
Damadian, the President, Chairman of the Board and principal stockholder of
Fonar. Dr. Diamond has been reading scans for HMCA-IMPERIAL managed facilities
for more than seven years. In connection with the sale, new management
agreements were substituted for the existing management agreements, providing,
for the same management services. The fees in fiscal 2009, however, were flat
monthly fees in the aggregate amount of $578,500 per month. The fees in fiscal
2010 were flat monthly fees in the aggregate amount of $696,000 per month and in
fiscal 2011 increased to $892,930 per month in the aggregate. Fees under the
management agreements are subject to adjustment by mutual agreement on an annual
basis.
In fiscal 2012, the
aggregate amount of management fees increased to $1,708,739 per month in the
aggregate.
Dr. Damadian still owns
the three MRI facilities in Florida managed by HMCA-IMPERIAL. The fees for the
three sites in Florida owned by Dr. Damadian are flat monthly fees ranging from
$194,051 to $241,266 per month. No MRI facilities or other medical facilities
are owned by HMCA-IMPERIAL.
HMCA-IMPERIAL contracts
with Tritech Healthcare Management (Plainview, New York) to perform billing and
collection for its clients’ No-Fault and Workers’ Compensation business for a
fee of 5% of all adjusted No-Fault and Workers’ Compensation claims with a
$30,000 monthly cap. As of June 30, 2012, the fee was $360,000. HMCA-IMPERIAL
handles all of its clients’ other billings and collections.
In June 2011, Health
Diagnostics, LLC, outsourced its billing, collections and credentialing
operations for the sites that it manages to HMCA-IMPERIAL. The fee is 5% of all
adjusted deposits. The revenue received by HMCA-IMPERIAL in fiscal 2011 from
this arrangement was $76,148 and in fiscal 2012 was $1,824,802. This agreement
is for a term of five years.
Since the types of medical
practices that Health Diagnostics manages are very similar to those that
HMCA-IMPERIAL manages, it is a natural expansion of HMCA-IMPERIAL services. With
HMCA-IMPERIAL’s 14 years of experience in billing, collecting and credentialing,
this agreement is expected to benefit the customer and enhance the profitability
of HMCA-IMPERIAL.
HMCA-IMPERIAL
MARKETING
HMCA-IMPERIAL's marketing
strategy is to expand the business and improve the facilities which it manages.
HMCA-IMPERIAL will seek to increase the number of locations of those facilities
where market conditions are promising and to promote growth of its clients'
patient volume and revenue.
DIAGNOSTIC IMAGING
FACILITIES AND OTHER ANCILLIARY SERVICES
Diagnostic imaging
facilities managed by HMCA-IMPERIAL provide diagnostic imaging services to
patients referred by physicians who are either in private practice or affiliated
with managed care providers or other payor groups. The facilities are operated
in a manner which eliminates the admission and other administrative
inconveniences of in-hospital diagnostic imaging services. Imaging services are
performed in an outpatient setting by trained medical technologists under the
direction of physicians employed by the diagnostic imaging facilities. Following
diagnostic procedures, the images are reviewed by the interpreting physicians
who prepare a report of these tests and their findings. These reports are
transcribed by HMCA-IMPERIAL personnel and then delivered to the referring
physician.
HMCA-IMPERIAL develops
marketing programs in an effort to establish and maintain profitable referring
physician relationships and to maximize reimbursement yields. These marketing
approaches identify and target selected market segments consisting of area
physicians with certain desirable medical specialties and reimbursement yields.
Corporate and facility managers determine these market segments based upon an
analysis of competition, imaging demand, medical specialty and payor mix of each
referral from the local market. HMCA-IMPERIAL also directs marketing efforts at
managed care providers.
Managed care providers
have become an important factor in the diagnostic imaging industry. To further
its position, HMCA-IMPERIAL is seeking to expand the imaging modalities offered
at its managed diagnostic imaging facilities.
REIMBURSEMENT
HMCA-IMPERIAL’s clients
receive reimbursements for their MRI scans through Medicare, Medicaid, managed
care and private insurance.
Medicare
The Medicare program
provides reimbursement for hospitalization, physician, diagnostic and certain
other services to eligible persons 65 years of age and over and certain other
individuals. Providers are paid by the federal government in accordance with
regulations promulgated by the Department of Health and Human Services, HSS, and
generally accept the payment with nominal deductible and co-insurance amounts
required to be paid by the service recipient, as payment in full. Hospital
inpatient services are reimbursed under a prospective payment system. Hospitals
receive a specific prospective payment for inpatient treatment services based
upon the diagnosis of the patient.
Under Medicare’s
prospective payment system for hospital outpatient services, or OPPS, a hospital
is paid for outpatient services on a rate per service basis that varies
according to the ambulatory payment classification group, or APC, to which the
service is assigned rather than on a hospital’s costs. Each year the Centers for
Medicare and Medicaid Services, or CMS, publishes new APC rates that are
determined in accordance with the promulgated methodology.
Services provided in
non-hospital based freestanding facilities, such as independent diagnostic
treatment facilities, are paid under the Medicare Physician Fee Schedule, or
MPFS. All of HMCA-IMPERIAL’s clients are presently in this category of
independent diagnostic treatment facilities. The MPFS is updated on an annual
basis.
Healthcare Reform
Legislation
Healthcare reform
legislation enacted in the first quarter of 2010 by the Patient Protection and
Affordable Care Act or PPACA, specifically requires the U.S. Department of
Health and Human Services, in computing physician practice expense relative
value units, to increase the equipment utilization factor for advanced
diagnostic imaging services (such as MRI, CT and PET) from a presumed
utilization rate of 50% to 65% for 2010 through 2012, 70% in 2013, and 75%
thereafter. Excluded from the adjustment are low-technology imaging modalities
such as ultrasound, X-ray and fluoroscopy. The Health Care and Education
Reconciliation Act of 2010 (H.R. 4872) or Reconciliation Act, which was passed
by the Senate and approved by the President on March 30, 2010, amends the
provision for higher presumed utilization of advanced diagnostic imaging
services to a presumed rate of 75%. These changes may result in decreased
revenue for the scans we perform for Medicare beneficiaries. Other changes in
reimbursement for services rendered by Medicare Advantage plans may also reduce
the revenues we receive for services rendered to Medicare Advantage
enrollees.
We have experienced
reimbursement reductions for radiology services provided to Medicare
beneficiaries, including reductions pursuant to the Deficit Reduction Act, or
DRA.
The DRA, which became
effective in 2007, set reimbursement for the technical component for imaging
services (excluding diagnostic and screening mammography) in non-hospital based
freestanding facilities at the lesser of OPPS or the MPFS.
In addition to the
foregoing changes to the usage assumptions, CMS’ 2010 regulatory changes to the
MPFS also included a downward adjustment to services primarily involving the
technical component rather than the physician work component, by adjusting
downward malpractice payments for these services. The reductions will affect the
services we provide, primarily impacting radiology and other diagnostic tests.
As noted above, the changes to the MPFS will be transitioned over a four-year
period such that beginning in 2013, CMS will fully implement the revised payment
rates. This change to the MPFS, could have an adverse effect on our financial
condition and results of operations. For our fiscal year ended June 30, 2012,
Medicare revenues represented approximately 8.3% of the revenues for
HMCA-IMPERIAL’s clients. The impact of the new MPFS will increase over the
four-year transition period unless mitigated by future legislation (either
currently proposed or pledged by Congress and the federal government
administration).
Many of PPACA’s provisions
will not take effect for months or several years, while others are effective
immediately. Many provisions also will require the federal government and
individual state governments to interpret and implement the new requirements. In
addition, PPACA remains the subject of significant debate, and proposals to
repeal, block or amend the law have been introduced in Congress and many state
legislatures. Finally, a number of state attorneys general have filed legal
challenges to PPACA seeking to block its implementation on constitutional
grounds. Because of the many variables involved, we are unable to predict how
many of the legislative mandates contained in PPACA will be implemented or in
what form, whether any additional or similar changes to statutes or regulations
(including interpretations), will occur in the future, or what effect any future
legislation or regulation would have on our business.
Medicaid
The Medicaid program is a
jointly-funded federal and state program providing coverage for low-income
persons. In addition to federally-mandated basic services, the services offered
and reimbursement methods vary from state to state. In many states, Medicaid
reimbursement is patterned after the Medicare program; however, an increasing
number of states have established or are establishing payment methodologies
intended to provide healthcare services to Medicaid patients through managed
care arrangements. In fiscal 2012, approximately 1.1% of the revenues of
HMCA-IMPERIAL’s clients were attributable to Medicaid.
Managed Care and Private
Insurance.
Health Maintenance
Organizations, or HMO’s, Preferred Provider Organizations, or PPOs, and other
managed care organizations attempt to control the cost of healthcare services by
a variety of measures, including imposing lower payment rates, preauthorization
requirements, limiting services and mandating less costly treatment
alternatives. Managed care contracting is competitive and reimbursement
schedules are at or below Medicare reimbursement levels. Some managed care
organizations have reduced or otherwise limited, and other managed care
organizations may reduce or otherwise limit, reimbursement in response to
reductions in government reimbursement. These reductions could have an adverse
impact on our financial condition and results of operations. These reductions
have been, and any future reductions may be, similar to the reimbursement
reductions proposed by CMS, Congress and the current federal government
administration. The development and expansion of HMOs, PPOs and other managed
care organizations within our core markets could have a negative impact on
utilization of our services in certain markets and/or affect the revenues per
procedure we can collect, since such organizations will exert greater control
over patients’ access to diagnostic imaging services, the selection of the
provider of such services and the reimbursement thereof.
HMCA-IMPERIAL
COMPETITION
The physician and
diagnostic management services field is highly competitive. A number of large
hospitals have acquired medical practices and this trend may continue.
HMCA-IMPERIAL expects that more competition will develop. Many competitors have
greater financial and other resources than HMCA-IMPERIAL.
With respect to the
diagnostic imaging facilities managed by HMCA-IMPERIAL, the outpatient
diagnostic imaging industry is highly competitive. Competition focuses primarily
on attracting physician referrals at the local market level and increasing
referrals through relationships with managed care organizations. HMCA-IMPERIAL
believes that principal competitors for the diagnostic imaging centers are
hospitals and independent or management company-owned imaging centers.
Competitive factors include quality and timeliness of test results, ability to
develop and maintain relationships with managed care organizations and referring
physicians, type and quality of equipment, facility location, convenience of
scheduling and availability of patient appointment times. HMCA-IMPERIAL believes
that it will be able to effectively meet the competition in the outpatient
diagnostic imaging industry with the new Fonar Upright® MRI scanners at its
facilities.
GOVERNMENT REGULATION
APPLICABLE TO HMCA-IMPERIAL
FEDERAL
REGULATION
The healthcare industry is
highly regulated and changes in laws and regulations can be significant. Changes
in the law or new interpretation of existing laws can have a material effect on
our permissible activities, the relative costs associated with doing business
and the amount of reimbursement by government and other third-party
payors.
Federal False Claims
Act
The federal False Claims
Act and, in particular, the False Claims Act’s “qui tam” or “whistleblower”
provisions allow a private individual to bring actions in the name of the
government alleging that a defendant has made false claims for payment from
federal funds. After the individual has initiated the lawsuit, the government
must decide whether to intervene in the lawsuit and to become the primary
prosecutor. If the government declines to join the lawsuit, the individual may
choose to pursue the case alone, although the government must be kept apprised
of the progress of the lawsuit, and may intervene later. Whether or not the
federal government intervenes in the case, it will receive the majority of any
recovery. If the litigation is successful, the individual is entitled to no less
than 15%, but no more than 30%, of whatever amount the government recovers that
is related to the whistleblower’s allegations. When an entity is determined to
have violated the federal False Claims Act, it must pay three times the actual
damages sustained by the government, plus mandatory civil penalties of between
$5,500 to $11,000 for each separate false claim, as well as the government’s
attorneys’ fees. Liability arises when an entity knowingly submits, or causes
someone else to submit, a false claim for reimbursement to the federal
government. The False Claims Act defines the term “knowingly” broadly, though
simple negligence will not give rise to liability under the False Claims Act.
Examples of the other actions which may lead to liability under the False Claims
Act:
Failure to comply with the
many technical billing requirements applicable to our Medicare and Medicaid
business.
Failure to comply with the
prohibition against billing for services ordered or supervised by a physician
who is excluded from any federal healthcare program, or the prohibition against
employing or contracting with any person or entity excluded from any federal
healthcare program.
Failure to comply with the
Medicare physician supervision requirements for the services we provide, or the
Medicare documentation requirements concerning physician supervision.
The Fraud Enforcement and
Recovery Act of 2009 expanded the scope of the False Claims Act by, among other
things, broadening protections for whistleblowers and creating liability for
knowingly retaining a government overpayment, acting in deliberate ignorance of
a government overpayment or acting in reckless disregard of a government
overpayment. The recently enacted healthcare reform bills in the form of the
Patient Protection and Affordable Care Act, as amended by the Health Care and
Education Reconciliation Act of 2010 (collectively, “PPACA”) expanded on changes
made by the 2009 Fraud Enforcement and Recovery Act with regard to such “reverse
false claims.” Under PPACA, the knowing failure to report and return an
overpayment within 60 days of identifying the overpayment or by the date a
corresponding cost report is due, whichever is later, constitutes a violation of
the False Claims Act. HMCA-IMPERIAL and its clients have never been sued under
the False Claims Act and believe they are in compliance with the law.
Stark Law
Under the federal
Self-Referral Law, also referred to as the "Stark Law", which is applicable to
Medicare and Medicaid patients, and the self-referral laws of various States,
certain health practitioners, including physicians, chiropractors and
podiatrists, are prohibited from referring their patients for the provision of
designated health services, including diagnostic imaging and physical therapy
services, to any entity with which they or their immediate family members have a
financial relationship, unless the referral fits within one of the specific
exceptions in the statutes or regulations. The federal government has taken the
position that a violation of the federal Stark Law is also a violation of the
Federal False Claims Act. Statutory exceptions under the Stark Law include,
among others, direct physician services, in-office ancillary services rendered
within a group practice, space and equipment rental and services rendered to
enrollees of certain prepaid health plans. Some of these exceptions are also
available under the State self-referral laws. HMCA-IMPERIAL believes that it and
its clients are in compliance with these laws.
Anti-kickback
Regulation
We are subject to federal
and state laws which govern financial and other arrangements between healthcare
providers. These include the federal anti-kickback statute which, among other
things, prohibits the knowing and willful solicitation, offer, payment or
receipt of any remuneration, direct or indirect, in cash or in kind, in return
for or to induce the referral of patients for items or services covered by
Medicare, Medicaid and certain other governmental health programs. Under PPACA,
knowledge of the anti-kickback statute or the specific intent to violate the law
is not required. Violation of the anti-kickback statute may result in civil or
criminal penalties and exclusion from the Medicare, Medicaid and other federal
healthcare programs, and according to PPACA, now provides a basis for liability
under the False Claims Act. In addition, it is possible that private parties may
file “qui tam” actions based on claims resulting from relationships that violate
the anti-kickback statute, seeking significant financial rewards. Many states
have enacted similar statutes, which are not limited to items and services paid
for under Medicare or a federally funded healthcare program. Neither
HMCA-IMPERIAL nor its clients engage in this practice.
In fiscal 2012,
approximately 8.3% of the revenues of HMCA-IMPERIAL’s clients were attributable
to Medicare and 1.1% were attributable to Medicaid. In fiscal 2011,
approximately 17.4% of the revenues of HMCA-IMPERIAL’s clients were attributable
to Medicare and 2.7% were attributable to Medicaid.
Deficit Reduction Act
(DRA)
On February 8, 2006, the
President signed into law the DRA. Effective January 1, 2007, the DRA provides
that Medicare reimbursement for the technical component for imaging services
(excluding diagnostic and screening mammography) performed in freestanding
facilities will be capped. Payment will be the lesser of the Medicare Physician
Fee Schedule or the Hospital Outpatient Prospective Payment System (HOPS) rates.
Implementation of these reimbursement reductions contained in the DRA has had an
adverse effect on our business. In fiscal 2012, however, we were able to counter
this effect by increasing our clients’ scan volumes through our vigorous
marketing efforts.
The DRA also codified the
reduction in reimbursement for multiple images on contiguous body parts
previously announced by CMS, the agency responsible for administering the
Medicare program. In November 2005, CMS announced that it would pay 100% of the
technical component of the higher priced imaging procedure and 50% of the
technical component of each additional imaging procedure for imaging procedures
involving contiguous body parts within a family of codes when performed in the
same session. CMS had indicated that it would phase in this 50% rate reduction
over two years, so that the reduction was 25% for each additional imaging
procedure in 2006 and another 25% reduction scheduled for 2007. However, for
services furnished on or after July 1, 2010, the PPACA which, as stated above,
was signed into law on March 23, 2010, requires the full 50% reduction to be
implemented. We have determined that the impact of this final 25% reduction is,
and will likely be in the future, immaterial to our operating
results.
Health Insurance
Portability and Accountability Act
Congress enacted the
Health Insurance Portability and Accountability Act of 1996, or HIPAA, in part,
to combat healthcare fraud and to protect the privacy and security of patients’
individually identifiable healthcare information. HIPAA, among other things,
amends existing crimes and criminal penalties for Medicare fraud and enacts new
federal healthcare fraud crimes, including actions affecting non-government
healthcare benefit program by means of false or fraudulent representations in
connection with the delivery of healthcare services is subject to a fine or
imprisonment, or potentially both. In addition, HIPAA authorizes the imposition
of civil money penalties against entities that employ or enter into contracts
with excluded Medicare or Medicaid program participants if such entities provide
services to federal health program beneficiaries. A finding of liability under
HIPAA could have a material adverse effect on our business, financial condition
and results of operations.
Further, HIPAA requires
healthcare providers and their business associates to maintain the privacy and
security of individually identifiable protected health information (“PHI”).
HIPAA imposes federal standards for electronic transactions, for the security of
electronic health information and for protecting the privacy of PHI. The Health
Information Technology for Economic and Clinical Health Act of 2009 (“HITECH”),
signed into law on February 17, 2009, dramatically expanded, among other things,
(1) the scope of HIPAA to now apply directly to “business associates,” or
independent contractors who receive or obtain PHI in connection with providing a
service to a covered entity, (2) substantive security and privacy obligations,
including new federal security breach notification requirements to affected
individuals, DHHS and prominent media outlets, of certain breaches of unsecured
PHI, (3) restrictions on marketing communications and a prohibition on covered
entities or business associates from receiving remuneration in exchange for PHI,
and (4) the civil and criminal penalties that may be imposed for HIPAA
violations, increasing the annual cap in penalties from $25,000 to $1.5 million
per year.
In addition, many states
have enacted comparable privacy and security statues or regulations that, in
some cases, are most stringent than HIPAA requirements. In those cases it may be
necessary to modify our operations and procedures to comply with the more
stringent state laws, which may entail significant and costly changes for us. We
believe that we are in compliance with such state laws and regulations. However,
if we fail to comply with applicable state laws and regulations, we could be
subject to additional sanctions.
We believe that we are in
compliance with the current HIPAA requirements, as amended by HITECH, and
comparable state laws, but we anticipate that we may encounter certain costs
associated with future compliance. Moreover, we cannot guarantee that
enforcement agencies or courts will not make interpretations of the HIPAA
standards that are inconsistent with ours, or the interpretations of our
contracted radiology practices or their affiliated physicians. A finding of
liability under the HIPAA standards may result in significant criminal and civil
penalties. Noncompliance also may result in exclusion from participation in
government programs, including Medicare and Medicaid. These actions could have a
material adverse effect on our business, financial condition, and results of
operations.
Civil Money Penalty Law
and Other Federal Statutes
The Civil Money Penalty,
or CMP, law covers a variety of practices. It provides a means of administrative
enforcement of the anti-kickback statute, and prohibits false claims, claims for
medically unnecessary services, violations of Medicare participating provider or
assignment agreements and other practices. The statute gives the Office of
Inspector General of the HHS the power to seek substantial civil fines,
exclusion and other sanctions against providers or others who violate the CMP
prohibitions.
In addition, in 1996,
Congress created a new federal crime: healthcare fraud and false statements
relating to healthcare matters. The healthcare fraud statute prohibits knowingly
and willfully executing a scheme to defraud any healthcare benefit program,
including private payors. A violation of this statute is a felony and may result
in fines, imprisonment or exclusion from government sponsored programs such as
the Medicare and Medicaid programs.
Certificates of
Need
Some states require
hospitals and certain other healthcare facilities and providers to obtain a
certificate of need, or CON, or similar regulatory approval prior to
establishing certain healthcare operations or services, incurring certain
capital projects and/or the acquisition of major medical equipment including MRI
and PET/CT systems. We are not operating in any such states.
Patient Protection and
Affordable Care Act
On March 23, 2010,
President Obama signed into law healthcare reform legislation in the form of
PPACA. The implementation of this law will likely have a profound impact on the
healthcare industry. Most of the provisions of PPACA will be phased in over the
next four years and can be conceptualized as a broad framework not only to
provide health insurance coverage to millions of Americans, but to fundamentally
change the delivery of care by bringing together elements of health information
technology, evidence-based medicine, chronic disease management, medical
“homes,” care collaboration and shared financial risk in a way that will
accelerate industry adoption and change. There are also many provisions
addressing cost containment, reductions of Medicare and other payments and
heightened compliance requirements and additional penalties, which will create
further challenges for providers. We are unable to predict the full impact of
PPACA at this time due to the law’s complexity and current lack of implementing
regulations or interpretive guidance. Moving forward, we believe that the
federal government will likely have greater involvement in the healthcare
industry than in prior years.
State
Regulation
In addition to the federal
self-referral law and federal Anti-kickback statute, many States, including
those in which HMCA-IMPERIAL and its clients operate, have their own versions of
self-referral and anti-kickback laws. These laws are not limited in their
applicability, as are the federal laws, to specific programs. HMCA-IMPERIAL
believes that it and its clients are in compliance with these laws.
Various States prohibit
business corporations from practicing medicine. Various States also prohibit the
sharing of professional fees or fee splitting. Consequently, HMCA-IMPERIAL
leases space and equipment to clients and provides clients with a range of
non-medical administrative and managerial services for agreed upon fees.
HMCA-IMPERIAL does not engage in the practice of medicine or establish standards
of medical practice or policies for its clients in any State even where
permitted.
HMCA-IMPERIAL's clients
generate revenue from patients covered by no-fault insurance and workers'
compensation programs. For the fiscal year ended June 30, 2012 approximately
33.8% of our clients’ receipts were from patients covered by no-fault insurance
and approximately 3.7% of our client’s receipts were from patients covered by
workers’ compensation programs. For the fiscal year ended June 30, 2011,
approximately 30.7% of HMCA-IMPERIAL’s clients’ receipts were from patients
covered by no-fault insurance and approximately 3.5% of HMCA-IMPERIAL’s clients’
receipts were from patients covered by workers’ compensation programs. In the
event that changes in these laws alter the fee structures or methods of
providing service, or impose additional or different requirements, HMCA-IMPERIAL
could be required to modify its business practices and services in ways that
could be more costly to HMCA-IMPERIAL or in ways that decrease the revenues
which HMCA-IMPERIAL receives from its clients.
Compliance
Program
We maintain a program to
monitor compliance with federal and state laws and regulations applicable to the
healthcare entities. We have a compliance officer who is charged with
implementing and supervising our compliance program, which includes the adoption
of (i) Standards of Conduct for our employees and affiliates and (ii) a process
that specifies how employees, affiliates and others may report regulatory or
ethical concerns to our compliance officer. We believe that our compliance
program meets the relevant standards provided by the Office of Inspector General
of the Department of Health and Human Services.
An important part of our
compliance program consists of conducting periodic audits of various aspects of
our operations and that of the contracted radiology practices. We also conduct
mandatory educational programs designed to familiarize our employees with the
regulatory requirements and specific elements of our compliance
program.
HMCA-IMPERIAL believes
that it and its clients are in compliance with applicable Federal, State and
local laws. HMCA-IMPERIAL does not believe that such laws will have any material
effect on its business.
EMPLOYEES
As of July 1, 2012, we
employed 244 persons on a full-time and part-time basis. Of such employees, 4
were engaged in marketing and sales, 9 in research and development, 17 in
production, 33 in customer support services, 21 in administration, 102 on site
at facilities and offices, 35 performing billing and collection functions
managed by HMCA-IMPERIAL and 23 performing transcription services for those
facilities.
FONAR CORPORATION AND
SUBSIDIARIES
ITEM 2.
PROPERTIES
Fonar leases approximately
117,000 square feet of office and plant space at its principal offices in
Melville, New York and at one other location in Melville, New York at a current
aggregate annual rental rate of $1,336,043, excluding utilities, taxes and other
related expenses. The term of one of the leases includes options to renew up
through 2016 and the terms of the other leases extend to 2013. Management
believes that the premises will be adequate for its current needs. HMCA-IMPERIAL
already has consolidated its headquarters with those of Fonar as part of Fonar’s
cost cutting program. HMCA-IMPERIAL maintains leased office premises for its
clients at the clients’ sites having an aggregate annual rental rate of
approximately $849,000 under leases having various terms.
ITEM 3. LEGAL
PROCEEDINGS
On or about June 30, 2010,
one of Fonar’s customers, Golden Triangle Company, commenced an action against
Fonar and certain individual defendants employed or formerly employed by Fonar,
in the United States District Court for the Eastern District of New York based
on the alleged wrongful failure of Fonar to deliver a scanner in Kuwait. The
claim alleges various causes of action including breach of contract, fraud,
conspiracy to defraud and conversion. Golden Triangle Company v. Fonar
Corporation et al, CV10-2933. Plaintiff contracted with Fonar to purchase a
scanner, and paid $1,455,500 in advance. The scanner was never delivered, but
Plaintiff never designed a site for delivery either. Alleging other damages,
fraud and deceptive trade practices, Plaintiff seeks as much as $5,000,000.
Fonar made a motion to dismiss the complaint, the outcome of which left
plaintiff with only a cause of action for breach of contract. The claims against
the individual officers and employees of Fonar were dismissed. Fonar now has
filed its answer, together with a counterclaim alleging that the plaintiff, by
attempting to overcharge the end-customer, has damaged Fonar’s reputation and
ability to sell in Kuwait. Golden Triangle has replied to Fonar’s counterclaim
and the case is now in discovery. The deadline for completing discovery is
December 31, 2012.
In addition, we are or
were party to additional less significant actions in which the customers are
seeking to obtain a return of their deposits for MRI scanners on the grounds
that various contingencies failed to materialize. Upright MRI of Chicago, LLC v.
Fonar, Circuit Court of Cook County, Illinois ($310,000), Matt Malek Madison v.
Fonar, U.S. District Court, Northern District of California ($300,000), and Jack
Shapiro v. Fonar Corporation, Supreme Court, Nassau County, New York ($500,000
although the actual deposit was $323,000). In the Upright MRI of Chicago case,
the case was settled by an arrangement whereby a third party took over the sales
agreement and agreed to pay the original purchaser the down payment it made. In
the Madison case, the Court granted summary judgment to Madison for the deposit
and prejudgment interest. We appealed the judgment but lost. Inexplicitly,
however, the plaintiff has not taken any action to enforce the judgment. As of
June 30, 2012, the Company recorded a liability of $372,000 in connection with
this judgment. In the Shapiro case, Shapiro, who was also a sales representative
for Fonar, and Fonar were attempting to negotiate a settlement, but the
plaintiff has served Fonar with discovery demands.
On December 2, 2011,
Bonutti Research filed an action filed in U.S. District Court for the Eastern
District Court of New York. The complaint alleges that Fonar’s Upright® MRI
scanners infringe plaintiff’s patent. Fonar believes plaintiff’s claims are
without merit. Fonar believes the claims of the Bonutti patent are invalidated
by bibliography of published prior art. In addition the Bonutti invention was
never built and does not work for multiple technologic reasons. The plaintiff
served the complaint on the last possible day permitted after filing. The
defendants obtained an extension of time to answer to May 18, 2012.
Subsequently, on or about July 3, 2012, Bonutti hired new substitute counsel and
requested a 60 day extension to answer Fonar’s counterclaims and to postpone the
initial conference. Bonutti has answered our counterclaims and an initial
conference with the magistrate judge has been scheduled. The conference with the
court is now scheduled for September 28, 2012. At this point we are unable to
assess the amount in controversy as no damages were specified. The patent in
question has now expired.
FONAR CORPORATION AND
SUBSIDIARIES
Part II
ITEM 5. MARKET FOR
REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
Our Common Stock is traded
in the Nasdaq SmallCap market under the National Association of Securities
Dealers Automated Quotation System, also referred to as "NASDAQ", symbol FONR.
The following table sets forth the high and low trades reported in NASDAQ System
for the periods shown.
Fiscal
Quarter
|
|
High
|
|
Low
|
January -
March 2010
|
|
|
3.81
|
|
|
|
1.19
|
|
April
- June
2010
|
|
|
2.24
|
|
|
|
1.40
|
|
July
- September 2010
|
|
|
1.94
|
|
|
|
1.31
|
|
October -
December 2010
|
|
|
2.29
|
|
|
|
1.00
|
|
January -
March 2011
|
|
|
2.57
|
|
|
|
1.25
|
|
April
- June
2011
|
|
|
3.20
|
|
|
|
1.65
|
|
July
- September 2011
|
|
|
2.70
|
|
|
|
1.63
|
|
October -
December 2011
|
|
|
2.16
|
|
|
|
1.36
|
|
January -
March 2012
|
|
|
2.89
|
|
|
|
1.68
|
|
April
- June
2012
|
|
|
6.80
|
|
|
|
2.68
|
|
July
- September 14, 2012
|
|
|
4.12
|
|
|
|
3.02
|
|
On September 6, 2012, we
had approximately 2,652 stockholders of record of our Common Stock, 12
stockholders of record of our Class B Common Stock, 3 stockholders of record of
our Class C Common Stock and 2,456 stockholders of record of our Class A
Non-voting Preferred Stock.
At the present time, the
only class of our securities for which there is a market is the Common
Stock.
We paid cash dividends in
fiscal 1998 and the first three quarters of fiscal 1999 on monies we received
from the enforcement of our patents. Except for these dividends, we have not
paid any cash dividends. Except for these dividends, we expect that we will
retain earnings to finance the development and expansion of our business for the
foreseeable future.
FONAR CORPORATION AND
SUBSIDIARIES
ITEM 7. MANAGEMENT'S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATION.
INTRODUCTION.
Fonar was formed in 1978
to engage in the business of designing, manufacturing and selling MRI scanners.
In 1997, we formed a wholly-owned subsidiary, Health Management Corporation of
America, also referred to as "HMCA-IMPERIAL", formerly known as U.S. Health
Management Corporation, in order to expand into the physician and diagnostic
management services business.
Fonar's principal MRI
products are its Stand-Up®/Upright® MRI and Fonar 360™ MRI scanners. The
Stand-Up® MRI allows patients to be scanned for the first time under
weight-bearing conditions. The Stand-Up® MRI is the only MRI capable of
producing images in the weight-bearing state.
At 0.6 Tesla field
strength, the Upright® MRI and Fonar 360™ magnets are among the highest field
open MRI scanners in the industry, offering non-claustrophobic MRI together with
high-field image quality. Fonar’s open MRI scanners were the first high field
strength open MRI scanners in the industry.
HMCA-IMPERIAL commenced
operations in July, 1997 and generates revenues from providing comprehensive
management services, including development, administration, accounting, billing
and collection services, together with office space, medical equipment, supplies
and non-medical personnel to its clients. Revenues are in the form of fees which
are earned under contracts with HMCA-IMPERIAL’s clients. Since July 2005,
HMCA-IMPERIAL has engaged only in the management of MRI facilities.
For the fiscal years ended
June 30, 2012 and June 30, 2011, 32.2% and 33.6%, respectively, of
HMCA-IMPERIAL’s revenues were derived from contracts with facilities owned by
Dr. Raymond V. Damadian, the President of Fonar and HMCA-IMPERIAL and principal
stockholder of Fonar. The agreements with these MRI facilities are for one-year
terms which renew automatically on an annual basis, unless terminated. The fees
for the sites owned by Dr. Damadian in Florida are flat monthly fees ranging
from $194,051 to $241,266. The balance of HMCA-IMPERIAL’s revenues are derived
from contracts with MRI facilities purchased by Dr. Robert Diamond from Dr.
Damadian. The MRI facilities owned by Dr. Diamond are charged a flat fee,
pursuant to contracts executed in connection with the sale of the MRI facilities
at the end of fiscal 2007. The fees are reviewed and if appropriate, adjusted on
an annual basis by mutual agreement. During fiscal 2012, these fees ranged from
$100,000 per month to $241,000 per month.
Industry
Updates
For services for which we
bill Medicare directly, we are paid under the Medicare Physician Fee Schedule,
which is updated on an annual basis. Under the Medicare statutory formula,
payments under the Physician Fee Schedule would have decreased for the past
several years if Congress failed to intervene.
For 2010, the Centers for
Medicare and Medicaid Services (“CMS”) projected a rate reduction of 21.2% in
the absence of Congressional intervention. However, over the course of the first
six months of 2010, various temporary solutions were enacted by Congress which
resulted in delaying any such change to the physician fee schedule. Ultimately,
a 2.2% increase in the conversion factor was passed by Congress effective June
1, 2010, further delaying the pending 21.2% conversion factor reduction to
November 30, 2010. On November 2, 2010, CMS released the calendar year 2011
Medicare Physician Fee Schedule. Again, the rule would have significantly
reduced physician fee schedule payments in 2011 had Congress not acted by
passing the Physician Payment and Therapy Relief Act of 2010 and the Medicare
and Medicaid Extenders Act of 2010, which together continued the 2.2% update
from June 2010 through December 31, 2011. Similarly, the calendar year 2012
Medicare Physician Fee Schedule provided for a 27.4% decrease to the physician
fee schedule which was averted by Congress passing the Middle Class Tax Relief
and Job Creation Act of 2012. While Congress has historically provided temporary
relief from the formula-driven reductions in the conversion factor, it cannot be
guaranteed that Congress will act to provide relief in the future. The failure
of Congress to act could adversely impact our revenues and results of
operations.
MIPPA also modified the
methodology by which the budget neutrality formula was applied to the 2009
physician fee schedule payment rates, resulting in an overall reduction in
payment rates for services performed by many specialties, including an estimated
1% reduction for nuclear medicine. The impact of the payment rates on specific
companies depends on their service mix. Also with respect to MIPPA, the
legislation requires all suppliers that provide the technical component of
diagnostic MRI, PET/CT, CT, and nuclear medicine to be accredited by an
accreditation organization designated by CMS (which currently include the ACR,
the IAC and The Joint Commission) by January 1, 2012. Our facilities are
currently accredited by the ACR.
A number of other
legislative changes impact our physician management and diagnostic services
business. For example, beginning on January 1, 2007, the DRA imposed caps on
Medicare payment rates for certain imaging services furnished in physician’s
offices and other non-hospital based settings. Under the cap, payments for
specified imaging services cannot exceed the hospital outpatient payment rates
for those services. The limitation is applicable only to the technical
components of the diagnostic imaging services. CMS issues on an annual basis the
hospital outpatient prospective payment rates, which are used to develop the
caps. If the technical component of the service established under the Physician
Fee Schedule (without including geographic adjustments) exceeds the hospital
outpatient payment amount for the service (also without including geographic
adjustments), then the payment is to be reduced. In other words, in those
instances where the technical component for the particular service is greater
for the non-hospital site, the DRA directs that the hospital outpatient payment
rate be substituted for the otherwise applicable Physician Fee Schedule payment
rate.
The DRA also codified the
reduction in reimbursement for multiple images on contiguous body parts, which
was previously announced by CMS. The DRA mandated payment at 100% of the
technical component of the higher priced imaging procedure and 50% for the
technical component of each additional imaging procedure for multiple images of
contiguous body parts within a family of codes performed in the same session.
Initially, CMS announced that it would phase in this reimbursement reduction
over a two-year period, to include a 25% reduction for each additional imaging
procedure on contiguous body parts in 2006 and an additional 25% reduction in
2007. CMS did not implement the additional 25% reduction scheduled for 2007, but
for services furnished on or after July 1, 2010, PPACA requires the full 50%
reduction to be implemented.
Regulatory updates to
payment rates for which we bill the Medicare program directly are published
annually by CMS. For payments under the Physician Fee Schedule for calendar year
2010, CMS changed the way it calculates components of the Medicare Physician Fee
Schedule. First, CMS reduced payment rates for certain diagnostic services using
equipment costing more than $1 million through revisions to usage assumptions
from the current 50% usage rate to a 90% usage rate. This change applied to MRI
and CT scans. However, for certain diagnostic services performed on or after
January 1, 2011, the Reconciliation Act reduces the assumed usage rate for such
equipment from CMS’s current rate of 90% to a rate of 75%, resulting in an
increase in payment rates for such services.
Recent global market and
economic conditions have been unprecedented. Concerns about the potential
long-term and widespread recession, weak recovery, inflation, energy costs,
geopolitical issues, the availability and cost of credit, the United States
mortgage market and a declining real estate market in the United States have
contributed to increased market volatility and diminished expectations for the
United States economy. These conditions, combined with declining business and
consumer confidence and increased unemployment, have contributed to unusual
volatility. At this time, it is unclear what impact this might have on our
future revenues or business.
As a result of these
market conditions, the cost and availability of credit has been and may continue
to be adversely affected by illiquid credit markets and wider credit spreads.
Concern about the stability of the markets generally and the strength of
counterparties specifically has led many lenders and institutional investors to
reduce, and in some cases, cease to provide funding to borrowers. If market
conditions continue, they may limit our ability to timely access the capital
markets to meet liquidity needs, resulting in adverse effects on our financial
condition and results of operations.
Critical Accounting
Policies
Our discussion and
analysis of our financial condition and results of operations are based upon our
consolidated financial statements, which have been prepared in accordance with
accounting principles generally accepted in the United States of America. The
preparation of these consolidated financial statements requires us to make
estimates and judgments that affect the reported amounts of assets, liabilities,
revenues and expenses, and related disclosure of contingent assets and
liabilities. On an on-going basis, we evaluate our estimates, including those
related to investments, intangible assets, income taxes, contingencies and
litigation. We base our estimates on historical experience and on various
assumptions that we believe to be reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other sources.
Actual results may differ from these estimates under different assumptions or
conditions.
We believe the following
critical accounting policies affect our more significant judgments and estimates
used in the preparation of our consolidated financial statements. We recognize
revenue and related costs of revenue from sales contracts for our MRI scanners,
under the percentage-of-completion method. Under this method, we recognize
revenue and related costs of revenue, as each sub-assembly is completed. Amounts
received in advance of our commencement of production are recorded as customer
advances.
We record a valuation
allowance to reduce our deferred tax assets to the amount that is more likely
than not to be realized. As of June 30, 2012, we recorded a valuation allowance
which reduced our deferred tax assets to equal our deferred tax
liability.
We amortize our intangible
assets, including patents, purchased management agreements and capitalized
software development costs, over the shorter of the contractual/legal life or
the estimated economic life. Our amortization life for patents and capitalized
software development costs is 15 to 17 years and 5 years,
respectively.
We periodically assess the
recoverability of long-lived assets, including property and equipment,
intangibles and management agreements, when there are indications of potential
impairment, based on estimates of undiscounted future cash flows. The amount of
impairment is calculated by comparing anticipated discounted future cash flows
with the carrying value of the related asset. In performing this analysis,
management considers such factors as current results, trends, and future
prospects, in addition to other economic factors.
RESULTS OF OPERATIONS.
FISCAL 2012 COMPARED TO FISCAL 2011
In fiscal 2012, we
experienced a net income of $6.9 million on revenues of $39.4 million, as
compared to net income of $3.3 million on revenues of $33.1 million for fiscal
2011. This represents an increase in revenues of 19.0%. Increased management
fees of 35.3% was the principal factor accounting for the increased revenues of
the Company. Related party management fees increased by 29.5%. In addition,
total costs and expenses increased by 9.9%. Our consolidated operating results
improved by $3.4 million to an operating income of $7.2 million for fiscal 2012
as compared to an operating income of $3.8 million for fiscal 2011.
Discussion of Operating
Results of Medical Equipment Segment
Fiscal 2012 Compared to
Fiscal 2011
Revenues attributable to
our medical equipment segment increased by 5% to $18.7 million in fiscal 2012
from $17.8 million in fiscal 2011, with product sales revenues increasing 3.6%
from $6.7 million in fiscal 2011 to $6.9 million in fiscal 2012. Service revenue
increased from $11.1 million in fiscal 2011 to $11.8 million in fiscal
2012.
The Upright® MRI is unique
in that it permits MRI scans to be performed on patients upright in the
weight-bearing state and in multiple positions that correlate with symptoms. An
important event in our ongoing effort to educate both the medical community and
payors about the benefits, if not necessity, of utilizing Upright® MRI scanning,
occurred in fiscal 2007 when we sold an Upright® MRI scanner to the largest
orthopedic hospital in the Netherlands, St. Maartenskliniek. Upon placing the
order, the Chairman of Spine Surgery at St. Maartenskliniek expressed the view
that for their hospital to continue to engage in spine surgery without Fonar’s
Upright® MRI technology, now that it was available was “unacceptable” and that
owning the scanner “was not optional, but mandatory”. He further stated that
“once our active research program has discovered the benefits of this new Fonar
technology for patients, we intend to publish the results in a lot of peer
reviewed scientific journals”.
Product sales to unrelated
parties increased by 3.6% in fiscal 2012 from $6.7 million in fiscal 2011 to
$6.9 million in fiscal 2012. There were no product sales to related parties in
fiscal 2012 or 2011.
We believe that one of our
principal challenges in achieving greater market penetration is attributable to
the better name recognition and larger sales forces of our larger competitors
such as General Electric, Siemens, Hitachi, Philips and Toshiba and the ability
of some of our competitors to offer attractive financing terms through
affiliates, such as G.E. Capital. Nevertheless, no other competitor offers a
whole body weight-bearing multi-position MRI scanner as the FONAR Upright®
MRI.
The operating results for
the medical equipment segment increased by $1.3 million from income of $1.4
million in 2011 to income of $2.7 million in fiscal 2012. This increase is
attributable most significantly to a decrease in our operating
expenses.
We recognized revenues of
$6.3 million from the sale of our Upright® MRI scanners in fiscal 2012, while in
fiscal 2011, we recognized revenues of $5.3 million from the sale of Upright®
MRI scanners.
None of our revenues for
fiscal 2012 or fiscal 2011 were attributable to sales to related
parties.
Research and development
expenses, net of capitalized costs, decreased by 13.7% to $1.2 million in fiscal
2012 as compared to $1.4 million in fiscal 2011. Our expenses for fiscal 2012
represented continued research and development of Fonar’s scanners, Fonar’s new
hardware and software product, Sympulse™ and new surface coils to be used with
the Upright® MRI scanner.
Discussion of Operating
Results of Physician and Diagnostic Services Management Segment.
Fiscal 2012 Compared to
Fiscal 2011
Revenues attributable to
the Company's physician and diagnostic services management segment,
HMCA-IMPERIAL, increased by 35% to $20.7 million in fiscal 2012 from $15.3
million in fiscal 2011. The increase in revenues was primarily due to the
renegotiation of some of the contracts between HMCA-IMPERIAL and its clients and
the recognition of $1.8 million in revenues from Health Diagnostics, LLC. All of
the MRI facilities managed by HMCA-IMPERIAL have Upright® MRI
scanners.
Cost of revenues as a
percentage of the related revenues for our physician and diagnostic services
management segment increased from $9.7 million or 63.4% of related revenues for
the year ended June 30, 2011 to $12.3 million, or 59.4% of related revenue for
the year ended June 30, 2012.
Operating results of this
segment increased from operating income of $2.4 million in fiscal 2011 to
operating income of $4.5 million in fiscal 2012. We believe that our efforts to
expand and improve the operation of our physician and diagnostic services
management segment are directly responsible for the profitability of this
segment and our company as a whole.
Discussion of Certain
Consolidated Results of Operations
Fiscal 2012 Compared to
Fiscal 2011
Interest and investment
income increased in 2012 compared to 2011. We recognized interest income of
$243,254 in 2012 as compared to $228,174 in fiscal 2011, representing a increase
of 6.6%.
Interest expense of
$478,663 was recognized in fiscal 2012, as compared to $518,532 in fiscal 2011,
representing a decrease of 7.7%.
While revenue increased by
19.0%, selling, general and administrative expenses, increased by only 3.4% to
$8.7 million in fiscal 2012 from $8.4 million in fiscal 2011.
Compensatory element of
stock issuances decreased from approximately $204,000 in fiscal 2011 to $180,000
in fiscal 2012, reflecting a decrease in Fonar’s use of its stock bonus plans to
pay employees and others.
The higher provision for
bad debts of $1.1 million in fiscal 2012 as compared to $963,000 in fiscal 2011,
reflected an increase in reserves for certain indebtedness in fiscal 2012 by our
physician and diagnostic services management segment. In fiscal 2012, the three
Florida sites managed by HMCA-IMPERIAL jointly and severally guaranteed the
payment of their management fees to HMCA-IMPERIAL, further securing
HMCA-IMPERIAL’s management fee receivables.
Revenue from service and
repair fees increased from $11.1 million in fiscal 2011 to $11.8 million in
fiscal 2012 as scanners previously under warranty entered into service
agreements with FONAR.
Continuing our tradition
as the originator of MRI, we remain committed to maintaining our position as the
leading innovator of the industry through investing in research and development.
In fiscal 2012 we continued our investment in the development of our new MRI
scanners, together with software and upgrades, with an investment of $1,242,656
in research and development, none of which was capitalized, as compared to
$1,507,290, $67,258 of which was capitalized, in fiscal 2011. The research and
development expenditures were approximately 6.6% of revenues attributable to our
medical equipment segment and 3.2% of total revenues in 2012, and 8.1% of
medical equipment segment revenues and 4.3% of total revenues in fiscal 2011.
This represented a 13.7% decrease in research and development expenditures in
fiscal 2012 as compared to fiscal 2011. Notwithstanding the decrease in research
and development expenditures in connection with our overall cost cutting
programs, we remain fully committed to developing new features, software and
upgrades to improve its products.
The physician and
diagnostic services management segment, HMCA-IMPERIAL, revenues increased, from
$15.3 in fiscal 2011 to $20.7 million in fiscal 2012. This is primarily
attributable to increased revenue received by HMCA-IMPERIAL from its contracts
with its clients.
We have been taking steps
to improve HMCA-IMPERIAL revenues by our marketing efforts, which focus on the
unique capability of our Upright® MRI scanners to scan patients in different
positions. We have also been increasing the number of health insurance plans in
which our clients participate.
Marketing expenditures may
increase, as the Company continues its efforts to promote sales.
Our management fees are
dependent on collection by our clients of fees from reimbursements from
Medicare, Medicaid, private insurance, no fault and workers’ compensation
carriers, self–pay and other third-party payors. The health care industry is
experiencing the effects of the federal and state governments’ trend toward cost
containment, as governments and other third-party payors seek to impose lower
reimbursement and utilization rates and negotiate reduced payment schedules with
providers. The cost-containment measures, consolidated with the increasing
influence of managed-care payors and competition for patients, have resulted in
reduced rates of reimbursement for services provided by our clients from time to
time. Our future revenues and results of operations may be adversely impacted by
future reductions in reimbursement rates.
Certain third-party payors
have proposed and implemented changes in the methods and rates of reimbursement
that have had the effect of substantially decreasing reimbursement for
diagnostic imaging services that HMCA-IMPERIAL’s clients provide. To the extent
reimbursement from third-party payors is reduced, it will likely have an adverse
impact on the rates they pay us, as they would need to reduce the management
fees they pay HMCA-IMPERIAL to offset such decreased reimbursement rates.
Furthermore, many commercial health care insurance arrangements are changing, so
that individuals bear greater financial responsibility through high deductible
plans, co-insurance and higher co-payments, which may result in patients
delaying or foregoing medical procedures. We expect that any further changes to
the rates or methods of reimbursement for services, which reduce the
reimbursement per scan of our clients may partially offset the increases in scan
volume we are working to achieve for our clients, and indirectly will result in
a decline in our revenues.
In 2009, the Obama
administration announced its intentions for healthcare reform in the United
States. Legislation adopting healthcare reform was passed in 2010. On March 23,
2010, President Obama signed into law healthcare reform legislation in the form
of the Patient Protection and Affordable Care Act, or PPACA. The implementation
of this law will likely have a profound impact on the healthcare industry, most
of which will be experienced in 2013 and thereafter. Healthcare cost
containment, reductions of Medicare and other payments, and increased regulation
will present additional challenges for healthcare providers. We are unable to
predict the full impact of PPACA at this time, but anticipate the possibility
that it may reduce the profitability of both our medical equipment segment and
physician and diagnostic services management segment. In addition there are also
political uncertainties which may result in the repeal or modification of PPACA
or the adoption of alternative medical cost containment and insurance
requirements.
In addition, the use of
radiology benefit managers, or RBM’s has increased in recent years. It is common
practice for health insurance carriers to contract with RBMs to manage
utilization of diagnostic imaging procedures for their insureds. In many cases,
this leads to lower utilization of imaging procedures based on a determination
of medical necessity. The efficacy of RBMs is still a high controversial topic.
We cannot predict whether the healthcare legislation or the use of RBMs will
negatively impact our business, but it is possible that our financial position
and results of operations could be negatively affected.
At the present time
healthcare reform has not directly affected our business, but we believe
uncertainty as to the ultimate impact of healthcare reform, taxes, and the state
of the economy have hurt our scanner sales.
As a result of our loss
for fiscal 2010, Fonar did not meet NASDAQ’s criteria for continued listing.
During fiscal 2011 Fonar was able to avoid delisting and to come into compliance
with NASDAQ’s requirements and has remained in compliance during fiscal
2012.
LIQUIDITY AND CAPITAL
RESOURCES
Cash, cash equivalents and
marketable securities increased by 30.0% from $9.3 million at June 30, 2011 to
$12.0 million at June 30, 2012.
Marketable securities
approximated $32,000 as of June 30, 2012, as compared to $33,000 as of June 30,
2011.
Cash provided by operating
activities for fiscal 2012 approximated $7.4 million. Cash provided by operating
activities was attributable to the net income of $6.9 million.
Cash used in investing
activities for fiscal 2012 approximated $1.2 million. The principal uses of cash
from investing activities were purchases of property and equipment of $1.1
million, and costs of patents of $146,000.
Cash used in financing
activities for fiscal 2012 approximated $3.4 million. The principal uses of cash
in financing activities was the repayment of loans and capital lease obligations
of $1.4 million, distributions to non-controlling interests of $1.1 million and
a redemption to non-controlling interests of $1.2 million.
Total liabilities
decreased by 12.4% during fiscal 2012, from approximately $25.7 million at June
30, 2011 to approximately $22.5 million at June 30, 2012.
As at June 30, 2012, our
obligations included approximately $2.8 million in various state sales
taxes.
At June 30, 2012, we had
working capital of approximately $4.8 million as compared to working capital of
$576,000 at June 30, 2011, and stockholders’ equity of $11.1 million at June 30,
2012 as compared to stockholders’ equity of $5.9 million at June 30, 2011. For
the year ended June 30, 2012, we realized a net income of $6.9
million.
Our principal sources of
liquidity has been derived from investments and revenues.
Our business plan includes
an program for manufacturing and selling our Upright® MRI scanners. In addition,
we are enhancing our revenue by participating in the physician and diagnostic
services management business through our subsidiary, HMCA-IMPERIAL and have
upgraded the facilities which it manages, most significantly by the replacement
of the original MRI scanners with new Upright® MRI scanners. Presently, all of
the 11 MRI facilities managed by HMCA-IMPERIAL are equipped with Upright® MRI
scanners. We have also intensified our marketing activities through the hiring
of additional marketers for HMCA-IMPERIAL’s clients.
Our business plan also
calls for a continuing emphasis on providing our customers with enhanced
equipment service and maintenance capabilities and delivering state-of-the-art,
innovative and high quality equipment upgrades at competitive prices. Fees for
on-going service and maintenance from our installed base of scanners were $11.1
million for the year ended June 30, 2011 and $11.8 million for the year ended
June 30, 2012.
In order to reduce our net
losses and demands on our cash and other liquid reserves, we instituted an
aggressive program of cost cutting during and following the end of fiscal 2008.
These measures included consolidating HMCA-IMPERIAL’s office space with Fonar’s
office space, reductions in the size of our workforce, compensation and
benefits, as well as across the board reduction of expenses. The cost reductions
were intended to enable us to withstand periods of low volumes of MRI scanner
sales, by keeping expenditures at levels which, if necessary, can be supported
by service revenues and HMCA-IMPERIAL revenues. We are also seeking equity and
debt financing and have been engaged in discussions with several possible
sources.
In order to promote sales,
we are continuing to focus on marketing campaigns to strengthen the demand for
our products and services. Management anticipates that Fonar’s capital resources
will continue to improve if Fonar’s MRI scanner products gain wider market
recognition and acceptance resulting in both increased product sales and scan
volumes. If we are not successful with our marketing efforts to increase sales,
we will experience a shortfall in cash, and it will be necessary to reduce
operating expenses or obtain funds through equity or debt financing in
sufficient amounts to avoid the need to curtail our operations subsequent to
June 30, 2013. Current economic credit conditions have contributed to a slowing
business environment. Given such liquidity and credit constraints in the
markets, the business may suffer, should the credit markets not improve in the
near future. The direct impact of these conditions is not fully known. However,
there can be no assurance that we would be able to secure additional funds if
needed and that if such funds were available, whether the terms or conditions
would be acceptable to us. In such case, the reduction in operating expenses
might need to be substantial in order for us to generate positive cash flow to
sustain our operations.
If we are unable to meet
expenditures with revenues or financing then it will be necessary to reduce
expenses further, or seek other sources of funds through the issuance of debt or
equity financing in order to conduct operations as now conducted subsequent to
fiscal 2013.
Capital expenditures for
fiscal 2012 approximated $1.2 million. Capitalized patent costs were
approximately $146,000. Purchases of property and equipment were approximately
$1.1 million.
Fonar has not committed to
making capital expenditures in the 2013 fiscal year.
The Company believes that
its business plan has been responsible for the past two consecutive fiscal years
of profitability (fiscal 2012 and fiscal 2011) and that its capital resources
will be adequate to support operations at current levels through June 30, 2013.
In fiscal 2010 and prior years, however, the Company also experienced losses and
periods of working capital deficits. The future effects on our business of
healthcare reform legislation, the Deficit Reduction Act, the tax on sales of
medical equipment and the general economic and business climate are not known at
the present time. Nevertheless, there is a possibility of adverse consequences
to our business operations from these causes. Consequently, we have not recorded
a deferred tax asset as a result of our carry-forward tax losses since we
presently believe that it is more likely than not that we will not be able to
utilize all of these losses in the short term.
ITEM 7A. QUALITATIVE AND
QUANTITATIVE DISCLOSURES ABOUT MARKET RISK
Fonar’s investments in
fixed rate instruments. None of the fixed rate instruments in which we invest
extend beyond June 30, 2013.
All of our revenue,
expense and capital purchasing activities are transacted in United States
dollars.
See Note 11 to the
consolidated Financial Statements for information on long-term debt.
Item 8.
FINANCIAL
STATEMENTS
FONAR CORPORATION AND
SUBSIDIARIES
INDEX TO CONSOLIDATED
FINANCIAL STATEMENTS
Reason for
Amendment: Adding XBRL files
|
Page
No.
|
REPORT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
|
|
CONSOLIDATED BALANCE
SHEETS
At June 30, 2012 and
2011
|
|
CONSOLIDATED
STATEMENTS OF INCOME
For the Years Ended
June 30, 2012 and 2011
|
|
CONSOLIDATED
STATEMENTS OF STOCKHOLDERS' EQUITY
AND COMPREHENSIVE
INCOME
For the Years Ended
June 30, 2012 and 2011
|
|
CONSOLIDATED
STATEMENTS OF CASH FLOWS
For the Years Ended
June 30, 2012 and 2011
|
|
NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS
|
|
REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM
To the Audit Committee of
the
Board of Directors and
Shareholders
of Fonar Corporation and
Subsidiaries
We have audited
the accompanying consolidated balance sheets of
Fonar Corporation and
Subsidiaries
(the “Company”) as of June 30, 2012 and
2011, and the related consolidated statements of income, stockholders’ equity
and comprehensive income and cash flows for the years then ended. These
consolidated financial statements are the responsibility of the Company’s
management. Our responsibility is to express an opinion on these consolidated
financial statements based on our audits.
We conducted our audits in
accordance with the standards of the Public Company Accounting Oversight Board
(United States). Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of
material misstatement.
The Company is not
required to have, nor were we engaged to perform, an audit of its internal
control over financial reporting. Our audit included consideration of internal
control over financial reporting as a basis for designing audit procedures that
are appropriate in the circumstances, but not for the purpose of expressing an
opinion on the effectiveness of the Company’s internal control over financial
reporting. Accordingly, we express no such opinion.
An audit
also includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles
used and significant estimates made by management, as well as evaluating the
overall financial statement presentation. We believe that our audits
provide a reasonable basis for our opinion.
In our opinion,
the consolidated financial statements referred to above present fairly, in all
material respects, the consolidated financial position of
Fonar
Corporation and Subsidiaries
, as of June 30, 2012 and
2011, and the consolidated results of its operations and its cash flows for the
years then ended in conformity with accounting principles generally accepted in
the United States of America
.
/s/ Marcum, LLP
New York, New York
September 28, 2012
FONAR CORPORATION AND
SUBSIDIARIES
CONSOLIDATED BALANCE
SHEETS
ASSETS
|
|
June 30,
|
|
|
2012
|
|
2011
|
Current
Assets:
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents
|
|
$
|
12,032,015
|
|
|
$
|
9,251,244
|
|
Accounts
receivable – net of allowances for doubtful accounts of $1,852,987 and
$1,777,794 at June 30, 2012 and 2011, respectively
|
|
|
5,094,687
|
|
|
|
5,263,903
|
|
Management
and other fees receivable – net of allowances for doubtful accounts of
$7,458,345 and $6,508,345 at June 30, 2012 and 2011, respectively
|
|
|
3,781,635
|
|
|
|
3,308,456
|
|
Management
and other fees receivable – related medical practices – net of allowances
for doubtful accounts of $403,047 at June 30, 2012 and 2011
|
|
|
1,311,195
|
|
|
|
1,668,880
|
|
Costs
and estimated earnings in excess of billings on uncompleted contracts
|
|
|
1,128,596
|
|
|
|
169,443
|
|
Inventories
|
|
|
2,194,949
|
|
|
|
2,400,240
|
|
Current
portion of note receivable – net of allowances for doubtful accounts of
$65,000 at June 30, 2012 and 2011
|
|
|
116,016
|
|
|
|
114,058
|
|
Prepaid
expenses and other current assets
|
|
|
206,328
|
|
|
|
384,437
|
|
Total Current
Assets
|
|
|
25,865,421
|
|
|
|
22,560,661
|
|
Property and
Equipment – Net
|
|
|
3,173,447
|
|
|
|
3,769,424
|
|
Notes
Receivable
|
|
|
275,966
|
|
|
|
358,769
|
|
Other Intangible
Assets – Net
|
|
|
3,835,179
|
|
|
|
4,318,311
|
|
Other
Assets
|
|
|
465,455
|
|
|
|
573,509
|
|
Total
Assets
|
|
$
|
33,615,468
|
|
|
$
|
31,580,674
|
|
See accompanying
notes to consolidated financial statements.
FONAR CORPORATION AND
SUBSIDIARIES
CONSOLIDATED BALANCE
SHEETS
LIABILITIES
|
|
June 30,
|
|
|
2012
|
|
2011
|
Current
Liabilities:
|
|
|
|
|
|
|
|
|
Current
portion of long-term debt and capital leases
|
|
$
|
1,853,623
|
|
|
$
|
2,025,836
|
|
Accounts
payable
|
|
|
2,076,846
|
|
|
|
2,187,115
|
|
Other
current liabilities
|
|
|
7,693,241
|
|
|
|
8,236,105
|
|
Unearned
revenue on service contracts
|
|
|
5,474,614
|
|
|
|
5,762,394
|
|
Customer
advances
|
|
|
3,881,284
|
|
|
|
4,845,794
|
|
Billings
in excess of costs and estimated earnings on uncompleted contracts
|
|
|
—
|
|
|
|
4,045
|
|
Income
tax payable
|
|
|
100,000
|
|
|
|
75,000
|
|
Total
Current Liabilities
|
|
|
21,079,608
|
|
|
|
23,136,289
|
|
Long-Term
Liabilities:
|
|
|
|
|
|
|
|
|
Accounts
payable
|
|
|
47,600
|
|
|
|
102,000
|
|
Due
to related medical practices
|
|
|
228,741
|
|
|
|
228,267
|
|
Long-term
debt and capital leases, less current portion
|
|
|
777,274
|
|
|
|
1,746,286
|
|
Other
liabilities
|
|
|
400,714
|
|
|
|
502,018
|
|
Total
Long-Term Liabilities
|
|
|
1,454,329
|
|
|
|
2,578,571
|
|
Total
Liabilities
|
|
|
22,533,937
|
|
|
|
25,714,860
|
|
Commitments, Contingencies
and Other Matters
See accompanying notes to
consolidated financial statements.
FONAR CORPORATION AND
SUBSIDIARIES
CONSOLIDATED BALANCE
SHEETS
STOCKHOLDERS'
EQUITY
|
|
June 30,
|
|
|
2012
|
|
2011
|
Stockholders'
Equity:
|
|
|
|
|
|
|
|
|
Class
A non-voting preferred stock $.0001 par value; 453,000 shares authorized
at June 30, 2012 and June 30, 2011, 313,438 issued and outstanding at June
30, 2012 and 2011
|
|
$
|
31
|
|
|
$
|
31
|
|
Preferred
stock $.001 par value; 567,000 shares authorized at June 30, 2012 and
2011, issued and outstanding – none
|
|
|
—
|
|
|
|
—
|
|
Common
stock $.0001 par value; 8,500,000 shares authorized at June 30, 2012 and
June 30, 2011, 5,912,905 and 5,636,571 issued at June 30, 2012 and 2011,
respectively; 5,901,262 and 5,624,928 outstanding at June 30, 2012 and
2011, respectively
|
|
|
590
|
|
|
|
562
|
|
Class
B common stock (10 votes per share) $.0001 par value; 227,000 shares
authorized at June 30, 2012 and June 30, 2011, 158 issued and
outstanding at June 30, 2012 and 2011
|
|
|
—
|
|
|
|
—
|
|
Class
C common stock (25 votes per share) $.0001 par value; 567,000 shares
authorized at June 30, 2012 and June 30, 2011, 382,513 issued and
outstanding at June 30, 2012 and 2011
|
|
|
38
|
|
|
|
38
|
|
Paid-in
capital in excess of par value
|
|
|
174,084,007
|
|
|
|
173,476,059
|
|
Accumulated
other comprehensive loss
|
|
|
(19,534
|
)
|
|
|
(16,179
|
)
|
Accumulated
deficit
|
|
|
(168,333,958
|
)
|
|
|
(174,110,439
|
)
|
Notes
receivable from employee stockholders
|
|
|
(70,813
|
)
|
|
|
(115,305
|
)
|
Treasury
stock, at cost – 11,643 shares of common stock at June 30, 2012 and
2011
|
|
|
(675,390
|
)
|
|
|
(675,390
|
)
|
Non
controlling interests
|
|
|
6,096,560
|
|
|
|
7,306,437
|
|
Total
Stockholders' Equity
|
|
|
11,081,531
|
|
|
|
5,865,814
|
|
Total
Liabilities and Stockholders' Equity
|
|
$
|
33,615,468
|
|
|
$
|
31,580,674
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to
consolidated financial statements.
FONAR CORPORATION AND
SUBSIDIARIES
CONSOLIDATED STATEMENTS OF
INCOME
|
|
For the Years Ended June 30,
|
|
|
2012
|
|
2011
|
Revenues
|
|
|
|
|
|
|
|
|
Product
sales – net
|
|
$
|
6,922,465
|
|
|
$
|
6,682,297
|
|
Service
and repair fees – net
|
|
|
11,674,541
|
|
|
|
10,936,839
|
|
Service
and repair fees – related parties – net
|
|
|
110,000
|
|
|
|
192,500
|
|
Management
and other fees - net
|
|
|
14,060,275
|
|
|
|
10,170,086
|
|
Management
and other fees – related medical practices – net
|
|
|
6,677,138
|
|
|
|
5,154,673
|
|
Total
Revenues – Net
|
|
|
39,444,419
|
|
|
|
33,136,395
|
|
Costs
and Expenses
|
|
|
|
|
|
|
|
|
Costs
related to product sales
|
|
|
5,387,923
|
|
|
|
5,768,601
|
|
Costs
related to service and repair fees
|
|
|
3,453,116
|
|
|
|
2,936,435
|
|
Costs
related to service and repair fees – related parties
|
|
|
32,536
|
|
|
|
51,684
|
|
Costs
related to management and other fees
|
|
|
8,733,823
|
|
|
|
6,781,638
|
|
Costs
related to management and other fees – related medical practices
|
|
|
3,588,282
|
|
|
|
2,941,192
|
|
Research
and development
|
|
|
1,242,656
|
|
|
|
1,440,032
|
|
Selling,
general and administrative, inclusive of compensatory element of stock
issuances of $180,418 and $204,486 for the years ended June 30, 2012 and
2011, respectively
|
|
|
8,749,090
|
|
|
|
8,462,335
|
|
Provision
for bad debts
|
|
|
1,050,442
|
|
|
|
963,009
|
|
Total
Costs and Expenses
|
|
|
32,237,868
|
|
|
|
29,344,926
|
|
Income
from Operations
|
|
|
7,206,551
|
|
|
|
3,791,469
|
|
Other
Income and (Expenses):
|
|
|
|
|
|
|
|
|
Interest
expense
|
|
|
(478,663
|
)
|
|
|
(514,703
|
)
|
Interest
expense – related parties
|
|
|
—
|
|
|
|
(3,829
|
)
|
Investment
income
|
|
|
243,254
|
|
|
|
226,610
|
|
Interest
income – related parties
|
|
|
—
|
|
|
|
1,564
|
|
Other
income (expense) – net
|
|
|
45,056
|
|
|
|
(116,617
|
)
|
Income
Before Provision For Income Taxes and Non Controlling Interests
|
|
|
7,016,198
|
|
|
|
3,384,494
|
|
Provision
for Income Taxes
|
|
|
141,125
|
|
|
|
75,475
|
|
Net
Income
|
|
$
|
6,875,073
|
|
|
$
|
3,309,019
|
|
Net
Income – Non Controlling Interests
|
|
|
(1,098,592
|
)
|
|
|
(148,109
|
)
|
Net
Income – Controlling Interests
|
|
$
|
5,776,481
|
|
|
$
|
3,160,910
|
|
See accompanying notes to
consolidated financial statements.
FONAR CORPORATION AND
SUBSIDIARIES
CONSOLIDATED STATEMENTS OF
INCOME
|
|
For the Years Ended June 30,
|
|
|
2012
|
|
2011
|
Net
Income Available to Common Stockholders
|
|
$
|
5,392,212
|
|
|
$
|
2,941,026
|
|
Net
Income Available to Class A Non-Voting Preferred Stockholders
|
|
$
|
286,406
|
|
|
$
|
163,886
|
|
Net
Income Available to Class C Common Stockholders
|
|
$
|
97,863
|
|
|
$
|
55,998
|
|
Basic
Net Income Per Common Share Available to Common Stockholders
|
|
$
|
0.93
|
|
|
$
|
0.56
|
|
Diluted
Net Income Per Common Share Available to Common Stockholders
|
|
$
|
0.91
|
|
|
$
|
0.55
|
|
Basic
and Diluted Income Per Share – Common C
|
|
$
|
0.26
|
|
|
$
|
0.15
|
|
Weighted
Average Basic Shares Outstanding – Common Stockholder
|
|
|
5,778,695
|
|
|
|
5,264,795
|
|
Weighted
Average Diluted Shares Outstanding – Common Stockholder
|
|
|
5,906,199
|
|
|
|
5,392,299
|
|
Weighted
Average Basic Shares
Outstanding – Class C Common
|
|
|
382,513
|
|
|
|
382,513
|
|
Weighted
Average Diluted Shares Outstanding – Class C
Common
|
|
|
382,513
|
|
|
|
382,513
|
|
See accompanying notes to
consolidated financial statements.
FONAR CORPORATION AND
SUBSIDIARIES
CONSOLIDATED STATEMENT OF
STOCKHOLDERS' EQUITY AND COMPREHENSIVE INCOME
FOR THE YEARS ENDED JUNE
30, 2012 AND 2011
|
|
Class A
Non-Voting
Preferred
|
|
Common Stock
|
|
|
Stock
|
|
Shares
|
|
Amount
|
Balance
- June 30, 2010
|
|
$
|
31
|
|
|
|
4,974,207
|
|
|
$
|
497
|
|
Net
income
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Other
comprehensive loss, net of tax:Unrealized gains on securities arising
during the year, net of tax
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Stock
issued to employees under stock bonus plans
|
|
|
—
|
|
|
|
128,803
|
|
|
|
13
|
|
Issuance
of stock for goods and services
|
|
|
—
|
|
|
|
521,918
|
|
|
|
52
|
|
Capital
contribution in Fair Haven acquisition
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Payments
on notes receivable from employee stockholders
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Proceeds
from non controlling interests
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Distributions
to non controlling interests
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Purchase
of non controlling interest
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Effect
of change from equity method to consolidation of investment (Note 10)
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Balance
- June 30, 2011
|
|
$
|
31
|
|
|
|
5,624,928
|
|
|
$
|
562
|
|
Net
income
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Other
comprehensive loss, net of tax: Unrealized losses on securities arising
during the year, net of tax
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Stock
issued to employees under stock bonus plans
|
|
|
—
|
|
|
|
58,334
|
|
|
|
6
|
|
Issuance
of stock for goods and services
|
|
|
—
|
|
|
|
218,000
|
|
|
|
22
|
|
Payments
on notes receivable from employee stockholders
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Redemption
of non controlling interests
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Distributions
to non controlling interests
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Sale
to non controlling interest
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Proceeds
from non controlling interest
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Balance
- June 30, 2012
|
|
$
|
31
|
|
|
|
5,901,262
|
|
|
$
|
590
|
|
See accompanying notes to
consolidated financial statements.
FONAR CORPORATION AND
SUBSIDIARIES
CONSOLIDATED STATEMENT OF
STOCKHOLDERS' EQUITY AND COMPREHENSIVE INCOME
FOR THE YEARS ENDED JUNE
30, 2012 AND 2011
|
|
Class B
Common
Stock
|
|
Class C
Common
Stock
|
|
Paid-in
Capital
in
Excess of
Par
Value
|
|
|
Shares
|
|
|
|
|
Balance
- June 30, 2010
|
|
|
158
|
|
|
$
|
38
|
|
|
$
|
172,379,863
|
|
Net
income
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Other
comprehensive loss, net of tax: Unrealized gains on securities arising
during the year, net of tax
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Stock
issued to employees under stock bonus plans
|
|
|
—
|
|
|
|
—
|
|
|
|
204,473
|
|
Issuance
of stock for goods and services
|
|
|
—
|
|
|
|
—
|
|
|
|
862,759
|
|
Capital
contribution in Fair Haven acquisition
|
|
|
—
|
|
|
|
—
|
|
|
|
28,964
|
|
Payments
on notes receivable from employee stockholders
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Proceeds
from non controlling interests
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Distributions
to non controlling interests
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Purchase
of non controlling interest
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Effect
of change from equity method to consolidation of investment (Note 10)
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Balance
- June 30, 2011
|
|
|
158
|
|
|
$
|
38
|
|
|
$
|
173,476,059
|
|
Net
income
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Other
comprehensive loss, net of tax: Unrealized losses on securities arising
during the year, net of tax
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Stock
issued to employees under stock bonus plans
|
|
|
—
|
|
|
|
—
|
|
|
|
180,412
|
|
Issuance
of stock for goods and services
|
|
|
—
|
|
|
|
—
|
|
|
|
427,536
|
|
Payments
on notes receivable from employee stockholders
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Redemption
of non controlling interests
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Distributions
to non controlling interests
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Sale
to non controlling interest
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Proceeds
from non controlling interest
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Balance
- June 30, 2012
|
|
|
158
|
|
|
$
|
38
|
|
|
$
|
174,084,007
|
|
See accompanying notes to
consolidated financial statements.
FONAR CORPORATION AND
SUBSIDIARIES
CONSOLIDATED STATEMENT OF
STOCKHOLDERS' EQUITY AND COMPREHENSIVE INCOME
FOR THE YEARS ENDED JUNE
30, 2012 AND 2011
|
|
Treasury
Stock
|
|
Notes
Receivable
From
Employee
Stockholders
|
|
Accumulated
Other
Comprehensive
Loss
|
Balance
- June 30, 2010
|
|
$
|
(675,390
|
)
|
|
$
|
(191,167
|
)
|
|
$
|
(18,489
|
)
|
Net
income
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Other
comprehensive loss, net of tax: Unrealized gains on securities arising
during the year, net of tax
|
|
|
—
|
|
|
|
—
|
|
|
|
2,310
|
|
Stock
issued to employees under stock bonus plans
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Issuance
of stock for goods and services
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Capital
contribution in Fair Haven acquisition
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Payments
on notes receivable from employee stockholders
|
|
|
—
|
|
|
|
75,862
|
|
|
|
—
|
|
Proceeds
from non controlling interests
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Distributions
to non controlling interests
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Purchase
of non controlling interest
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Effect
of change from equity method to consolidation of investment (Note 10)
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Balance
- June 30, 2011
|
|
$
|
(675,390
|
)
|
|
$
|
(115,305
|
)
|
|
$
|
(16,179
|
)
|
Net
income
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Other
comprehensive loss, net of tax: Unrealized losses on securities arising
during the year, net of tax
|
|
|
—
|
|
|
|
—
|
|
|
|
(3,355
|
)
|
Stock
issued to employees under stock bonus plans
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Issuance
of stock for goods and services
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Payments
on notes receivable from employee stockholders
|
|
|
—
|
|
|
|
44,492
|
|
|
|
—
|
|
Redemption
of non controlling interests
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Distributions
to non controlling interests
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Sale
to non controlling interest
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Proceeds
from non controlling interest
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Balance
– June 30, 2012
|
|
$
|
(675,390
|
)
|
|
$
|
(70,813
|
)
|
|
$
|
(19,534
|
)
|
See accompanying notes to
consolidated financial statements.
FONAR CORPORATION AND
SUBSIDIARIES
CONSOLIDATED STATEMENT OF
STOCKHOLDERS' EQUITY AND COMPREHENSIVE INCOME
FOR THE YEARS ENDED JUNE
30, 2012 AND 2011
|
|
Accumulated Deficit
|
|
Non Controlling Interests
|
Balance
- June 30, 2010
|
|
$
|
(177,271,349
|
)
|
|
$
|
—
|
|
Net
income
|
|
|
3,160,910
|
|
|
|
148,109
|
|
Other
comprehensive loss, net of tax: Unrealized gains on securities arising
during the year, net of tax
|
|
|
—
|
|
|
|
—
|
|
Stock
issued to employees under stock bonus plan
|
|
|
—
|
|
|
|
—
|
|
Issuance
of stock for goods and services
|
|
|
—
|
|
|
|
—
|
|
Capital
contribution in Fair Haven acquisition
|
|
|
—
|
|
|
|
—
|
|
Payments
on notes receivable from employee stockholders
|
|
|
—
|
|
|
|
—
|
|
Proceeds
from non controlling interests
|
|
|
—
|
|
|
|
6,700,000
|
|
Distributions
to non controlling interests
|
|
|
—
|
|
|
|
(22,500
|
)
|
Purchase
of non controlling interest
|
|
|
—
|
|
|
|
(10,500
|
)
|
Effect
of change from equity method to consolidation of investment (Note 10)
|
|
|
—
|
|
|
|
491,328
|
|
Balance
- June 30, 2011
|
|
$
|
(174,110,439
|
)
|
|
$
|
7,306,437
|
|
Net
income
|
|
|
5,776,481
|
|
|
|
1,098,592
|
|
Other
comprehensive loss, net of tax: Unrealized losses on securities arising
during the year, net of tax
|
|
|
—
|
|
|
|
—
|
|
Stock
issued to employees under stock bonus plans
|
|
|
—
|
|
|
|
—
|
|
Issuance
of stock for goods and services
|
|
|
—
|
|
|
|
—
|
|
Payments
on notes receivable from employee stockholders
|
|
|
—
|
|
|
|
—
|
|
Redemption
of non controlling interests
|
|
|
—
|
|
|
|
(1,200,000
|
)
|
Distributions
to non controlling interests
|
|
|
—
|
|
|
|
(1,135,000
|
)
|
Sale
to non controlling interest
|
|
|
—
|
|
|
|
10,500
|
|
Proceeds
from non controlling interest
|
|
|
—
|
|
|
|
16,031
|
|
Balance
– June 30, 2012
|
|
$
|
(168,333,958
|
)
|
|
$
|
6,096,560
|
|
See accompanying notes to
consolidated financial statements.
FONAR CORPORATION AND
SUBSIDIARIES
CONSOLIDATED STATEMENT OF
STOCKHOLDERS' EQUITY AND COMPREHENSIVE INCOME
FOR THE YEARS ENDED JUNE
30, 2012 and 2011
|
|
Total
|
|
Comprehensive Income
|
Balance
- June 30, 2010
|
|
$
|
(5,775,966
|
)
|
|
$
|
—
|
|
Net
income
|
|
|
3,309,019
|
|
|
|
3,309,019
|
|
Other
comprehensive loss, net of tax: Unrealized gains on securities arising
during the year, net of tax
|
|
|
2,310
|
|
|
|
2,310
|
|
Stock
issued to employees under stock bonus plans
|
|
|
204,486
|
|
|
|
—
|
|
Issuance
of stock for goods and services
|
|
|
862,811
|
|
|
|
—
|
|
Capital
contribution in Fair Haven acquisition
|
|
|
28,964
|
|
|
|
—
|
|
Payments
on notes receivable from employee stockholders
|
|
|
75,862
|
|
|
|
—
|
|
Proceeds
from non controlling interests
|
|
|
6,700,000
|
|
|
|
—
|
|
Distributions
to non controlling interests
|
|
|
(22,500
|
)
|
|
|
—
|
|
Purchase
of non controlling interest
|
|
|
(10,500
|
)
|
|
|
—
|
|
Effect
of change from equity method to consolidation of investment (Note 10)
|
|
|
491,328
|
|
|
|
—
|
|
Balance
- June 30, 2011
|
|
$
|
5,865,814
|
|
|
$
|
3,311,329
|
|
Net
income
|
|
|
6,875,073
|
|
|
|
6,875,073
|
|
Other
comprehensive loss, net of tax: Unrealized losses on securities arising
during the year, net of tax
|
|
|
(3,355
|
)
|
|
|
(3,355
|
)
|
Stock
issued to employees under stock bonus plans
|
|
|
180,418
|
|
|
|
—
|
|
Issuance
of stock for goods and services
|
|
|
427,558
|
|
|
|
—
|
|
Payments
on notes receivable from employee stockholders
|
|
|
44,492
|
|
|
|
—
|
|
Redemption
of non controlling interests
|
|
|
(1,200,000
|
)
|
|
|
—
|
|
Distributions
to non controlling interests
|
|
|
(1,135,000
|
)
|
|
|
—
|
|
Sale
to non controlling interest
|
|
|
10,500
|
|
|
|
—
|
|
Proceeds
from non controlling interest
|
|
|
16,031
|
|
|
|
|
|
Balance
– June, 2012
|
|
$
|
11,081,531
|
|
|
$
|
6,871,781
|
|
See accompanying notes to
consolidated financial statements.
FONAR CORPORATION AND
SUBSIDIARIES
CONSOLIDATED STATEMENTS OF
CASH FLOWS
|
|
For the Years
Ended June 30,
|
|
|
2012
|
|
2011
|
CASH FLOWS FROM
OPERATING ACTIVITIES
|
|
|
|
|
|
|
|
|
Net
income
|
|
$
|
6,875,073
|
|
|
$
|
3,309,019
|
|
Adjustments
to reconcile net income to net cash provided by operating activities:
|
|
|
|
|
|
|
|
|
Depreciation
and amortization
|
|
|
2,230,250
|
|
|
|
2,073,006
|
|
Abandoned
patents written off
|
|
|
76,231
|
|
|
|
79,958
|
|
Provision
for bad debts
|
|
|
1,050,442
|
|
|
|
963,009
|
|
Compensatory
element of stock issuances
|
|
|
180,418
|
|
|
|
204,486
|
|
Stock
issued for costs and expenses
|
|
|
427,558
|
|
|
|
862,811
|
|
(Increase)
decrease in operating assets, net:
|
|
|
|
|
|
|
|
|
Accounts
and management fee receivables
|
|
|
(996,720
|
)
|
|
|
(1,550,287
|
)
|
Notes
receivable
|
|
|
80,845
|
|
|
|
(336,717
|
)
|
Costs
and estimated earnings in excess of billings on uncompleted contracts
|
|
|
(959,153
|
)
|
|
|
107,941
|
|
Inventories
|
|
|
205,291
|
|
|
|
425,971
|
|
Prepaid
expenses and other current assets
|
|
|
177,593
|
|
|
|
200,894
|
|
Other
assets
|
|
|
108,054
|
|
|
|
(57,724
|
)
|
Advances
and notes to related parties medical practices
|
|
|
—
|
|
|
|
83,423
|
|
Increase
(decrease) in operating liabilities, net:
|
|
|
|
|
|
|
|
|
Accounts
payable
|
|
|
(164,669
|
)
|
|
|
(1,012,493
|
)
|
Other
current liabilities
|
|
|
(830,644
|
)
|
|
|
699,929
|
|
Customer
advances
|
|
|
(964,510
|
)
|
|
|
32,467
|
|
Billings
in excess of costs and estimated earnings on uncompleted contracts
|
|
|
(4,045
|
)
|
|
|
(2,739,353
|
)
|
Other
liabilities
|
|
|
(101,304
|
)
|
|
|
27,255
|
|
Due
to related medical practices
|
|
|
474
|
|
|
|
(299,624
|
)
|
Income
tax payable
|
|
|
25,000
|
|
|
|
75,000
|
|
NET
CASH PROVIDED BY OPERATING ACTIVITIES
|
|
|
7,416,184
|
|
|
|
3,148,971
|
|
See accompanying notes to
consolidated financial statements.
FONAR CORPORATION AND
SUBSIDIARIES
CONSOLIDATED STATEMENTS OF
CASH FLOWS
|
|
For the Years Ended June 30,
|
|
|
2012
|
|
2011
|
CASH
FLOWS FROM INVESTING ACTIVITIES
|
|
|
|
|
|
|
|
|
Sales
of marketable securities
|
|
$
|
(2,839
|
)
|
|
$
|
(2,608
|
)
|
Purchases
of property and equipment
|
|
|
(1,081,209
|
)
|
|
|
(532,562
|
)
|
Costs
of capitalized software development
|
|
|
—
|
|
|
|
(67,258
|
)
|
Cash
acquired from business combination
|
|
|
—
|
|
|
|
290,102
|
|
Cost
of patents
|
|
|
(146,163
|
)
|
|
|
(135,210
|
)
|
NET
CASH USED IN INVESTING ACTIVITIES
|
|
|
(1,230,211
|
)
|
|
|
(447,536
|
)
|
CASH
FLOWS FROM FINANCING ACTIVITIES
|
|
|
|
|
|
|
|
|
Proceeds
from non controlling interests
|
|
|
—
|
|
|
|
6,700,000
|
|
Proceeds
from debt
|
|
|
246,000
|
|
|
|
—
|
|
Repayment
of borrowings and capital lease obligations
|
|
|
(1,387,225
|
)
|
|
|
(1,492,546
|
)
|
Repayment
of notes receivable from employee stockholders
|
|
|
44,492
|
|
|
|
75,862
|
|
Distributions
to non controlling interests
|
|
|
(1,135,000
|
)
|
|
|
(22,500
|
)
|
Redemption
of non controlling interests
|
|
|
(1,200,000
|
)
|
|
|
—
|
|
Purchase
of non controlling interest
|
|
|
—
|
|
|
|
(10,500
|
)
|
Proceeds
from non controlling interest
|
|
|
16,031
|
|
|
|
—
|
|
Sale
to non controlling interest
|
|
|
10,500
|
|
|
|
—
|
|
NET
CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES
|
|
|
(3,405,202
|
)
|
|
|
5,250,316
|
|
NET
INCREASE IN CASH AND CASH EQUIVALENTS
|
|
|
2,780,771
|
|
|
|
7,951,751
|
|
CASH
AND CASH EQUIVALENTS – BEGINNING OF YEAR
|
|
|
9,251,244
|
|
|
|
1,299,493
|
|
CASH
AND CASH EQUIVALENTS – END OF YEAR
|
|
$
|
12,032,015
|
|
|
$
|
9,251,244
|
|
See accompanying notes to
consolidated financial statements.
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 1 - DESCRIPTION OF
BUSINESS AND LIQUIDITY AND CAPITAL RESOURCES
Description of
Business
FONAR Corporation (the
“Company” or “FONAR”) is a Delaware corporation, which was incorporated on July
17, 1978. FONAR is engaged in the research, development, production and
marketing of medical scanning equipment, which uses principles of Magnetic
Resonance Imaging ("MRI") for the detection and diagnosis of human diseases. In
addition to deriving revenues from the direct sale of MRI equipment, revenue is
also generated from our installed-base of customers through our service and
upgrade programs.
FONAR, through its
wholly-owned subsidiary Health Management Corporation of America ("HMCA")
provides comprehensive management services to diagnostic imaging facilities. The
services provided by the Company include development, administration, leasing of
office space, facilities and medical equipment, provision of supplies, staffing
and supervision of non-medical personnel, legal services, accounting, billing
and collection and the development and implementation of practice growth and
marketing strategies. As of June 30, 2012, Imperial manages 11 diagnostic
imaging facilities located in states of New York and Florida.
During May 2011, HMCA
contributed all of its assets together with its liabilities to a newly formed
limited liability company, Imperial Management Services, LLC
(“Imperial”).
On October 1, 2010, the
Company purchased 100% of the stock of Fair Haven Services Inc., an entity
wholly owned by Raymond Damadian. The entity is in the business of leasing
medical equipment to various unrelated PC’s.
Liquidity
At June 30, 2012, the
Company had working capital of approximately $4.8 million as compared to working
capital of $576,000 at June 30, 2011, and stockholders’ equity of $11.1 million
at June 30, 2012 as compared to stockholders’ equity of $5.9 million at June 30,
2011. For the year ended June 30, 2012, we realized a net income of $6.9
million.
The Company believes that
its business plan has been responsible for the past two consecutive fiscal years
of profitability (fiscal 2012 and fiscal 2011) and that its capital resources
will be adequate to support operations at current levels through June 30, 2013.
In fiscal 2010 and prior years, however, the Company also experienced losses and
periods of working capital deficits. The future effects on our business of
healthcare reform legislation, the Deficit Reduction Act, the tax on sales of
medical equipment and the general economic and business climate are not known at
the present time. Nevertheless, there is a possibility of adverse consequences
to our business operations from these causes.
In order to promote sales,
the Company is continuing to focus on marketing campaigns to strengthen the
demand for our products and services. Management anticipates that the Company’s
capital resources will continue to improve if the Company’s MRI scanner products
gain wider market recognition and acceptance resulting in both increased product
sales and scan volumes. If the Company is not successful with our marketing
efforts to increase sales, the Company will experience a shortfall in cash, and
it will be necessary to reduce operating expenses or obtain funds through equity
or debt financing.
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 1 - DESCRIPTION OF
BUSINESS AND LIQUIDITY AND CAPITAL RESOURCES (Continued)
Liquidity
(Continued)
If the Company is unable
to meet expenditures with revenues or financing then it will be necessary to
reduce expenses further, or seek other sources of funds through the issuance of
debt or equity financing in order to conduct operations as now conducted
subsequent to fiscal 2013.
NOTE 2 - SUMMARY OF
SIGNIFICANT ACCOUNTING POLICIES
Principles of
Consolidation
The consolidated financial
statements include the accounts of FONAR Corporation, its majority and
wholly-owned subsidiaries and partnerships. All significant intercompany
accounts and transactions have been eliminated in consolidation.
Use of
Estimates
The preparation of the
consolidated financial statements in conformity with accounting principles
generally accepted in the United States requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities in the consolidated financial
statements and accompanying notes. The most significant estimates relate to
accounts receivable allowances, intangible assets, income taxes, useful lives of
property and equipment, contingencies, revenue recognition and litigation. In
addition, healthcare industry reforms and reimbursement practices will continue
to impact the Company's operations and the determination of contractual and
other allowance estimates. Actual results could differ from those
estimates.
Inventories
Inventories consist of
purchased parts, components and supplies, as well as work-in-process, and are
stated at the lower of cost, determined on the first-in, first-out method, or
market.
Property and
Equipment
Property and equipment
procured in the normal course of business is stated at cost. Property and
equipment purchased in connection with an acquisition is stated at its estimated
fair value, generally based on an appraisal. Property and equipment is being
depreciated for financial accounting purposes using the straight-line method
over their estimated useful lives, generally five to seven years. Leasehold
improvements are being amortized over the shorter of the useful life or the
remaining lease term. Upon retirement or other disposition of these assets, the
cost and related accumulated depreciation of these assets are removed from the
accounts and the resulting gains or losses are reflected in the results of
operations. Expenditures for maintenance and repairs are charged to operations.
Renewals and betterments are capitalized. Maintenance and repair expenses
totaled approximately $371,000 and $334,000 for the years ended June 30, 2012
and 2011, respectively.
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 2 - SUMMARY OF
SIGNIFICANT ACCOUNTING POLICIES (Continued)
Other Intangible
Assets
1) Capitalized Software
Development Costs
Capitalization of software
development costs begins upon the establishment of technological feasibility.
Technological feasibility for the Company’s computer software is generally based
upon achievement of a detail program design free of high risk development issues
and the completion of research and development on the product hardware in which
it is to be used. The establishment of technological feasibility and the ongoing
assessment of recoverability of capitalized computer software development costs
require considerable judgment by management with respect to certain external
factors, including, but not limited to, technological feasibility, anticipated
future gross revenue, estimated economic life and changes in software and
hardware technology. Prior to reaching technological feasibility those costs are
expensed as incurred and included in research and development.
Amortization of
capitalized software development costs commences when the related products
become available for general release to customers. Amortization is provided on a
product by product basis. The annual amortization is the greater of the amount
computed using (a) the ratio that current gross revenue for a product bears to
the total of current and anticipated future gross revenue for that product, or
(b) the straight-line method over the remaining estimated economic life of the
product.
The Company periodically
performs reviews of the recoverability of such capitalized software development
costs. At the time a determination is made that capitalized amounts are not
recoverable, based on the estimated cash flows to be generated from the
applicable software, any remaining capitalized amounts are written
off.
2) Patents and
Copyrights
Amortization is calculated
on the straight-line basis over a period ranging from 15 to 17 years.
3) Management
Agreement
The management agreement
is being amortized on the straight line basis over the length of the agreement
(15 years).
Long-Lived
Assets
The Company periodically
assesses the recoverability of long-lived assets, including property and
equipment and intangibles, when there are indications of potential impairment,
based on estimates of undiscounted future cash flows. The amount of impairment
is calculated by comparing anticipated discounted future cash flows with the
carrying value of the related asset. In performing this analysis, management
considers such factors as current results, trends, and future prospects, in
addition to other economic factors.
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 2 - SUMMARY OF
SIGNIFICANT ACCOUNTING POLICIES (Continued)
Revenue
Recognition
Revenue on sales contracts
for scanners, included in “product sales” in the accompanying consolidated
statements of operations, is recognized under the percentage-of-completion
method in accordance with FASB ASC 605-35, “Revenue Recognition –
Construction-Type and Production-Type Contracts”. The Company manufactures its
scanners under specific contracts that provide for progress payments. Production
and installation take approximately three to six months. The percentage of
completion is determined by the ratio of costs incurred to date on completed
sub-assemblies to the total estimated cost for each scanner. Contract costs
include purchased parts and components, direct labor and overhead. Revisions in
cost estimates and provisions for estimated losses on uncompleted contracts, if
any, are made in the period in which such losses are determined. The asset,
"Costs and Estimated Earnings in Excess of Billings on Uncompleted Contracts",
represents revenues recognized in excess of amounts billed. The liability,
"Billings in Excess of Costs and Estimated Earnings on Uncompleted Contracts",
represents amounts billed in excess of revenues recognized.
Revenue on scanner service
contracts is recognized on the straight-line method over the related contract
period, usually one year.
Revenue from sales of
other items is recognized upon shipment.
Revenue under management
contracts is recognized based upon contractual agreements for management
services rendered by the Company primarily under various long-term agreements
with various medical providers (the "PCs"). As of June 30, 2012, the Company has
eleven management agreements of which three are with PC’s owned by Raymond V.
Damadian, M.D., President and Chairman of the Board of FONAR (“the Related
medical practices”) and eight are with PC’s, which are all located in the state
of New York (“the New York PC’s”), owned by one unrelated radiologist. The
contractual fees for services rendered to the PCs consists of fixed monthly fees
per diagnostic imaging facility ranging from approximately $100,000 to $241,000.
All fees are re-negotiable at the anniversary of the agreements and each year
thereafter. Revenue under lease contracts is recognized based upon contractual
agreements for the leasing of medical equipment primarily under long term
contracts to various unrelated PC’s. The lease fees for the medical equipment
consist of fixed monthly fees ranging from $2,000 to $21,000. All fees are
re-negotiable at the anniversary of the agreements and each year
thereafter.
Research and
Development Costs
Research and development
costs are charged to expense as incurred. The costs of materials and equipment
that are acquired or constructed for research and development activities, and
have alternative future uses (either in research and development, marketing or
production), are classified as property and equipment and depreciated over their
estimated useful lives.
Advertising
Costs
Advertising costs are
expensed as incurred. Advertising expense approximated $715,000 and $466,000 for
the years ended June 30, 2012 and 2011, respectively.
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 2 - SUMMARY OF
SIGNIFICANT ACCOUNTING POLICIES (Continued)
Shipping
Costs
The Company’s shipping and
handling costs are included in revenue from product sales and the related
expense included in costs related to product sales is $26,425 and $49,712 for
the years ended June 30, 2012 and 2011, respectively.
Income
Taxes
Deferred tax assets and
liabilities are determined based on the difference between the financial
statement carrying amounts and tax basis of assets and liabilities using enacted
tax rates in effect in the years in which the differences are expected to
reverse.
Customer
Advances
Cash advances and progress
payments received on sales orders are reflected as customer advances until such
time as revenue recognition begins.
Earnings Per
Share
Basic earnings per share
(“EPS”) is computed based on weighted average shares outstanding and excludes
any potential dilution. In accordance with ASC topic 260-10, “Participating
Securities and the Two-Class Method”, the Company used the Two-Class method for
calculating basic earnings per share and applied the if converted method in
calculating diluted earnings per share for the years ended June 30, 2012 and
2011.
Diluted EPS reflects the
potential dilution from the exercise or conversion of all dilutive securities
into common stock based on the average market price of common shares outstanding
during the period. For both the year ended June 30, 2012 and June 30, 2011,
diluted EPS for common shareholders includes 127,504 shares upon conversion of
Class C Common. For the year ended June 30, 2012 and June 30, 2011, the number
of common shares potentially issuable upon the exercise of certain options of
14,022 and 22,537; respectively, have not been included in the computation of
diluted EPS since the effect would be antidilutive.
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 2 - SUMMARY OF
SIGNIFICANT ACCOUNTING POLICIES (Continued)
Earnings Per Share
(Continued)
|
June 30, 2012
|
|
June 30, 2011
|
|
(000's omitted, except per share data)
|
Basic
|
|
Total
|
|
|
Common
Stock
|
|
|
Class
C Common Stock
|
|
|
|
Total
|
|
|
Common
Stock
|
|
|
Class
C Common Stock
|
|
Numerator:
Net income
Available
to common
stockholders
|
$
|
5,776,481
|
|
$
|
5,392,212
|
|
$
|
97,863
|
|
|
$
|
3,160,910
|
|
$
|
2,941,026
|
|
$
|
55,998
|
|
Denominator:
Weighted
Average
Shares
outstanding
|
|
5,778,695
|
|
|
5,778,695
|
|
|
382,513
|
|
|
|
5,264,795
|
|
|
5,264,795
|
|
|
382,513
|
|
Basic
income
per
common
share
|
$
|
1.00
|
|
$
|
0.93
|
|
$
|
0.26
|
|
|
$
|
0.60
|
|
$
|
0.56
|
|
$
|
0.15
|
|
Diluted
Denominator:
Weighted
Average
Shares
outstanding
|
|
|
|
|
5,778,695
|
|
|
382,513
|
|
|
|
|
|
|
5,264,795
|
|
|
382,513
|
|
Class
C
Common
Stock
|
|
|
|
|
127,504
|
|
|
—
|
|
|
|
|
|
|
127,504
|
|
|
—
|
|
Total
Denominator
for
diluted
earnings
per share
|
|
|
|
|
5,906,199
|
|
|
382,513
|
|
|
|
|
|
|
5,392,299
|
|
|
382,513
|
|
Diluted
income per
common
share
|
|
|
|
$
|
0.91
|
|
$
|
0.26
|
|
|
|
|
|
$
|
0.55
|
|
$
|
0.15
|
|
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 2 – SUMMARY OF
SIGNIFICANT ACCOUNTING POLICIES (Continued)
Cash and Cash
Equivalents
The Company considers all
short-term highly liquid investments with a maturity of three months or less
when purchased to be cash or cash equivalents.
Concentration of Credit
Risk
Cash: The Company
maintains its cash and cash equivalents with various financial institutions,
which exceed federally insured limits throughout the year. At June 30, 2012, the
Company had cash on deposit of approximately $10,771,000 in excess of federally
insured limits of $250,000.
Related Parties: Net
revenues from related parties accounted for approximately 17% and 16% of the
consolidated net revenues for the years ended June 30, 2012 and 2011,
respectively. Net management fee receivables from the related medical practices
accounted for approximately 13% and 16% of the consolidated accounts receivable
for the years ended June 30, 2012 and 2011, respectively.
See Note 3 regarding the
Company’s concentrations in the healthcare industry.
Fair Value of Financial
Instruments
The financial statements
include various estimated fair value information at June 30, 2012 and 2011, as
required by ASC topic 820, "Disclosures about Fair Value of Financial
Instruments". Such information, which pertains to the Company's financial
instruments, is based on the requirements set forth in that Statement and does
not purport to represent the aggregate net fair value to the Company.
The following methods and
assumptions were used to estimate the fair value of each class of financial
instruments for which it is practicable to estimate that value:
Cash and cash equivalents:
The carrying amount approximates fair value because of the short-term maturity
of those instruments.
Accounts receivable and
accounts payable: The carrying amounts approximate fair value because of the
short maturity of those instruments.
Notes receivable: The
carrying amount approximates fair value because the discounted present value of
the cash flow generated by the parties approximates the carrying value of the
amounts due to the Company.
Long-term debt, notes
payable and accounts payable: The carrying amounts of debt and notes payable
approximate fair value due to the length of the maturities, the interest rates
being tied to market indices and/or due to the interest rates not being
significantly different from the current market rates available to the
Company.
All of the Company's
financial instruments are held for purposes other than trading.
Accumulated Other
Comprehensive Loss
Accumulated other
comprehensive loss generally includes all changes in equity during a period,
except those resulting from investments by stockholders and distributions to
stockholders.
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 2 - SUMMARY OF
SIGNIFICANT ACCOUNTING POLICIES (Continued)
Recent Accounting
Pronouncements
In December 2011, the
Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update
(“ASU”) No. 2011-12, Deferral of the Effective Date for Amendments to the
Presentation of Reclassifications of Items Out of Accumulated Other
Comprehensive Income in ASU 2011-05. ASU 2011-12 defers the requirement that
companies present reclassification adjustments for each component of Accumulated
Other Comprehensive Income in both net income and Other Comprehensive Income on
the face of the financial statements. All other requirements in ASU No. 2011-05
are not affected by ASU No. 2011-12, including the requirement to report
comprehensive income either in a single continuous financial statement or in two
separate but consecutive financial statements. The guidance provided by this
update becomes effective for fiscal years, and interim periods within those
years, beginning after December 15, 2011. The adoption of this standard is not
expected to have a material impact on the Company’s consolidated position and
results of operations.
In July 2012, the FASB
issued ASU No. 2012-02, Intangibles-Goodwill and Other (Topic 350) Testing
Indefinite-Lived Intangible Assets for Impairment. This ASU simplifies how
entities test indefinite-lived intangible assets for impairment which improve
consistency in impairment testing requirements among long-lived asset
categories. These amended standards permit an assessment of qualitative factors
to determine whether it is more likely than not that the fair value of an
indefinite-lived intangible asset is less than its carrying value. For assets in
which this assessment concludes it is more likely than not that the fair value
is more than its carrying value, these amended standards eliminate the
requirement to perform quantitative impairment testing as outlined in previously
issued standards. The guidance is effective for annual and interim impairment
tests performed for fiscal years beginning after September 15, 2012, early
adoption is permitted. The adoption of this standard is not expected to have a
material impact on the Company’s consolidated financial position and results of
operations.
FASB, the Emerging Issues
Task Force and the SEC have issued certain other accounting standards, updates,
and regulations as of June 30, 2012 that will become effective in subsequent
periods; however, management does not believe that any of those updates would
have significantly affected our financial accounting measures or disclosures had
they been in effect during 2012 or 2011, and it does not believe that any of
those pronouncements will have a significant impact on our consolidated
financial statements at the time they become effective.
Reclassifications
Certain prior year amounts
have been reclassified to conform to the current year presentation. The
reclassifications did not have any effect on reported net income for any periods
presented.
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 3 - MANAGEMENT FEE
RECEIVABLE AND ACCOUNTS RECEIVABLE
The Company’s customers
are concentrated in the healthcare industry.
Management Fee
Receivable
The Company’s receivables
from the related and non-related professional corporations (“PCs”) substantially
consist of fees outstanding under management agreements. Payment of the
outstanding fees is dependent on collection by the PCs of fees from third party
medical reimbursement organizations, principally insurance companies and health
management organizations.
Payment of the management
fee receivables from the PC’s may be impaired by the inability of the PC’s to
collect in a timely manner their medical fees from the third party payors,
particularly insurance carriers covering automobile no-fault and workers
compensation claims due to longer payment cycles and rigorous informational
requirements and certain other disallowed claims. Approximately 38% and 34%,
respectively, of the PCs’ 2012 and 2011 net revenues were derived from no-fault
and personal injury protection claims. The Company considers the aging of its
accounts receivable in determining the amount of allowance for doubtful
accounts. The Company generally takes all legally available steps to collect its
receivables. Credit losses associated with the receivables are provided for in
the consolidated financial statements and have historically been within
management's expectations.
Net revenues from
management and other fees charged to the related medical practices accounted for
approximately 17% and 16%, of the consolidated net revenues for the years ended
June 30, 2012 and 2011, respectively.
Tallahassee Magnetic
Resonance Imaging, PA, Stand Up MRI of Boca Raton, PA and Stand Up MRI &
Diagnostic Center, PA (all related medical practices) entered into a guaranty
agreement, pursuant to which they cross guaranteed all management fees which are
payable to the Company, which have arisen under each individual management
agreement.
Accounts
Receivable
Credit risk with respect
to the Company’s accounts receivable related to product sales and service and
repair fees is limited due to the customer advances received prior to the
commencement of work performed and the billing of amounts to customers as
sub-assemblies are completed. Service and repair fees are billed on a monthly or
quarterly basis and the Company does not continue providing these services if
accounts receivable become past due. The Company controls credit risk with
respect to accounts receivable from service and repair fees through its credit
evaluation process, credit limits, monitoring procedures and reasonably short
collection terms. The Company performs ongoing credit authorizations before a
product sales contract is entered into or service and repair fees are
provided.
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 4 - COSTS AND
ESTIMATED EARNINGS ON UNCOMPLETED CONTRACTS AND CUSTOMER ADVANCES
1) Information relating to
uncompleted contracts as of June 30, 2012 and 2011 is as follows:
|
|
As of June 30,
|
|
|
2012
|
|
2011
|
Costs
incurred on uncompleted Contracts
|
|
$
|
3,745,307
|
|
|
$
|
1,868,568
|
|
Estimated
earnings
|
|
|
2,670,289
|
|
|
|
1,077,387
|
|
|
|
|
6,415,596
|
|
|
|
2,945,955
|
|
Less:
Billings to date
|
|
|
5,287,000
|
|
|
|
2,780,557
|
|
|
|
$
|
1,128,596
|
|
|
$
|
165,398
|
|
Included in the
accompanying consolidated balance sheets under the following
captions:
|
|
As of June 30,
|
|
|
2012
|
|
2011
|
Costs
and estimated earnings in excess of billings on uncompleted
contracts
|
|
$
|
1,128,596
|
|
|
$
|
169,443
|
|
Less:
Billings in excess of costs and estimated earnings on uncompleted
contracts
|
|
|
—
|
|
|
|
4,045
|
|
|
|
$
|
1,128,596
|
|
|
$
|
165,398
|
|
2) Customer advances
consist of the following:
|
|
As of June 30,
|
|
|
2012
|
|
2011
|
Total
advances
|
|
$
|
9,168,284
|
|
|
$
|
7,626,351
|
|
Less:
Advances on contracts under construction
|
|
|
5,287,000
|
|
|
|
2,780,557
|
|
|
|
$
|
3,881,284
|
|
|
$
|
4,845,794
|
|
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 5 –
INVENTORIES
Inventories included in
the accompanying consolidated balance sheets consist of:
|
|
As of June 30,
|
|
|
2012
|
|
2011
|
Purchased
parts, components and supplies
|
|
$
|
1,672,494
|
|
|
$
|
1,818,542
|
|
Work-in-process
|
|
|
522,455
|
|
|
|
581,698
|
|
|
|
$
|
2,194,949
|
|
|
$
|
2,400,240
|
|
NOTE 6 - PROPERTY AND
EQUIPMENT
Property and equipment, at
cost, less accumulated depreciation and amortization, at June 30, 2012 and 2011,
is comprised of:
|
|
As of June 30,
|
|
|
2012
|
|
2011
|
Diagnostic
equipment under capital leases
|
|
$
|
1,417,300
|
|
|
$
|
2,270,719
|
|
Diagnostic
equipment
|
|
|
4,138,898
|
|
|
|
2,518,035
|
|
Research,
development and demonstration equipment
|
|
|
9,861,199
|
|
|
|
9,605,961
|
|
Machinery
and equipment
|
|
|
4,985,215
|
|
|
|
4,982,085
|
|
Furniture
and fixtures
|
|
|
2,212,149
|
|
|
|
2,127,809
|
|
Leasehold
improvements
|
|
|
4,545,974
|
|
|
|
4,663,666
|
|
Building
|
|
|
939,614
|
|
|
|
939,614
|
|
|
|
|
28,100,349
|
|
|
|
27,107,889
|
|
Less:
Accumulated depreciation and amortization
|
|
|
24,926,902
|
|
|
|
23,338,465
|
|
|
|
$
|
3,173,447
|
|
|
$
|
3,769,424
|
|
Depreciation and
amortization of property and equipment for the years ended June 30, 2012 and
2011 was $1,677,186 and $1,464,055, respectively.
Depreciation and
amortization of diagnostic equipment under capital leases for the years ended
June 30, 2012 and 2011 was $646,620 and $433,859, respectively. Accumulated
depreciation and amortization of diagnostic equipment under capital leases for
the years ended June 30, 2012 and 2011 was $1,074,152 and $1,067,534,
respectively.
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 7 - OTHER INTANGIBLE
ASSETS
Other intangible assets,
net of accumulated amortization, at June 30, 2012 and 2011 are comprised
of:
|
|
As of June 30,
|
|
|
2012
|
|
2011
|
Capitalized
software development costs
|
|
$
|
6,368,960
|
|
|
$
|
6,368,960
|
|
Patents
and copyrights
|
|
|
4,100,511
|
|
|
|
4,030,579
|
|
Management
agreement
|
|
|
513,333
|
|
|
|
513,333
|
|
|
|
|
10,982,804
|
|
|
|
10,912,872
|
|
Less:
Accumulated amortization
|
|
|
7,147,625
|
|
|
|
6,594,561
|
|
|
|
$
|
3,835,179
|
|
|
$
|
4,318,311
|
|
Information related to the
above intangible assets for the years ended June 30, 2012 and 2011 is as
follows:
|
|
2012
|
|
2011
|
Balance
– Beginning of Year
|
|
$
|
4,318,311
|
|
|
$
|
4,291,419
|
|
Amounts
capitalized
|
|
|
146,163
|
|
|
|
715,801
|
|
Abandon
patents written off
|
|
|
(76,231
|
)
|
|
|
(79,958
|
)
|
Amortization
|
|
|
(553,064
|
)
|
|
|
(608,951
|
)
|
Balance
– End of Year
|
|
$
|
3,835,179
|
|
|
$
|
4,318,311
|
|
Amortization of patents
and copyrights for the years ended June 30, 2012 and 2011 amounted to $156,310
and $142,049, respectively.
Amortization of
capitalized software development costs for the years ended June 30, 2012 and
2011 was $360,087 and $448,569, respectively.
Amortization of management
agreement for the years ended June 30, 2012 and 2011 amounted to $36,667 and
$18,333, respectively.
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 7 - OTHER INTANGIBLE
ASSETS (Continued)
The estimated amortization
of patents and copyrights and capitalized software development costs for the
five years ending June 30, 2017 and thereafter is as follows:
For the Years Ending June 30,
|
|
Total
|
|
Patents
and
Copyrights
|
|
Capitalized Software Development Costs
|
|
Management Agreement
|
|
2013
|
|
|
$
|
496,776
|
|
|
$
|
174,025
|
|
|
$
|
286,084
|
|
|
$
|
36,667
|
|
|
2014
|
|
|
|
449,502
|
|
|
|
190,159
|
|
|
|
222,676
|
|
|
|
36,667
|
|
|
2015
|
|
|
|
420,802
|
|
|
|
206,293
|
|
|
|
177,842
|
|
|
|
36,667
|
|
|
2016
|
|
|
|
439,926
|
|
|
|
221,848
|
|
|
|
181,411
|
|
|
|
36,667
|
|
|
2017
|
|
|
|
453,001
|
|
|
|
229,334
|
|
|
|
187,000
|
|
|
|
36,667
|
|
|
Thereafter
|
|
|
|
1,575,172
|
|
|
|
1,197,062
|
|
|
|
103,112
|
|
|
|
274,998
|
|
|
|
|
|
$
|
3,835,179
|
|
|
$
|
2,218,721
|
|
|
$
|
1,158,125
|
|
|
$
|
458,333
|
|
The weighted average
amortization period for other intangible assets is 9.6 years and they have no
expected residual value.
NOTE 8 – NOTES
RECEIVABLE
Notes receivable as of
June 30, 2012 and 2011 consist of the following:
|
|
As of June 30,
|
|
|
2012
|
|
2011
|
Note
Receivable – (a)
|
|
$
|
65,000
|
|
|
|
65,000
|
|
Note
Receivable – (b)
|
|
|
233,182
|
|
|
|
264,985
|
|
Note
Receivable – (c)
|
|
|
158,800
|
|
|
|
207,842
|
|
Total
Notes Receivable
|
|
|
456,982
|
|
|
|
537,827
|
|
Allowance
|
|
|
(65,000
|
)
|
|
|
(65,000
|
)
|
Net
Notes Receivable
|
|
$
|
391,982
|
|
|
$
|
472,827
|
|
Current
Portion
|
|
$
|
116,016
|
|
|
$
|
114,058
|
|
Long-Term
Portion
|
|
$
|
275,966
|
|
|
$
|
358,769
|
|
a) This note receivable
represents a note due from a customer for the purchase of a system. The note is
past due. The Company has an allowance for doubtful accounts of $65,000 as of
June 30, 2012 and 2011 on this note.
b) This note receivable
represents a note due from a customer for the purchase of an Upright MRI system.
The note is payable in 60 consecutive equal monthly payments of principal and
interest of $5,798 commencing November 2010.
c) This represents notes
from a customer for past due service provided to two Upright MRI systems. The
notes are payable in monthly payments of principal and interest of
$5,444.
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 9 - CAPITAL
STOCK
Common
Stock
Cash dividends payable on
the common stock shall, in all cases, be on a per share basis, one hundred
twenty percent (120%) of the cash dividend payable on shares of Class B common
stock and three hundred sixty percent (360%) of the cash dividend payable on a
share of Class C common stock.
Class B Common
Stock
Class B common stock is
convertible into shares of common stock on a one-for-one basis. Class B common
stock has 10 votes per share. There were 158 of such shares outstanding at June
30, 2012 and 2011.
Class C Common
Stock
On April 3, 1995, the
stockholders ratified a proposal creating a new Class C common stock and
authorized the exchange offering of three shares of Class C common stock for
each share of the Company's outstanding Class B common stock. The Class C common
stock has 25 votes per share, as compared to 10 votes per share for the Class B
common stock and one vote per share for the common stock. The Class C common
stock was offered on a three-for-one basis to the holders of the Class B common
stock. Although having greater voting power, each share of Class C common stock
has only one-third of the rights of a share of Class B common stock to dividends
and distributions. Class C common stock is convertible into shares of common
stock on a three-for-one basis.
Class A Non-Voting
Preferred Stock
On April 3, 1995, the
stockholders ratified a proposal consisting of the creation of a new class of
Class A non-voting preferred stock with special dividend rights and the
declaration of a stock dividend on the Company's common stock consisting of one
share of Class A non-voting preferred stock for every five shares of common
stock. The stock dividend was payable to holders of common stock on October 20,
1995. Class A non-voting preferred stock issued pursuant to such stock dividend
approximates 313,000 shares.
The Class A non-voting
preferred stock is entitled to a special dividend equal to 3-1/4% of first $10
million, 4-1/2% of next $20 million and 5-1/2% on amounts in excess of $30
million of the amount of any cash awards or
settlements received by
the Company in connection with the enforcement of five of the Company's patents
in its patent lawsuits, less the revised special dividend payable on the common
stock with respect to one of the Company's patents.
The Class A non-voting
preferred stock participates on an equal per share basis with the common stock
in any dividends declared and ranks equally with the common stock on
distribution rights, liquidation rights and other rights and preferences (other
than the voting rights).
Stock Bonus
Plans
On April 23, 2010, the
Board approved the 2010 Stock Bonus Plan. The plan entitles the Company to
reserve 2,000,000 shares of common stock. On August 10, 2010, the Company filed
Form S-8 to register the 2,000,000 shares. As of June 30, 2012, 1,072,945 shares
of common stock of FONAR were available for future grant under this plan.
276,334 shares were issued during the year ended June 30, 2012.
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 9 - CAPITAL STOCK
(Continued)
Options
The Company has stock
option plans, which provide for the awarding of incentive and non-qualified
stock options to employees, directors and consultants who may contribute to the
success of the Company. The options granted vest either immediately or ratably
over a period of time from the date of grant, typically three or four years, at
a price determined by the Board of Directors or a committee of the Board of
Directors, generally the fair value of the Company's common stock at the date of
grant. The options must be exercised within ten years from the date of
grant.
FONAR’s 1997 Nonstatutory
Stock Option Plan, adopted on May 9, 1997, permits the issuance of stock options
covering an aggregate of 200,000 shares of common stock of FONAR. The options
may be issued at such prices and upon such terms and conditions as are
determined by FONAR. The 1997 Plan terminated on May 8, 2007. During the year
ended June 30, 2012, 8,272 options expired, therefore of the options granted
under this plan zero shares remain outstanding.
FONAR’s 2002 Incentive
Stock Option Plan (the “FONAR 2002 Plan”), adopted on July 1, 2002, is intended
to qualify as an incentive stock option plan under Section 422A of the Internal
Revenue Code of 1954, as amended. The FONAR 2002 Plan permits the issuance of
stock options covering an aggregate of 100,000 shares of common stock of FONAR.
The options have an exercise price equal to the fair market value of the
underlying stock on the date the option is granted, are nontransferable, are
exercisable for a period not exceeding ten years and expire upon the voluntary
termination of employment. The FONAR 2002 Plan terminated on June 30, 2012.
During the year ended June 30, 2012, 243 options were forfeited, therefore
14,022 options remain outstanding.
FONAR’s 2005 Incentive
Stock Option Plan (the “FONAR 2005 Plan”), adopted on February 16, 2005, is
intended to qualify as an incentive stock option plan under Section 422A of the
Internal Revenue Code of 1954, as amended. The FONAR 2005 Plan permits the
issuance of stock options covering an aggregate of 80,000 shares of common stock
of FONAR. The options have an exercise price equal to the fair market value of
the underlying stock on the date the option is granted, are non-transferable,
are exercisable for a period not exceeding ten years, and expire upon the
voluntary termination of employment. The FONAR 2005 Plan will terminate on
February 14, 2015. As of June 30, 2012, 80,000 shares of common stock of FONAR
were available for future grant under this Plan.
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 9 - CAPITAL STOCK
(Continued)
Options
(Continued)
Stock option activity and
weighted average exercise prices under these plans and grants for the years
ended June 30, 2012 and 2011 were as follows:
|
|
Number of Options
|
|
Weighted Average Exercise Price
|
|
Aggregate Intrinsic Value
|
Outstanding,
June 30, 2010
|
|
|
68,234
|
|
|
|
29.63
|
|
|
|
—
|
|
Granted
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Exercised
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Forfeited
/ Expired
|
|
|
(45,697
|
)
|
|
|
29.31
|
|
|
|
—
|
|
Outstanding,
June 30, 2011
|
|
|
22,537
|
|
|
|
30.27
|
|
|
|
—
|
|
Granted
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Exercised
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Forfeited
/ Expired
|
|
|
(8,515
|
)
|
|
|
34.41
|
|
|
|
—
|
|
Outstanding,
June 30, 2012
|
|
|
14,022
|
|
|
|
27.76
|
|
|
|
—
|
|
Exercisable
at:
|
|
|
|
|
|
|
|
|
|
|
|
|
June
30, 2011
|
|
|
22,537
|
|
|
$
|
30.27
|
|
|
|
|
|
June
30, 2012
|
|
|
14,022
|
|
|
$
|
27.76
|
|
|
|
|
|
The range of exercise
prices for options outstanding as of June 30, 2012 was as follows:
Range of Exercise Price
|
|
Number of Options Outstanding
|
|
Weighted Average Remaining Contractual Life in Years
|
|
$25.00 -
$28.13
|
|
|
|
5,932
|
|
|
|
0.28
|
|
|
$29.00 -
$34.38
|
|
|
|
8,090
|
|
|
|
1.26
|
|
|
|
|
|
|
14,022
|
|
|
|
|
|
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 10 – CONTROLLING
INTERESTS
On May 2, 2011, the
Company completed a private placement of equity and succeeded in raising
$6,000,000. The offering consisted of Preferred Class A membership interests in
a newly formed limited liability company, Imperial Management Services, LLC
(“Imperial”). The Class B membership interests in Imperial, all of which were
retained by the Company’s subsidiary, HMCA, hold a 75% equity interest in
Imperial. The Class A membership interests are entitled to receive a dividend of
18% per annum of their cash capital contribution of $6,000,000. HMCA contributed
all of its assets, together with its liabilities, to Imperial as HMCA’s capital
contribution. The Imperial operating agreement provides for the Class A members
to receive priority distributions until their original capital contributions are
returned. Dividends are payable quarterly beginning August 1, 2011. On May 1,
2012, the Company returned a portion of the Class A Members capital contribution
in the amount of $1,200,000. The Company’s subsidiary, HMCA, now owns an 80%
interest in Imperial Management Services.
On May 1, 2010, the
Company purchased a 15.2% interest from an unrelated party of an entity that
provides management services to a diagnostic center in the New York Metropolitan
area. On January 1, 2011, the Company purchased an additional 34.8% interest by
the issuance of a promissory note of $400,000. Commencing January 1, 2011, the
Company consolidates the activity of this entity. The fair values assigned to
the assets acquired and liabilities assumed were as follows:
Cash
|
|
$
|
289,185
|
|
Property
and equipment
|
|
|
303,659
|
|
Management
contracts
|
|
|
513,333
|
|
Security
deposits
|
|
|
45,784
|
|
Accounts
payable
|
|
|
(47,026
|
)
|
Notes
payable
|
|
|
(130,650
|
)
|
Non-controlling
interests
|
|
|
(491,328
|
)
|
Less
prior investment
|
|
|
(82,957
|
)
|
Subtotal
|
|
|
400,000
|
|
Purchase
price
|
|
|
(400,000
|
)
|
Cash
used in purchase
|
|
$
|
0
|
|
The Company also has a 50%
controlling interest in an entity which the Company consolidates, that provides
management services to a diagnostic center in the New York Metropolitan area.
The center began operations during January 2012.
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 11 - LONG-TERM DEBT,
NOTES PAYABLE AND CAPITAL LEASES
Long-term debt, notes
payable and capital leases consist of the following:
|
|
June 30,
|
|
|
2012
|
|
2011
|
Capital
lease requiring monthly payments of $13,623, including interest at a rate
of 10.51% per annum through July 2010. The lease was restructured in July
2008, requiring twelve monthly payments of $6,923 followed by 31 monthly
payments of $9,585 through January 2012, including interest at a rate of
11.82%. The lease is collateralized by the related equipment.
|
|
$
|
—
|
|
|
$
|
73,390
|
|
Notes
payable of $580,000 requiring aggregate monthly payments of $20,106,
including interest at a rate of 15% per annum through June 2013. Amount
due to a related party as of June 30, 2012 is $30,725.
|
|
|
214,355
|
|
|
|
399,024
|
|
Note
payable requiring monthly payments of interest at a rate of 7% until May
2009 followed by 240 monthly payments of $4,472 through October 2026. The
loan is collateralized by a building with a net book value of $720,841 as
of June 30, 2012.
|
|
|
481,615
|
|
|
|
500,411
|
|
Note
payable requiring monthly payments of $12,150, including interest at a
rate of 5% per annum through January 2014, seven monthly payments of
$31,000 commencing February 2014 and a final payment of $5,091 in
September 2014.
|
|
|
423,280
|
|
|
|
544,555
|
|
Note
payable requiring monthly payments of $8,325, including interest at a rate
of 10% per annum through April 2012.
|
|
|
—
|
|
|
|
72,341
|
|
Note
payable from the Fair Haven acquisition requires three monthly payments of
$15,000, twelve monthly payments of $20,000 and six monthly payments of
$25,000, including interest at a rate of 8.58% per annum through November
2011 then 6 payments of $25,000. The loan is collateralized by equipment
which, as of June 30, 2012, has been fully depreciated.
|
|
|
42,500
|
|
|
|
257,246
|
|
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 11 - LONG-TERM DEBT,
NOTES PAYABLE AND CAPITAL LEASES (Continued)
|
|
June 30,
|
|
|
2012
|
|
2011
|
Note
payable from the Fair Haven acquisition requires monthly payments of
$21,000, including interest at a rate of 4.5% per annum through February
2011 and a final payment of $533,783 in March 2011. The loan is
collateralized by equipment which, as of June 30, 2012, has been fully
depreciated. The Company expects to have this loan paid in full by
December 2012.
|
|
$
|
187,707
|
|
|
$
|
510,771
|
|
Note
payable from the Fair Haven acquisition requires monthly payments of
$18,850, including interest at a rate of 11.2% per annum through January
2014. The loan is collateralized by equipment with a net book value of
$343,148 as of June 30, 2012.
|
|
|
326,890
|
|
|
|
533,502
|
|
Note
payable of $400,000 entered into for the purchase of 34.2% interest in a
management company requiring payments of $100,000 on January 2, 2012 and
$300,000 on January 2, 2013 including interest at a rate of 10% per annum
through January 2013. The lender has a security interest in Imperial’s
members interest until the note has been paid in full.
|
|
|
300,000
|
|
|
|
400,000
|
|
Note
payable requiring monthly principal installments of $4,100 and interest
computed on the unpaid principal amount at a rate of 5% per annum through
April 2017. The note is secured by certain assets of the Company.
|
|
|
237,800
|
|
|
|
—
|
|
Other
(including capital leases for property and equipment).
|
|
|
416,750
|
|
|
|
480,882
|
|
|
|
|
2,630,897
|
|
|
|
3,772,122
|
|
Less:
Current portion
|
|
|
1,853,623
|
|
|
|
2,025,836
|
|
|
|
$
|
777,274
|
|
|
$
|
1,746,286
|
|
The maturities of
long-term debt over the next five years and thereafter are as
follows:
Years Ending June 30,
|
|
|
|
2013
|
|
|
$
|
1,853,623
|
|
|
2014
|
|
|
|
197,962
|
|
|
2015
|
|
|
|
72,372
|
|
|
2016
|
|
|
|
73,991
|
|
|
2017
|
|
|
|
67,688
|
|
|
Thereafter
|
|
|
|
365,261
|
|
|
|
|
|
$
|
2,630,897
|
|
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 12 - INCOME
TAXES
Effective January 1, 2007,
the Company adopted the provisions of ASC topic 740 (formerly FASB
Interpretation No. 48/FASB Statement No. 109, “Accounting for Uncertainty in
Income Taxes”). ASC topic 740 prescribes a recognition threshold and a
measurement attribute for the financial statement recognition and measurement of
tax positions taken or expected to be taken in a corporate tax return. For those
benefits to be recognized, a tax position must be more-likely-than-not to be
sustained upon examination by taxing authorities. Differences between tax
positions taken or expected to be taken in a tax return and the benefit
recognized and measured pursuant to the interpretation are referred to as
“unrecognized benefits”. A liability is recognized (or amount of net operating
loss carryforward or amount of tax refundable is reduced) for an unrecognized
tax benefit because it represents an enterprise’s potential future obligation to
the taxing authority for a tax position that was not recognized as a result of
applying the provisions of ASC topic 740.
In accordance with ASC
topic 740, interest costs related to unrecognized tax benefits are required to
be calculated (if applicable) and would be classified as “Interest expense,
net”. Penalties if incurred would be recognized as a component of “Selling,
general and administrative” expenses.
The Company files
corporate income tax returns in the United States (federal) and in various state
and local jurisdictions. In most instances, the Company is no longer subject to
federal, state and local income tax examinations by tax authorities for years
prior to 2008.
As of June 30, 2012, no
liability for unrecognized tax benefits was required to be recorded. The Company
does not expect its unrecognized tax benefit position to change during the next
12 months.
The ultimate realization
of deferred tax assets is dependent on the generation of future taxable income
during the periods in which those temporary differences become deductible. The
Company considers projected future taxable income and tax planning strategies in
making this assessment. At present, the Company does not have a sufficient
history of income or knowledge of future effects on our business of healthcare
reform legislation, the Deficit Reduction Act, the tax on sales of medical
equipment and the general economic and business climate to conclude that it is
more-likely-than-not that the Company will be able to realize any of its tax
benefits in the near future and therefore a valuation allowance was established
for the full value of the deferred tax asset.
A valuation allowance will
be maintained until sufficient positive evidence exists to support the reversal
of any portion or all of the valuation. Should the Company become profitable in
future periods with supportable trends, the valuation allowance will be reversed
accordingly.
Components of the current
provision for income taxes are as follows:
|
|
Years Ended June 30,
|
|
|
2012
|
|
2011
|
Current:
Federal
|
|
$
|
112,000
|
|
|
$
|
75,000
|
|
State
|
|
|
29,125
|
|
|
|
475
|
|
|
|
$
|
141,125
|
|
|
$
|
75,475
|
|
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 12 - INCOME TAXES
(Continued)
A reconciliation of the
federal statutory income tax rate to the Company's effective tax rate as
reported is as follows:
|
|
Years Ended June 30,
|
|
|
2012
|
|
2011
|
Taxes
at federal statutory rate
|
|
|
(34.0
|
)%
|
|
|
(34.0
|
)%
|
State
and local income benefit, net of federal benefit
|
|
|
(6.0
|
)
|
|
|
(6.0
|
)
|
Permanent
differences
|
|
|
1.2
|
|
|
|
1.9
|
|
Decrease
in the valuation allowance and true ups
|
|
|
40.8
|
|
|
|
40.3
|
|
Effective
income tax rate
|
|
|
2.0
|
%
|
|
|
2.2
|
%
|
As of June 30, 2012, the
Company has net operating loss (“NOL’s”) carryforwards of approximately
$154,431,000 that will be available to offset future taxable income. The NOLs
are due to expire during the years ending from June 30, 2019 to June 30, 2031.
The utilization of certain of the NOLs is limited by separate return limitation
year rules pursuant to Section 1502 of the Internal Revenue Code.
The Company has, for
federal income tax purposes, research and development tax credit carryforwards
aggregating $4,323,000, which are accounted for under the flow-through method.
In addition, for New York State income tax purposes, the Company has tax credit
carryforwards, aggregating approximately $1,103,000, which are accounted for
under the flow-through method. The tax credit carryforwards expire during the
years ending June 30, 2013 to June 30, 2031. The Company also has $210,000 in
alternative minimum tax credits.
Significant components of
the Company's deferred tax assets and liabilities at June 30, 2012 and 2011 are
as follows:
|
|
June 30,
|
|
|
2012
|
|
2011
|
Deferred
tax
assets:
Allowance for doubtful accounts
|
|
$
|
4,656,468
|
|
|
$
|
4,256,391
|
|
Accrued
liabilities
|
|
|
221,897
|
|
|
|
273,497
|
|
Net
operating carryforwards
|
|
|
61,772,391
|
|
|
|
65,464,211
|
|
Tax
credit carryforward
|
|
|
5,769,943
|
|
|
|
5,559,462
|
|
Property
and equipment
|
|
|
1,990,284
|
|
|
|
1,742,367
|
|
|
|
|
74,410,983
|
|
|
|
77,295,928
|
|
Valuation
allowance
|
|
|
(73,754,414
|
)
|
|
|
(76,468,787
|
)
|
Net
deferred tax assets
|
|
|
656,569
|
|
|
|
827,141
|
|
Deferred
tax liabilities:
Inventory
|
|
|
(51,109
|
)
|
|
|
(42,793
|
)
|
Capitalized
software development costs
|
|
|
(605,460
|
)
|
|
|
(784,348
|
)
|
Gross
deferred tax liabilities
|
|
|
(656,569
|
)
|
|
|
(827,141
|
)
|
Net
deferred tax liabilities
|
|
$
|
—
|
|
|
$
|
—
|
|
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 12 - INCOME TAXES
(Continued)
The net change in the
valuation allowance for deferred tax assets decreased by approximately
$2,433,000 and $632,000 during the years ended June 30, 2012 and 2011,
respectively, which primarily represents the tax benefit from the utilization of
the net operating loss carryforward.
NOTE 13 - OTHER CURRENT
LIABILITIES
Included in other current
liabilities are the following:
|
|
June 30,
|
|
|
2012
|
|
2011
|
Accrued
salaries, commissions and payroll taxes
|
|
$
|
569,966
|
|
|
$
|
839,531
|
|
Accrued
interest
|
|
|
190,712
|
|
|
|
156,571
|
|
Litigation
accruals
|
|
|
493,349
|
|
|
|
193,349
|
|
Sales
tax payable
|
|
|
2,764,297
|
|
|
|
2,731,751
|
|
Legal
and other professional fees
|
|
|
577,435
|
|
|
|
693,590
|
|
Accounting
fees
|
|
|
345,000
|
|
|
|
435,000
|
|
Insurance
premiums
|
|
|
12,634
|
|
|
|
21,633
|
|
Interest
and penalty – sales tax
|
|
|
2,115,539
|
|
|
|
1,922,804
|
|
Penalty
– 401k plan
|
|
|
250,000
|
|
|
|
250,000
|
|
Purchase
scanners
|
|
|
—
|
|
|
|
105,000
|
|
Rent
|
|
|
207,823
|
|
|
|
461,413
|
|
Other
|
|
|
166,486
|
|
|
|
425,463
|
|
|
|
$
|
7,693,241
|
|
|
$
|
8,236,105
|
|
NOTE 14 – ACQUISITION OF
FAIR HAVEN SERVICES
On October 1, 2010, the
Company purchased 100% of the stock of Fair Haven Services, an entity wholly
owned by Raymond V. Damadian for $10. The entity is in the business of leasing
medical equipment to various unrelated PCs. The transaction was accounted for as
a merger of commonly-controlled entities. The carrying value of the assets and
liabilities at the acquisition date approximated the fair value. The carrying
value of the assets acquired and liabilities assumed consisted of the
following:
Accounts
Receivable
|
|
$
|
182,000
|
|
Equipment
|
|
|
2,288,703
|
|
Short
term portion of debt
|
|
|
(1,733,955
|
)
|
Other
accrued expenses
|
|
|
(13,955
|
)
|
Long
term debt less current portion
|
|
|
(693,829
|
)
|
Net
Capital Contributed
|
|
$
|
28,964
|
|
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012
NOTE 15 - COMMITMENTS AND
CONTINGENCIES
Leases
The Company rents its
operating facilities and certain equipment, pursuant to operating lease
agreements expiring at various dates through May 2018. The leases for certain
facilities contain escalation clauses relating to increases in real property
taxes as well as certain maintenance costs.
Future minimum operating
lease commitments consisted of the following at June 30, 2012:
Year Ending June 30,
|
|
Facilities And Equipment (Operating Lease)
|
|
2013
|
|
|
$
|
2,200,953
|
|
|
2014
|
|
|
|
1,689,231
|
|
|
2015
|
|
|
|
1,611,230
|
|
|
2016
|
|
|
|
1,144,736
|
|
|
2017
|
|
|
|
136,766
|
|
|
Thereafter
|
|
|
|
129,745
|
|
|
Total minimum
obligations
|
|
|
$
|
6,912,661
|
|
Rent expense for operating
leases approximated $2,253,000 and $2,436,000 for the years ended June 30, 2012
and 2011, respectively.
Employee Benefit
Plans
The Company has a
non-contributory 401(k) Plan (the “401(k) Plan”). The 401(k) Plan covers all
non-union employees who are at least 21 years of age with no minimum service
requirements. There were no employer contributions to the Plan for the years
ended June 30, 2012 and 2011. (see Other Matters below)
The stockholders of the
Company approved the 2000 Employee Stock Purchase Plan (“ESPP”) at the Company’s
annual stockholders’ meeting in April 2000. The ESPP provides for eligible
employees to acquire common stock of the Company at a discount, not to exceed
15%. This plan has not been put into effect as of June 30, 2012.
Litigation
The Company is subject to
legal proceedings and claims arising from the ordinary course of its business,
including personal injury, customer contract and employment claims. In the
opinion of management, the aggregate liability, if any, with respect to such
actions, will not have a material adverse effect on the consolidated financial
position or results of operations of the Company.
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012
NOTE 15 - COMMITMENTS AND
CONTINGENCIES (Continued)
Litigation
(Continued)
On or about June 30, 2010,
one of Fonar’s customers, Golden Triangle Company, commenced an action against
Fonar and certain individual defendants employed or formerly employed by Fonar,
in the United States District Court for the Eastern District of New York based
on the alleged wrongful failure of Fonar to deliver a scanner in Kuwait. The
claim alleges various causes of action including breach of contract, fraud,
conspiracy to defraud and conversion.
Golden Triangle Company v. Fonar
Corporation et al
, CV10-2933. The Plaintiff contracted with Fonar to
purchase a scanner, and paid $1,455,500 in advance. The scanner was never
delivered, but Plaintiff never designed a site for delivery either. Alleging
other damages, fraud and deceptive trade practices, Plaintiff seeks as much as
$5,000,000. Fonar made a motion to dismiss the complaint, the outcome of which
left Plaintiff with only a cause of action for breach of contract. The claims
against the individual officers and employees of Fonar were dismissed. Fonar now
has filed its answer, together with a counterclaim alleging that the Plaintiff,
by attempting to overcharge the end-customer, has damaged Fonar’s reputation and
ability to sell in Kuwait. Golden Triangle has replied to Fonar’s counterclaim
and the case is now in discovery. The deadline for completing discovery is
December 31, 2012.
In addition, we are or
were party to additional less significant actions in which the customers are
seeking to obtain a return of their deposits for MRI scanners on the grounds
that various contingencies failed to materialize.
Upright MRI of Chicago, LLC
v. Fonar
, Circuit Court of Cook County, Illinois ($310,000),
Matt Malek
Madison v. Fonar,
U.S. District Court, Northern District of California
($300,000), and
Jack Shapiro v. Fonar Corporation
, Supreme Court, Nassau
County, New York ($500,000 although the actual deposit was $323,000). In the
Upright MRI of Chicago
case, the case was settled by an arrangement
whereby a third party took over the sales agreement and agreed to pay the
original purchaser the down payment it made. In the
Madison
case, the
Court granted summary judgment to Madison for the deposit and prejudgment
interest. We appealed the judgment but lost. The Plaintiff has not taken any
action to enforce the judgment. As of June 30, 2012, the Company recorded a
liability of $372,000 in connection with this judgement. In the
Shapiro
case, Shapiro, who was also a sales representative for Fonar, and Fonar were
attempting to negotiate a settlement, but the Plaintiff has served Fonar with
discovery demands.
On December 2, 2011,
Bonutti Research filed an action filed in U.S. District Court for the Eastern
District Court of New York. The complaint alleges that Fonar’s Upright® MRI
scanners infringe plaintiff’s patent. Fonar believes plaintiff’s claims are
without merit. The plaintiff served the complaint on the last possible day
permitted after filing. The defendants obtained an extension of time to answer
to May 18, 2012. Subsequently, on or about July 3, 2012, Bonutti hired new
substitute counsel and requested a 60 day extension to answer Fonar’s
counterclaims and to postpone the initial conference. Bonutti has answered our
counterclaims and an initial conference with the magistrate judge has been
scheduled. The conference with the court is now scheduled for September 28,
2012. At this point we are unable to assess the amount in controversy as no
damages were specified. We cannot at this time determine the impact of an
adverse determination of this case.
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012
NOTE 15 - COMMITMENTS AND
CONTINGENCIES (Continued)
Stipulation
Agreements
The Company has entered
into stipulation agreements with a number of its creditors that in the aggregate
totals $253,167 as of June 30, 2012. The monthly payments total
$26,452.
The amounts to be paid
over the next two years are as follows:
Year
Ending
June
30,
|
|
|
|
2013
|
|
|
$
|
205,567
|
|
|
2014
|
|
|
|
47,600
|
|
|
|
|
|
$
|
253,167
|
|
Other
Matters
The Company is also
delinquent in filing sales tax returns for certain states, for which the Company
has transacted business. The Company has recorded tax obligations of $2,442,000
plus interest and penalties of approximately $2,116,000. The Company is in the
process of determining its regulatory requirements in order to become
compliant.
The Company has determined
they may not be in compliance with the Department of Labor and Internal Revenue
Service regulations concerning the requirements to file Form 5500 to report
activity of its 401K Employee Benefit Plan. The filings do not require the
Company to pay tax, however they may be subject to penalty for non-compliance.
The Company has recorded provisions for any potential penalties totaling
$250,000. The amount was the Company’s best estimate of potential penalties.
Management is unable to determine the outcome of this uncertainty. The Company
has engaged outside counsel to handle such matters to determine the necessary
requirements to ensure compliance. On August 31, 2011, the Company submitted
with the Internal Revenue Service a request for a compliance statement and a
determination letter for our 401K plan. On December 9, 2011, the Internal
Revenue Service issued a favorable determination letter on our 401K plan. The
Company is still working with outside counsel to complete and file forms with
the US Department of Labor.
NOTE 16 - OTHER INCOME
(EXPENSE)
Other income (expense)
consists of:
|
|
For the Years Ended June 30,
|
|
|
2012
|
|
2011
|
(Loss)
income from investment
|
|
$
|
—
|
|
|
$
|
(61,466
|
)
|
Litigation
settlement
|
|
|
56,194
|
|
|
|
—
|
|
Loss
on abandonment of property
|
|
|
—
|
|
|
|
(64,565
|
)
|
Other
(expense) income
|
|
|
(11,138
|
)
|
|
|
9,414
|
|
|
|
$
|
45,056
|
|
|
$
|
(116,617
|
)
|
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012
NOTE 17 - SUPPLEMENTAL
CASH FLOW INFORMATION
During the years ended
June 30, 2012 and 2011, the Company paid $168,062 and $309,003 for interest,
respectively.
During the years ended
June 30, 2012 and 2011, the Company paid $116,125 and $0 for income taxes,
respectively.
Non-cash investing and
financing activities related to business combinations:
|
|
October 1, 2010 Acquisition
|
|
January 1, 2011 Acquisition
|
|
Total
|
Accounts
receivable
|
|
$
|
182,000
|
|
|
$
|
—
|
|
|
$
|
182,000
|
|
Property
& equipment
|
|
$
|
2,288,703
|
|
|
$
|
303,659
|
|
|
$
|
2,592,362
|
|
Management
agreement
|
|
$
|
—
|
|
|
$
|
513,333
|
|
|
$
|
513,333
|
|
Other
assets
|
|
$
|
—
|
|
|
$
|
45,784
|
|
|
$
|
45,784
|
|
Other
current liabilities
|
|
$
|
(13,955
|
)
|
|
$
|
—
|
|
|
$
|
(13,955
|
)
|
Accounts
payable
|
|
$
|
—
|
|
|
$
|
(47,026
|
)
|
|
$
|
(47,026
|
)
|
Notes
payable
|
|
$
|
(2,427,784
|
)
|
|
$
|
(530,650
|
)
|
|
$
|
(2,958,434
|
)
|
Paid
in capital
|
|
$
|
(28,964
|
)
|
|
$
|
—
|
|
|
$
|
(28,964
|
)
|
Non-controlling
interests
|
|
$
|
—
|
|
|
$
|
(491,328
|
)
|
|
$
|
(491,328
|
)
|
Reclassification
of investment from other assets
|
|
$
|
—
|
|
|
$
|
(82,957
|
)
|
|
$
|
(82,957
|
)
|
NOTE 18 – DUE TO RELATED
MEDICAL PRACTICES
In June 2009, an entity
owned by the Company’s Chairman of the Board, Tallahassee Scanning Services PA,
sold its Upright MRI scanning system to the Company for $550,000 in exchange for
35 monthly payments of $18,769 to be made over a three year period, commencing
October 18, 2009 including interest at a rate of 10.41% per annum. The Company
used this scanning system to fulfill a sales order with an unrelated customer.
The unpaid balance of as of June 30, 2012 and 2011 was $134,880.
NOTE 19 - SEGMENT AND
RELATED INFORMATION
The Company provides
segment data in accordance with the provisions of ASC topic 280, “Disclosures
about Segments of an Enterprise and Related Information”.
The Company operates in
two industry segments - manufacturing and the servicing of medical equipment and
management of diagnostic imaging centers.
The accounting policies of
the segments are the same as those described in the summary of significant
accounting policies. All intersegment sales are market-based. The Company
evaluates performance based on income or loss from operations.
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012
NOTE 19 - SEGMENT AND
RELATED INFORMATION (Continued)
Summarized financial
information concerning the Company’s reportable segments is shown in the
following table:
|
|
Manufacturing and Servicing of Medical Equipment
|
|
Management of Diagnostic Imaging Centers
|
|
Totals
|
Fiscal
2012:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
revenues from external customers
|
|
$
|
18,707,006
|
|
|
$
|
20,737,413
|
|
|
$
|
39,444,419
|
|
Intersegment
net revenues
|
|
$
|
810,000
|
|
|
$
|
—
|
|
|
$
|
810,000
|
|
Income
from operations
|
|
$
|
2,666,574
|
|
|
$
|
4,539,977
|
|
|
$
|
7,206,551
|
|
Depreciation
and amortization
|
|
$
|
697,100
|
|
|
$
|
1,533,150
|
|
|
$
|
2,230,250
|
|
Compensatory
element of stock issuances
|
|
$
|
155,068
|
|
|
$
|
25,350
|
|
|
$
|
180,418
|
|
Total
identifiable assets
|
|
$
|
15,144,291
|
|
|
$
|
18,471,177
|
|
|
$
|
33,615,468
|
|
Capital
expenditures
|
|
$
|
404,530
|
|
|
$
|
822,842
|
|
|
$
|
1,227,372
|
|
Fiscal
2011:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
revenues from external customers
|
|
$
|
17,811,636
|
|
|
$
|
15,324,759
|
|
|
$
|
33,136,395
|
|
Intersegment
net revenues
|
|
$
|
924,166
|
|
|
$
|
—
|
|
|
$
|
924,166
|
|
Income
from operations
|
|
$
|
1,433,331
|
|
|
$
|
2,358,138
|
|
|
$
|
3,791,469
|
|
Depreciation
and amortization
|
|
$
|
806,117
|
|
|
$
|
1,266,889
|
|
|
$
|
2,073,006
|
|
Compensatory
element of stock issuances
|
|
$
|
139,308
|
|
|
$
|
65,178
|
|
|
$
|
204,486
|
|
Total
identifiable assets
|
|
$
|
13,439,701
|
|
|
$
|
18,140,973
|
|
|
$
|
31,580,674
|
|
Capital
expenditures
|
|
$
|
202,468
|
|
|
$
|
532,562
|
|
|
$
|
735,030
|
|
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 19 - SEGMENT AND
RELATED INFORMATION (Continued)
Export Product
Sales
The Company’s areas of
operations are principally in the United States. The Company had export sales of
medical equipment amounting to 17.0% and 28.0% of product sales revenues to
third parties for the years ended June 30, 2012 and 2011,
respectively.
The foreign product sales,
as a percentage of product sales to unrelated parties, were made to customers in
the following countries:
|
|
For the Years Ended June 30,
|
|
|
2012
|
|
2011
|
Holland
|
|
|
0.1
|
%
|
|
|
- %
|
|
England
|
|
|
16.9
|
|
|
|
—
|
|
Germany
|
|
|
—
|
|
|
|
19.5
|
|
Greece
|
|
|
—
|
|
|
|
5.8
|
|
Australia
|
|
|
—
|
|
|
|
0.7
|
|
Puerto
Rico
|
|
|
—
|
|
|
|
0.9
|
|
Libya
|
|
|
—
|
|
|
|
1.1
|
|
|
|
|
17.0
|
%
|
|
|
28.0
|
%
|
Foreign Service and
Repair Fees
The Company’s areas of
service and repair are principally in the United States. The Company had foreign
revenues of service and repair of medical equipment amounting to 9.9% and 7.8%
of consolidated net service and repair fees for the years ended June 30, 2012
and 2011, respectively. The foreign service and repair fees, as a percentage of
total service and repair fees, were provided principally to the following
countries:
|
|
For the Years Ended June 30,
|
|
|
2012
|
|
2011
|
Spain
|
|
|
0.8
|
%
|
|
|
1.1
|
%
|
Puerto
Rico
|
|
|
0.9
|
|
|
|
1.0
|
|
Switzerland
|
|
|
1.0
|
|
|
|
0.5
|
|
Germany
|
|
|
0.3
|
|
|
|
0.3
|
|
England
|
|
|
1.8
|
|
|
|
1.7
|
|
Holland
|
|
|
2.6
|
|
|
|
1.3
|
|
Scotland
|
|
|
0.7
|
|
|
|
0.9
|
|
Canada
|
|
|
0.8
|
|
|
|
0.3
|
|
Australia
|
|
|
0.4
|
|
|
|
0.4
|
|
Libya
|
|
|
0.2
|
|
|
|
0.3
|
|
Greece
|
|
|
0.4
|
|
|
|
—
|
|
|
|
|
9.9
|
%
|
|
|
7.8
|
%
|
The Company does not have
any material assets outside of the United States.
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 20 – ALLOWANCE FOR
DOUBTFUL ACCOUNTS
The following represents a
summary of allowance for doubtful accounts for the years ended June 30, 2012 and
2011, respectively:
Description
|
|
Balance
June 30,
2011
|
|
Additions
|
|
Deductions
|
|
Balance
June 30,
2012
|
Receivables
from equipment sales and service contracts
|
|
$
|
1,777,794
|
|
|
|
(1
|
)
|
|
$
|
100,442
|
|
|
$
|
25,249
|
|
|
$
|
1,852,987
|
|
Management
fee receivable
|
|
|
6,508,345
|
|
|
|
(1
|
)
|
|
|
950,000
|
|
|
|
—
|
|
|
|
7,458,345
|
|
Management
fee receivable from related medical practices
|
|
|
403,047
|
|
|
|
|
|
|
|
—
|
|
|
|
—
|
|
|
|
403,047
|
|
Medical
receivables
|
|
|
1,622,000
|
|
|
|
|
|
|
|
—
|
|
|
|
—
|
|
|
|
1,622,000
|
|
Advance
and notes to related parties
|
|
|
264,791
|
|
|
|
|
|
|
|
-
|
|
|
|
25,000
|
|
|
|
239,791
|
|
Notes
receivable
|
|
|
65,000
|
|
|
|
|
|
|
|
-
|
|
|
|
—
|
|
|
|
65,000
|
|
Description
|
|
Balance June 30, 2010
|
|
Additions
|
|
Deductions
|
|
Balance June 30, 2011
|
Receivables
from equipment sales and service contracts
|
|
$
|
2,289,049
|
|
|
|
(1
|
)
|
|
$
|
127,323
|
|
|
$
|
638,578
|
|
|
$
|
1,777,794
|
|
Management
fee receivable
|
|
|
5,808,345
|
|
|
|
(1
|
)
|
|
|
700,000
|
|
|
|
—
|
|
|
|
6,508,345
|
|
Management
fee receivable from related medical practices
|
|
|
1,129,818
|
|
|
|
|
|
|
|
—
|
|
|
|
726,771
|
|
|
|
403,047
|
|
Medical
receivables
|
|
|
1,622,000
|
|
|
|
|
|
|
|
—
|
|
|
|
—
|
|
|
|
1,622,000
|
|
Advance
and notes to related parties
|
|
|
264,791
|
|
|
|
|
|
|
|
—
|
|
|
|
—
|
|
|
|
264,791
|
|
Notes
receivable
|
|
|
115,000
|
|
|
|
(1
|
)
|
|
|
135,686
|
|
|
|
185,686
|
|
|
|
65,000
|
|
(1) Included in provision
for bad debts.
FONAR CORPORATION AND
SUBSIDIARIES
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
JUNE 30, 2012 and
2011
NOTE 21 – SUBSEQUENT
EVENTS
The Company evaluates
events that have occurred after the balance sheet date, but before the
consolidated financial statements are issued.
FONAR CORPORATION AND
SUBSIDIARIES
ITEM 9. CHANGES IN AND
DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE.
There have been no
disagreements with our independent registered public accounting firm or other
matters requiring disclosure under Regulation S-K, Item 304(b).
ITEM 9A(T). CONTROLS AND
PROCEDURES
Disclosure Controls and
Procedures
Disclosure controls and
procedures (as defined in Rule 13(a) – 15(e)) are controls and other procedures
that are designed to ensure that information required to be disclosed by a
public company in the reports that it files or submits under the Exchange Act is
recorded, processed, summarized and reported within the time periods specified
in the SEC’s rules and forms. Disclosure controls and procedures include,
without limitation, controls and procedures designed to ensure that information
required to be disclosed by a public company in the reports that it files or
submits under the Exchange Act is accumulated and communicated to the company’s
management, including its principal executive and principal financial officers,
or persons performing similar functions, as appropriate to allow timely
decisions regarding required disclosure. Disclosure controls and procedures
include many aspects of internal control over financial reporting.
Based on their evaluation,
our Chief Executive Officer and Chief Financial Officer have concluded that our
disclosure controls and procedures were effective at June 30, 2012.
Our management is
responsible for establishing and maintaining adequate internal control over
financial reporting as defined in Rule 13a-15(f) under the Exchange Act.
Internal control over financial reporting refers to a process designed by, or
under the supervision of, our Chief Executive Officer and Chief Financial
Officer and effected by our Board, management and other personnel, to provide
reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with
generally accepted accounting principles, including those policies and
procedures that:
* pertain to the
maintenance of records that, in reasonable detail, accurately and fairly reflect
the transactions and dispositions of our assets;
* provide reasonable
assurance that transactions are recorded as necessary to permit preparation of
financial statements in accordance with generally accepted accounting
principles, and that our receipts and expenditures are being made only in
accordance with authorizations of our management and directors; and
* provide reasonable
assurance regarding prevention or timely detection of unauthorized acquisition,
use or disposition of our assets that could have a material effect on our
consolidated financial statements.
It should be noted,
however, that because of its inherent limitations, internal control over
financial reporting cannot provide absolute assurance of the prevention or
detection of misstatements. In addition, projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree of compliance
with the policies or procedures may deteriorate.
FONAR CORPORATION AND
SUBSIDIARIES
Management’s Report on
Internal Control over Financial Reporting
Our management is
responsible for establishing and maintaining adequate internal control over our
financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange
Act of 1934, as amended). Our management assessed the effectiveness of our
internal controls over financial reporting as of June 30, 2012. In making its
assessment of the effectiveness of our internal controls over financial
reporting, our management used the criteria set forth by the Committee of
Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal
Control-Integrated Framework. Based on these criteria, our management has
concluded that, as of June 30, 2012, our internal control over financial
reporting is effective. This annual report does not include an attestation
report of our independent registered public accounting firm regarding internal
control over financial reporting.
There was no changes in
our internal controls or in other factors that could significantly affect these
controls, during our fourth quarter ended June 30, 2012, that have materially
affected, or are reasonably likely to materially affect, our internal control
over financial reporting.
PART III
ITEM 10. DIRECTORS AND
EXECUTIVE OFFICERS OF THE REGISTRANT.
Directors serve from the
date of their election until the next annual meeting of stockholders and until
their successors are elected and qualify. With the exception of Dr. Raymond V.
Damadian, who does not receive any fees for serving as a director, each director
receives $20,000 per annum for his or her service as a director. Officers serve
at the discretion of the Board of Directors.
A majority of our board of
directors is composed of independent directors: Robert J. Janoff, Charles N.
O’Data and Ronald G. Lehman. The outside directors also serve as the members of
the audit committee, which is a standing committee of board of directors having
a charter describing its responsibilities. Mr. O’Data has been designated as the
audit committee financial expert. His relevant experience is described in his
biographical information.
We have adopted a code of
ethics applicable to, among other personnel, our principal executive officer,
principal financial officer, controllers and persons performing similar
functions. The code is designed to deter wrongdoing and to promote: 1. honest
and ethical conduct, including the ethical handling of actual or apparent
conflicts of interest between personal and professional relationships; 2. full,
fair, accurate, timely and understandable disclosure in reports and documents
that we file or submit to the Securities and Exchange Commission and in other
public communications we make; 3. compliance with applicable governmental laws,
rules and regulations; 4. the prompt internal reporting of violations of the
code to an appropriate person or persons identified in the code and 5.
accountability for adherence to the code. We will provide a copy of the code to
any person who requests a copy. A person may request a copy by writing to Fonar
Corporation, 110 Marcus Drive, Melville, New York 11747, to the attention of the
Legal Department or Investor Relations.
FONAR CORPORATION AND
SUBSIDIARIES
The officers and directors
of the Company are set forth below:
Raymond V. Damadian, M.D.
76 President, Treasurer,
Chairman of the
Board
and a Director
Claudette J.V. Chan 74
Director and Secretary
Robert J. Janoff 85
Director
Charles N. O'Data 76
Director
Ronald G. Lehman 36
Director
Raymond V. Damadian, M.D.
has been the Chairman of the Board and President of Fonar since its inception in
1978 and Treasurer since February, 2001. Dr. Damadian was employed by the State
University of New York, Downstate Medical Center, New York, as an Associate
Professor of Biophysics and Associate Professor of Internal Medicine from 1967
until September 1979. Dr. Damadian received an M.D. degree in 1960 from Albert
Einstein College of Medicine, New York, and a B.S. degree in mathematics from
the University of Wisconsin in 1956. In addition, Dr. Damadian conducted
post-graduate work at Harvard University, where he studied extensively in the
fields of physics, mathematics and electronics. Dr. Damadian is the author of
numerous articles and books on the nuclear magnetic resonance effect in human
tissue, which is the theoretical basis for the Fonar MRI scanners. Dr. Damadian
is a 1988 recipient of the National Medal of Technology and in 1989 was inducted
into the National Inventors Hall of Fame, for his contributions in conceiving
and developing the application of magnetic resonance technology to medical
applications including whole body scanning and diagnostic imaging. Dr. Damadian
is the President, Treasurer and director of HMCA and a Manager of
IMPERIAL.
Claudette J.V. Chan has
been a Director of Fonar since October 1987 and Secretary of Fonar since January
2008. Mrs. Chan was employed from 1992 through 1997 by Raymond V. Damadian, M.D.
MR Scanning Centers Management Company and since 1997 by HMCA-IMPERIAL, as "site
inspector," in which capacity she is responsible for supervising and
implementing standard procedures and policies for MRI scanning centers. From
1989 to 1994 Mrs. Chan was employed by St. Matthew's and St. Timothy's
Neighborhood Center, Inc., as the director of volunteers in the "Meals on
Wheels" program, a program which cares for the elderly. In approximately 1983,
Mrs. Chan formed the Claudette Penot Collection, a retail mail-order business
specializing in women's apparel and gifts, of which she was the President until
she stopped operating the business in approximately 1989. Mrs. Chan practiced
and taught in the field of nursing until 1973, when her son was born. She
received a bachelor of science degree in nursing from Cornell University in
1960. Mrs. Chan is the sister of Raymond V. Damadian.
Robert J. Janoff has been
a Director of Fonar since February 1989. Mr. Janoff has been a self-employed New
York State licensed private investigator for more than thirty-five years and was
a Senior Adjustor in Empire Insurance Group for more than 15 years until
retiring from that position on July 1, 1997. Mr. Janoff also served, from June
1985 to June 1991, as President of Action Data Management Strategies, Ltd., a
supplier of computer programs for use by insurance companies. Mr. Janoff was a
member of the Board of Directors of Harmony Heights of Oyster Bay, New York for
over 25 years, which is a nonprofit residential school for girls with learning
disabilities.
FONAR CORPORATION AND
SUBSIDIARIES
Charles N. O'Data has been
a Director of Fonar since February 1998. From 1968 to 1997, Mr. O'Data was the
Vice President for Development for Geneva College, a liberal arts college
located in western Pennsylvania. In that capacity, he acted as the College's
chief investment officer. His responsibilities included management of the
College's endowment fund and fund raising. In July 1997, Mr. O'Data retired from
Geneva College after 36 years of service to assume a position of National Sales
Executive for SC Johnson Company's Professional Markets Group, a unit of SC
Johnson Wax, and specialized in healthcare and education sales, a position he
held until the spring of 1999. In his capacity with SC Johnson he was
responsible for sales to the nation’s three largest Group Purchasing
Organizations which included some 4,000 hospitals. Mr. O'Data presently acts as
an independent financial consultant to various entities. Mr. O'Data served on
the board of The Medical Center, Beaver, Pennsylvania, now a part of Heritage
Valley Health System, a 500 bed acute care facility, for 26 years, three as its
Chair. Mr. O’Data also served on the board of the Hospital Council of Western
Pennsylvania, a shared-services and group purchasing organization covering seven
states. He founded The Beaver County Foundation, a Community Foundation, in
1992, and serves as its President. He also serves as Director of Philanthropic
Advisors for McKinley Carter Wealth Management, a regional wealth management
firm in Pennsylvania, Ohio and West Virginia. Mr. O'Data is listed as a finance
associate in the Middle States Association, Commission on Higher Education. The
commission is the formal accrediting body for higher education in the eastern
region of the country. In this capacity he evaluates the financial aspects of
educational organizations. Mr. O’Data is a graduate of Geneva College, where he
received a B.S. degree in Economics in 1958.
Ronald G. Lehman, has been
a Director of Fonar since April, 2012, when he was unanimously appointed by the
remaining four Directors to fill the vacancy resulting from the death of former
Director Robert Djerejian. From October, 2009 to the present, Mr. Lehman has
served as Managing Director of Investment Banking with Bruderman Brothers, Inc.,
a private New York-based broker-dealer registered with the Securities and
Exchange Commission and which is a member of the Financial Industry Regulatory
authority (FINRA) and the Securities Investor Protection Corporation (SIPC). Mr.
Lehman directly manages all facets of the firm’s transaction processes, from
deal origination, to sourcing capital, to negotiating deal structures, through
documentation and closing. The firm provides buy and sell-side advisory, capital
raising, and consulting services to lower middle-market companies. Mr. Lehman
specializes in advising healthcare services companies and has recently completed
several recapitalizations in the industry. He also participates in the firm’s
merchant banking investments and oversees many of these assignments. From May,
2008 to October, 2009, Mr. Lehman served as Senior Vice President of
Acquisitions at Health Diagnostics, LLC, where he managed the company’s
acquisition and corporate finance activities. From March, 2000 to May, 2008, Mr.
Lehman worked for various Bruderman entities as a buy and sell-side advisor and
as a principal in several private equity transactions. From September, 1998 to
March, 2000, Mr. Lehman worked at Deutsche Bank Securities, Inc. and last held
the position of Associate in their Global Custody Group. Mr. Lehman graduated
from Columbia University with a B.A. in 1998.
FONAR CORPORATION AND
SUBSIDIARIES
Robert Djerejian served as
a Director for Fonar from June 2002 until his death on August 21, 2011. Since
1996 he served as a senior consultant for Haines, Lundberg & Waehler
International (HLW International), an architectural, engineering, planning
interior design firm, which among other hi-tech specialties designs hospitals
and laboratories. Prior to that time he was the Senior Managing Partner of HLW
International for a period of 22 years where he received numerous design awards
including the National Honor Award from the Endowment for the Arts and The
Design Excellence Award from the NY Society of the American Institute of
Architects. During his management of the firm he brought the firm to
international prominence with offices in London, Shanghai and Saudi Arabia. He
also consulted for private clientele in design management in planning, design
and construction services. Mr. Djerejian was an Emeritus member of the Board of
Trustees of Pratt Institute since 1992, where he chaired the Nominations
Committee and was the Vice Chairman of the Executive Committee. He served as a
Board Member coordinating the joint venture of Corcoran College of Art &
Design in Washington DC with Pratt Institute as one of the founding directors
forming the Delaware College of Art and Design. He is a member of the American
institute of Architects and the NY Society of Architects. Mr. Djerejian was a
graduate of Pratt Institute School of Architecture, where he received his B.A.
in Architecture in 1955.
ITEM 11. EXECUTIVE
COMPENSATION.
With the exception of the
Chief Executive Officer, the compensation of the Company's executive officers is
based on a combination of salary and bonuses based on performance. The Chief
Executive Officer's compensation consists of a salary.
The Chief Executive
Officer’s salary varies only slightly and is by his own decision relatively low.
It is not expected to increase materially in the near future. At such time as we
become consistently and sufficiently profitable or there is a reconsideration of
our compensation policy, the compensation payable to the Chief Executive Officer
may be reconsidered. As presently existing, the Chief Executive Officer’s
compensation package includes no understandings with respect to bonuses, options
or other incentives; as such, it is not subject to our general policy later
discussed.
The Board of Directors
does not have a compensation Committee. Dr. Raymond V. Damadian, President,
Chief Executive Officer and Chairman of the Board, controls over 50% of the
voting power of our capital stock. Dr. Damadian is the only executive officer
who is a member of the Board of Directors. Dr. Damadian participates in the
determination of executive compensation for our officers.
The Board of Directors has
established an audit committee. The members of the committee are Robert J.
Janoff, Charles N. O'Data and Ronald G. Lehman.
Our compensation policy
includes a combination of salary, commissions, bonuses, stock bonuses and stock
options, designed to incentivize our employees. There is no universal plan
applicable to all of our employees. The fixed and variable components of our
employees’ compensation tend to be individualized, based on a combination of the
employees’ performance, responsibilities and position, our assessment of how
best to motivate a person in such a position and the needs and preferences of
the particular employees, as negotiated between employees and their supervisors
or management.
There is set forth in the
following Summary Compensation Table the compensation provided by us during
fiscal 2012 to our Principal Executive Officer, who also serves as our acting
Principal Financial Officer. There is set forth in the following Outstanding
Equity Awards Table and Director Compensation Table the required
information.
FONAR CORPORATION AND
SUBSIDIARIES
I. SUMMARY COMPENSATION
TABLE
Name
and All Other Principal Position (a)
|
|
Year (b)
|
|
Salary ($) (c)
|
|
Bonus ($) (d)
|
|
All Other Compensation
|
|
Total Compensation
|
Raymond
V,
|
|
|
2012
|
|
|
$
|
35,934.76
|
|
|
|
—
|
|
|
|
—
|
|
|
$
|
35,934.76
|
|
Damadian
|
|
|
2011
|
|
|
$
|
35,934.29
|
|
|
|
—
|
|
|
|
—
|
|
|
$
|
35,934.29
|
|
PEO/PFO
|
|
|
2010
|
|
|
$
|
57,358.12
|
|
|
|
—
|
|
|
|
—
|
|
|
$
|
57,358.12
|
|
II. OUTSTANDING EQUITY
AWARDS AT FISCAL YEAR-END
Name
|
|
Number of Securities Underlying Unexercised Options (#)
Exercisable (a)
|
|
Option Exercise
Price ($)
(b)
|
|
Option Expiration
Date
(c)
|
Raymond
V. Damadian, PEO/PFO
|
|
|
0
|
|
|
|
0
|
|
|
N/A
|
III. DIRECTOR
COMPENSATION
Name
|
|
Fees
Earned
or
Paid in
Cash
($)
|
|
Total
($)
|
Raymond
V.Damadian
|
|
|
0
|
|
|
|
0
|
|
Claudette
J.V.Chan
|
|
$
|
19,999.98
|
|
|
$
|
19,999.98
|
|
Robert
J.Janoff
|
|
$
|
20,769.48
|
|
|
$
|
20,769.48
|
|
Charles
N. O’Data
|
|
$
|
20,769.48
|
|
|
$
|
20,769.48
|
|
Ronald
G. Lehman
|
|
$
|
3,076.92
|
|
|
$
|
3,076.92
|
|
Robert
Djerejian
|
|
$
|
3,846.15
|
|
|
$
|
3,846.15
|
|
FONAR CORPORATION AND
SUBSIDIARIES
EMPLOYEE COMPENSATION
PLANS
Equity Compensation Plan
Information as of June 30, 201
|
|
(a)
|
|
(b)
|
|
(c)
|
Plan
category
|
|
Number of securities to be issued upon exercise of outstanding
options, warrants and rights
|
|
Weighted-average exercise price of outstanding options, warrants
and rights
|
|
Number of securities remaining available for future issuance
under equity compensation plans (excluding securities reflected in column
(a)
|
Equity
compensation plans approved by security holders
|
|
|
14,022
|
|
|
$
|
27.76
|
|
|
|
130,943
|
|
Equity
compensation plans not approved by security holders
|
|
|
—
|
|
|
|
N/A
|
|
|
|
—
|
|
Total
|
|
|
14,022
|
|
|
|
27.76
|
|
|
|
130,943
|
|
Fonar’s 2002 Incentive
Stock Option Plan, adopted on July 1, 2002, was intended to qualify as an
incentive stock option plan under Section 422A of the Internal Revenue Code of
1954, as amended. The 2002 Incentive Stock Option Plan permitted the issuance of
stock options covering an aggregate of 100,000 shares of Common Stock of Fonar.
The options have an exercise price equal to the fair market value of the
underlying stock on the date the option was granted, are nontransferable, are
exercisable for a period not exceeding ten years and expire upon the voluntary
termination of employment. The 2002 Stock Option Plan terminated on June 30,
2012. Of the options granted under this plan, 14,022 remain
outstanding.
Fonar’s 2005 Incentive
Stock Option Plan, adopted on February 15, 2005, is intended to qualify as an
incentive stock option plan under Section 422A of the Internal Revenue code of
1954, as amended. The Plan permits the issuance of stock options covering an
aggregate of 80,000 shares of common stock of Fonar. The options have an
exercise price equal to the fair market value of the underlying stock on the
date the option is granted, are non-transferable, are exercisable for a period
not exceeding ten years, and expire upon the voluntary termination of
employment. The Plan will terminate on February 14, 2015. As of June 30, 2012,
80,000 shares of common stock of Fonar were available for future grant under
this plan.
Fonar adopted its 2010
Stock Bonus Plan, on June 28, 2010. This Plan permits Fonar to issue an
aggregate of 2,000,000 shares of common stock of Fonar as bonus or compensation.
As of June 30, 2012, 1,072,945 shares were available for issuance.
FONAR CORPORATION AND
SUBSIDIARIES
ITEM 12. SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.
The following table sets
forth the number and percentage of shares of Fonar’s securities held by each
director, by each person known by us to own in excess of five percent of Fonar’s
voting securities and by all officers and directors as a group as of September
6, 2012.
Name and Address
of
Beneficial Owner
(1)
|
|
Shares
Beneficially
Owned
|
|
Percent
of
Class
|
Raymond V. Damadian,
M.D.
c/o Fonar
Corporation
Melville, New
York
Director, President,
Treasurer
CEO, 5% +
Stockholder
|
|
|
|
|
|
|
|
|
Common
Stock
|
|
|
120,302
|
|
|
|
2.04
|
%
|
Class
C Stock
|
|
|
382,447
|
|
|
|
99.98
|
%
|
Class
A Preferred
|
|
|
19,093
|
|
|
|
6.09
|
%
|
Claudette
Chan
Director and
Secretary
|
|
|
|
|
|
|
|
|
Common
Stock
|
|
|
106
|
|
|
|
*
|
|
Class
A Preferred
|
|
|
32
|
|
|
|
*
|
|
Robert J.
Janoff
Director
|
|
|
|
|
|
|
|
|
Common
Stock
|
|
|
3,000
|
|
|
|
*
|
|
Class
A Preferred
|
|
|
79
|
|
|
|
*
|
|
Charles N.
O'Data
Director
|
|
|
|
|
|
|
|
|
Common
Stock
|
|
|
528
|
|
|
|
*
|
|
Ronald G.
Lehman
Director
|
|
|
|
|
|
|
|
|
Common
Stock
|
|
|
|
|
|
|
*
|
|
Robert
Djerejian
Director until
August 21, 2011
|
|
|
|
|
|
|
|
|
Common
Stock
|
|
|
0
|
|
|
|
*
|
|
All Officers and
Directors
as a Group (5
persons)
|
|
|
|
|
|
|
|
|
Common
Stock
|
|
|
123,936
|
|
|
|
2.10
|
%
|
Class
C Stock
|
|
|
382,447
|
|
|
|
99.98
|
%
|
Class
A Preferred
|
|
|
19,204
|
|
|
|
6.13
|
%
|
___________________________
* Less than one
percent
1. Address provided for
each beneficial owner owning more than five percent of the voting securities of
Fonar.
FONAR CORPORATION AND
SUBSIDIARIES
ITEM 13. CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS.
Background.
Between 1990 and 1996,
Raymond V. Damadian, M.D. MRI Scanning Centers Management Company, also referred
to as “RVDC”, a Delaware corporation of which Dr. Damadian was the sole
stockholder, director and President, purchased and leased scanners from Fonar to
establish a network of professional corporations operating MRI scanning centers,
also referred to as the "Centers", in New York, Florida, Georgia and other
locations. Dr. Raymond V. Damadian is the Chairman, President and principal
stockholder of Fonar and was also the owner, director and President of each of
these professional corporations. RVDC provided the necessary management and the
scanners to the Centers, although in certain situations, a Center would acquire
the scanner directly from Fonar.
ACQUISITION OF
RVDC.
Effective June 30, 1997,
Fonar’s wholly-owned subsidiary, Health Management Corporation of America, also
referred to as "HMCA", formerly known as U.S. Health Management Corporation,
acquired RVDC by purchasing all of the issued and outstanding shares of RVDC
from Dr. Damadian for 400 shares of the Common Stock of Fonar. The transactions
can be rescinded by Dr. Damadian, however, in the event of a change of control
in Fonar or the bankruptcy of Fonar. There is no time limit on the right to
rescind. In connection with the transaction, Fonar granted RVDC a nonexclusive
royalty free license to Fonar’s patents and software. These licenses may be
terminated by Fonar in the event of the bankruptcy of RVDC or a change in
control of RVDC.
AGREEMENTS WITH
HMCA-IMPERIAL.
Effective July 1, 1997,
new management agreements were entered into by the Centers and HMCA-IMPERIAL.
Since that time certain of the original Centers have been closed and new Centers
opened. Each new Center also entered into a management agreement with
HMCA-IMPERIAL.
Pursuant to the management
agreements, HMCA-IMPERIAL is providing comprehensive management and
administrative services and office facilities, including billing and collection
of accounts, payroll and accounts payable processing, supplies and utilities to
the Centers. Under the management agreements, HMCA-IMPERIAL provides service
through Fonar for the scanners at the Centers. In total, 11 MRI Centers have
management agreements with HMCA-IMPERIAL.
At the end of fiscal 2007,
Dr. Damadian sold all of his stock in the MRI Centers located in New York State.
The new owner is one of the radiologists who has been reading and interpreting
scans performed at those facilities, Dr. Robert A. Diamond. In connection with
the sale, HMCA-IMPERIAL entered into new management agreements with the MRI
Centers under which HMCA-IMPERIAL performs essentially the same services for the
MRI Centers as prior to the sale. The fees charged, however, are flat fees
charged on a monthly basis ranging from $100,000 to $212,311 in fiscal
2012.
Dr. Damadian remains the
owner of three MRI Centers in Florida. The MRI Centers owned by Dr. Damadian in
Florida pay flat rate monthly fees ranging from $194,050 to $241,266 to
HMCA-IMPERIAL per month. These fees are renegotiable on an annual
basis.
During the fiscal years
ended June 30, 2012 and June 30, 2011 the net revenues received by HMCA-IMPERIAL
from the MRI Centers owned by Dr. Damadian were approximately $6.7 million and
$5.2 million respectively.
FONAR CORPORATION AND
SUBSIDIARIES
During April 2009, Fair
Haven Services, Inc. lent HMCA-IMPERIAL $258,000. The loan bears interest at a
rate of 10% per annum and was payable in 36 installments. This loan has been
paid in full. Dr Damadian is the President of Fair Haven Services,
Inc.
In June 2009, Tallahassee
Scanning Services, P.A. an entity owned by Dr Damadian, sold its Upright MRI
scanning system to HMCA-IMPERIAL for $550,000 payable in 35 monthly installments
beginning on October 18, 2009 with interest at the rate of 10.41% per
annum.
On October 1, 2010,
HMCA-IMPERIAL purchased 100% of the stock of Fair Haven Services, Inc., an
entity wholly owned by Dr. Damadian for $10. Fair Haven is in the business of
leasing medical equipment to various unrelated PCs.
On May 2, 2011, Dr.
Damadian participated in the private placement of equity in Imperial by
investing $100,000 in Imperial’s Class A membership interests.
ITEM 14.PRINCIPAL
ACCOUNTANT FEES AND SERVICES.
Audit Fees
The aggregate fees billed
by Marcum LLP for the audit of our annual consolidated financial statements for
the fiscal year ended June 30, 2012 and the reviews of the financial statements
included in our Forms 10-Q for the fiscal year ended June 30, 2012 were
$446,417.
The aggregate fees billed
by Marcum LLP for the audit of our annual financial statements for the fiscal
year ended June 30, 2011 and the reviews of the financial statements included in
our Forms 10-Q for the fiscal year ended June 30, 2011 were $448,482.
Audit Related
Fees
No fees were billed by
Marcum LLP for the fiscal years ended June 30, 2012 or June 30, 2011 for
services related to the Audit or review of our financial statements that are not
included under the caption “Audit Fees”.
No fees were billed by
Marcum LLP for the fiscal years ended June 30, 2012 or June 30, 2011 for
designing, operating, supervising or implementing any of our financial
information systems or any hardware or software systems for our financial
information.
Tax Fees
The aggregate fees billed
by Marcum LLP for tax compliance, tax advice and tax planning in the fiscal year
ended June 30, 2012 were $90,317.
The aggregate fees billed
by Marcum LLP for tax compliance, tax advice and tax planning in the fiscal year
ended June 30, 2011 were $106,107.
All Other Fees
The aggregate fees billed
by Marcum LLP for all other services rendered by them during the fiscal years
ended June 30, 2012 and June 30, 2011 were $7,597 and $63,138, respectively,
which included services in connection with the registration of securities,
employee benefit plan audits and reviews and procedures that we requested Marcum
LLP to undertake to provide assurances on matters not required by laws or
regulations.
FONAR CORPORATION AND
SUBSIDIARIES
Since January 1, 2003, the
audit committee has adopted policies and procedures for pre-approving all
non-audit work performed by the auditors. Specifically, the committee must
pre-approve the use of the auditors for all such services. The audit committee
has pre-approved all non-audit work since that time and in making its
determination has considered whether the provision of such services was
compatible with the independence of the auditors.
Our audit committee
believes that the provision by Marcum LLP of services in addition to audit
services in fiscal 2012 and 2011 were compatible with maintaining their
independence.
PART IV
ITEM 15. EXHIBITS,
FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K.
a) FINANCIAL STATEMENTS
AND SCHEDULES
The following consolidated
financial statements are included in Part II, Item 8.
Report of Independent
Registered Public Accounting Firm
Consolidated Balance
Sheets as at June 30, 2012 and 2011.
Consolidated Statements of
Operations/Income for the Years Ended June 30, 2012 and 2011.
Consolidated Statements of
Stockholders' Equity(Deficiency)and Comprehensive Income(Loss)for the Years
Ended June 30, 2012 and 2011.
Consolidated Statements of
Cash Flows for the Years Ended June 30, 2012 and 2011.
Notes to Consolidated
Financial Statements.
Information required by
schedules called for under Regulation S-X is either not applicable or is
included in the consolidated financial statements or notes to the financial
statements.
b) REPORTS ON FORM
8-K
Registrant’s Report on
Form 8-K containing the Company’s Earnings Report for the first nine months of
Fiscal 2012. May 10, 2012, Commission File No. 0-10248.
c) EXHIBITS
3.1 Certificate of
Incorporation, as amended, of the Registrant incorporated by reference to
Exhibit 3.1 to the Registrant's registration statement on Form S-1,Commission
File No. 33-13365.
3.2 Article Fourth of the
Certificate of Incorporation, as amended, of the Registrant incorporated by
reference to Exhibit 4.1 to the Registrant's registration statement on Form S-8,
Commission File No. 33-62099.
3.3 Section A of Article
Fourth of the Certificate of Incorporation, as amended, of the Registrant
incorporated by reference to Exhibit 4.3 to the Registrant’s registration
statement on Form S-3, Commission File No. 333-63782.
FONAR CORPORATION AND
SUBSIDIARIES
3.4 Section A of Article
Fourth of the Certificate of Incorporation, as amended, of the Registrant
incorporated by reference to Exhibit 3.3 of the Registrant’s Annual Report on
Form 10-K for the fiscal year ended June 30, 2003, Commission File No.
0-10248.
3.5 By-Laws, as amended,
of the Registrant incorporated by reference to Exhibit 3.2 to the Registrant's
registration statement on Form S-1, Commission File No. 33-13365.
4.1 Specimen Common Stock
Certificate incorporated
by reference to Exhibit
4.1 to the Registrant's registration statement on Form S-1, Commission File No.
33-13365.
4.2 Specimen Class B
Common Stock Certificate incorporated by reference to Exhibit 4.2 to the
Registrant's registration statement on Form S-1, Commission File No.
33-13365.
4.3 Form of 4% Convertible
Debentures due June 30, 2002 incorporated by reference to Exhibit 4.1 of the
Registrant’s current report on Form 8-K filed on June 11, 2001. Commission File
No. 0-10248.
4.4 Form of Purchase
Warrants incorporated by reference to Exhibit 4.2 of the Registrant’s current
report on Form 8-K filed on June 11, 2001. Commission File No.
0-10248.
4.5 Form of Callable
Warrants incorporated by reference to Exhibit 4.3 of the Registrant’s current
report on Form 8-K filed on June 11, 2001. Commission File No.
0-10248.
4.6 Form of Replacement
Callable Warrants incorporated by reference to Exhibit 4.7 of the Registrant’s
registration statement on Form S-3, Commission File No. 333-10677.
4.7 Form of Amended and
Restated Purchase Warrant for The Tail Wind Fund, Ltd. incorporated by reference
to Exhibit 4.7 of the Registrants registration statement on Form S-3, Commission
File No. 333-116908.
4.8 Form of Amended and
Restated Purchase Warrant for Placement Agent and Designees incorporated by
reference to Exhibit 4.8 of the Registrant’s registration statement on Form S-3,
Commission File No. 333-116908.
10.1 License Agreement
between the Registrant and Raymond V. Damadian incorporated by reference to
Exhibit 10 (e) to Form 10-K for the fiscal year ended June 30, 1983, Commission
File No. 0-10248.
10.2 1983 Nonstatutory
Stock Option Plan incorporated by reference to Exhibit 10 (a) to Form 10-K for
the fiscal year ended June 30, 1983, Commission File No. 0-10248, and amendments
thereto dated as of March 7, 1984 and dated August 22, 1984, incorporated by
referenced to Exhibit 28 (a) to Form 10-K for the year ended June 30, 1984,
Commission File No. 0-10248.
10.3 1984 Incentive Stock
Option Plan incorporated by reference to Exhibit 28 (c) to Form 10-K for the
year ended June 30, 1984, Commission File No. 0-10248.
10.4 1986 Nonstatutory
Stock Option Plan incorporated by reference to Exhibit 10.7 to Form 10-K for the
fiscal year ended June 30, 1986, Commission File No. 0-10248.
FONAR CORPORATION AND
SUBSIDIARIES
10.5 1986 Stock Bonus Plan
incorporated by reference to Exhibit 10.8 to Form 10-K for the fiscal year ended
June 30, 1986, Commission File No. 0-10248.
10.6 1986 Incentive Stock
Option Plan incorporated by reference to Exhibit 10.9 to Form 10-K for the
fiscal year ended June 30, 1986, Commission File No. 0-10248.
10.7 Lease Agreement,
dated as of August 18, 1987, between the Registrant and Reckson Associates
incorporated by reference to Exhibit 10.26 to Form 10-K for the fiscal year
ended June 30, 1987, Commission File No. 0-10248.
10.8 1993 Incentive Stock
Option Plan incorporated by reference to Exhibit 28.1 to the Registrant's
registration statement on Form S-8, Commission File No. 33-60154.
10.9 1993 Non-Statutory
Stock Option Plan incorporated by reference to Exhibit 28.2 to the Registrant's
registration statement on Form S-8, Commission File No. 33-60154.
10.10 1993 Stock Bonus
Plan incorporated by reference to Exhibit 28.3 to the Registrant's registration
statement on Form S-8, Commission File No. 33-60154.
10.11 1994 Non-Statutory
Stock Option Plan incorporated by reference to Exhibit 28.1 to the Registrant's
registration statement on Form S-8, Commission File No. 33-81638.
10.12 1994 Stock Bonus
Plan incorporated by reference to Exhibit 28.2 to the Registrant's registration
statement on Form S-8, Commission File No. 33-81638.
10.13 1995 Non-Statutory
Stock Option Plan incorporated by reference to Exhibit 28.1 to the Registrant's
registration statement on Form S-8, Commission File No. 33-62099.
10.14 1995 Stock Bonus
Plan incorporated by reference to Exhibit 28.2 to the Registrant's registration
statement on Form S-8, Commission File No. 33-62099.
10.15 1997 Non-Statutory
Stock Option Plan incorporated by reference to Exhibit 28.1 to the Registrant's
registration statement on Form S-8, Commission File No.: 333-27411.
10.16 1997 Stock Bonus
Plan incorporated by reference to Exhibit 28.2 to the Registrant's registration
statement on Form S-8, Commission File No: 333-27411.
10.17 Stock Purchase
Agreement, dated July 31, 1997, by and between U.S. Health Management
Corporation, Raymond V. Damadian, M.D. MR Scanning Centers Management Company
and Raymond V. Damadian, incorporated by reference to Exhibit 2.1 to the
Registrant's Form 8-K, July 31, 1997, commission File No: 0-10248.
10.18 Merger Agreement and
Supplemental Agreement dated June 17, 1997 and Letter of Amendment dated June
27, 1997 by and among U.S. Health Management Corporation and Affordable
Diagnostics Inc. et al., incorporated by reference to Exhibit 2.1 to the
Registrant's 8-K, June 30, 1997, Commission File No: 0-10248.
FONAR CORPORATION AND
SUBSIDIARIES
10.19 Stock Purchase
Agreement dated March 20, 1998 by and among Health Management Corporation of
America, Fonar Corporation, Giovanni Marciano, Glenn Muraca et al., incorporated
by reference to Exhibit 2.1 to the Registrant's 8-K, March 20, 1998, Commission
File No: 0-10248.
10.20 Stock Purchase
Agreement dated August 20, 1998 by and among Health Management Corporation of
America, Fonar Corporation, Stuart Blumberg and Steven Jonas, incorporated by
reference to Exhibit 2 to the Registrant's 8-K, September 3, 1998, Commission
File No. 0-10248.
10.21 2000 Stock Bonus
Plan incorporated by reference to Exhibit 99.1 to the Registrant’s registration
Statement on Form S-8, Commission File No.: 333-66760.
10.22 2002 Stock Bonus
Plan incorporated by reference to Exhibit 99.1 to the Registrant’s registration
statement on Form S-8, Commission File No.: 333-89578.
10.23 2002 Incentive Stock
Option Plan incorporated by reference to Exhibit 99.1 to the Registrant’s
registration statement on Form S-8, Commission File No.: 333-96557.
10.24 2003 Stock Bonus
Plan incorporated by reference to Exhibit 99.1 to the Registrant’s registration
statement on Form S-8, Commission File No: 333-106626.
10.25 2003 Supplemental
Stock Bonus Plan incorporated by reference to Exhibit 99.1 to the Registrant’s
registration statement on Form S-8, Commission File No: 333-106626.
10.26 2004 Stock Bonus
Plan incorporated by reference to Exhibit 99.1 to the Registrant’s registration
statement on Form S-8, Commission File No. 333-112577.
10.27 2005 Stock Bonus
Plan incorporated by reference to Exhibit 99.1 to the Registrant’s registration
statement on Form S-8, Commission File No. 333-122859.
10.28 2005 Supplemental
Stock Bonus Plan incorporated by reference to Exhibit 99.1 to the Registrant’s
registration statement on Form S-8, Commission File No. 333-126658.
10.29 Purchase Agreement
dated May 24, 2001 by and between the Registrant and The Tail Wind Fund Ltd.
incorporated by reference to Exhibit 10.1 to the Registrant’s current report on
Form 8-K filed June 11, 2001. Commission File No. 0-10248.
10.30 Registration Rights
Agreement dated May 24, 2001 by and among the Registrant, The Tail Wind Fund
Ltd. and Roan Meyers, Inc. incorporated herein by reference to Exhibit 10.2 to
the Registrant’s current report on Form 8-K filed June 11, 2001. Commission File
No. 0-10248.
10.31 Amendment to
Callable Warrant dated April 28, 2004 by and between The Tail Wind Fund, Ltd.
and the Registrant incorporated by reference to Exhibit 10.17 to the
Registrant’s registration statement on Form S-3, Commission File No.
333-116908.
FONAR CORPORATION AND
SUBSIDIARIES
10.32 First Amendment to
Purchase Warrant dated April 28, 2004 by and between The Tail Wind Fund, Ltd.
and the Registrant incorporated by reference to Exhibit 10.18 to the
Registrant’s registration statement on Form S-3, Commission File No.
333-116908
10.33 Form of First
Amendment to Purchase Warrant dated June 1, 2004 by and between each of
Roan/Meyers Associates, L.P. and its designees and the Registrant, incorporated
by reference to Exhibit 10.19 to the Registrant’s registration statement on Form
S-3, Commission File No. 333-116908.
10.34 Asset Purchase
Agreement dated July 28, 2005 among Health Plus Management Services, L.L.C.,
Health Management Corporation of America, Dynamic Healthcare Management, Inc.
and Fonar Corporation, incorporated by reference to Exhibit 2 to the
Registrant’s Form 8-K, August 2, 2005, Commission File No. 0-10248.
10.35 Partnership Interest
Purchase Agreement dated September 29, 2008 by and between Diagnostic
Management, LLC and Raymond V. Damadian, M.D. MR Scanning Centers Management
Company, incorporated by reference to Exhibit 10.35 to Form 10-K for the fiscal
year ended June 30, 2008. Commission File No. 0-10248.
10.36 2010 Stock Bonus
Plan, incorporated by reference to Exhibit 99.1 to the Registrant’s registration
statement on Form S-8, Commission File No. 333-168771.
10.37 Operating Agreement
for Imperial Management Services, LLC, incorporated by reference to Exhibit
10.37 to Form 10-K for the fiscal year ended June 30, 2011. Commission File No.
0-10248.
14.1 Code of Ethics,
incorporated by reference to Exhibit 14.1 of registrant’s Form 10-K for the
fiscal year ended June 30, 2004, Commission File No.: 0-10248.
21.1 Subsidiaries of the
Registrant. See Exhibits.
23.1 Independent
Registered Public Accounting Firm’s Report
See Exhibits.
31.1 Section 302
Certification. See Exhibits.
32.1 Section 906
Certification. See Exhibits.
99.1 Press Release on Sale
to Largest Orthopedic Hospital in the Netherlands, incorporated by reference to
Exhibit 99.1 of registrant’s Form 10-K for the fiscal year ended June 30, 2006,
Commission File No.: 0-10248.
99.2 XBLR Detail tagging
extension.
FONAR CORPORATION AND
SUBSIDIARIES
SIGNATURES
Pursuant to the
requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
FONAR
CORPORATION
Dated: October 26,
2012
By:/s/Raymond V.
Damadian
Raymond V. Damadian,
President
Pursuant to the
requirements of the Securities Exchange Act of 1934, this report has been signed
below by the following persons on behalf of the registrant and in the capacities
and on the dates indicated.
Signature
|
Title
|
Date
|
/s/Raymond
V. Damadian
Raymond
V. Damadian
|
Chairman
of the Board of Directors, President, Director, Principal Executive,
Officer and Acting, Principal Financial Officer
|
October
26, 2012
|
/s/
Claudette J.V. Chan
Claudette
J.V. Chan
|
Secretary
Director
|
October
26, 2012
|
/s/
Robert J. Janoff
Robert
J. Janoff
|
Director
|
October
26, 2012
|
/s/
Charles N. O'Data
Charles
N. O'Data
|
Director
|
October
26, 2012
|
/s/
Ronald G. Lehman
Ronald
G. Lehman
|
Director
|
October
26, 2012
|
CORPORATE INFORMATION
Corporate Headquarters
110 Marcus Drive
Melville, NY 11747
(631) 694-2929
Investor Relations
FONAR Corporation
110 Marcus Drive
Melville, NY 11747
(631) 694-2929
Stock Transfer Agency
Computershare Trust Company, Inc.
144 Fernwood Avenue
Edison, New Jersey 08837
Auditors
Marcum LLP
New York, New York
Board of Directors
Raymond V. Damadian, M.D.
Chairman of the Board
Claudette Chan, Director
Robert Janoff, Director
Charles O'Data, Director
Ronald G. Lehman, Director
Officers
Raymond V. Damadian, M.D.
President, Chief Executive Officer and Treasurer
Claudette J.V. Chan
Secretary
Fonar (NASDAQ:FONR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fonar (NASDAQ:FONR)
Historical Stock Chart
From Apr 2023 to Apr 2024